var title_f1_36_1600="Prevention readhesion clitoris";
var content_f1_36_1600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prevention of readhesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Resection of a segment of the clitoral hood in the shape of a tricorn, (B) Circumcision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1600=[""].join("\n");
var outline_f1_36_1600=null;
var title_f1_36_1601="Gangrene due to pneumococcus";
var content_f1_36_1601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gangrene due to pneumococcus in a bacteremic splenectomized patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEBAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0kC2sxglcgdKp3GsoSFg+Y9MiuEGqzXrM88rN/sjgD/GtGG7RAu5uAMf59qTfRG7oyW50RunlyXbg9hxVW7lSNCz4wvNYGo+IrWyiZnlTB6AuBXB6x4ovdYfyNPVy2cEjtQot7k8tjrdZ8V21nuCtuIBwDxXFX/ijUNUdorKJwG+6wGfb+tW9J8ETXknnX7FwQNwx976nr+XpXa6boVlp4xHFHuGOSKq6iaRaRxWkeEr3U5Fk1OUsB0Gcfn6V3mj+HLLT4wY4UVw244GK04MKu1VAUHAxViNSw68/nUObYpTbInUBCFUYHGKyr3OcsBtJxn/GtqVOM98dfSsTUZNsigEk57CpQU1dmBdq7PtPuT357detc7qh5UhnIXdlsEnPoe3/AOuui1B1MLGQNx0Oeh6Vy2pM0iEM2zG7ceSMZzjp6CtD1KMWzClEisVZTlQFfHA/GqyjKgjuM5LdB6foenrVi8HGMMu0En3P8vWs4zYKZztAwBjgH1Pr2qrnpQ91DriXcwI2g7eTjP40xJhyxOQRlhjOBx6VWuJgJDvccEjNUnucAZYbS3pWd+iOerio03qaU10vAJ+YYByAR/njpWZe3W4s5Y9c5HTPt71SluTk5OPcmqcjbjhjyOxPSne55WJx7muWITzO7sp6ZPsP881XHQ8Z/pQTz1OPQ0bTtJyKs8tu+4089hn3FJj1z6U5hyRuGPWg+oxjpQAz3peMZwOaUj1oxyc0BcQe/wDKjgfjS47Y69qTB9KAAdiDj8KUHAzSDj6ilHf9OKADjBzS/wAXPIpB6ce1LglScfjmgQnXrz9KU9cfnS4IByOe2cfyo64I4HTmkAH16fhQF564oIIznnn1pRk9fxxQAgB3ZxgUuBnHc84zikXPTHPXrS7eucEg84pgKmCQOOvNAHIPc070PH+RTTnJHb9KAFHT2zz70vb2x9M0Dpz+tGCSOpB5pCHEbeOlPX73IHXnPPNNA69MkZPPWnoDkHAx1zTZIBcM2cHjPAp5AwenXrjGKjUM3YnIznHvUhByc+vfvTE9x4UAqeTxwTxUijB6cGmADoT9ff6U5cfL+PfvRZkMkVQxAUnH5mpVG48g4ye3vUYXnocE9PepF64xyDyPXmggkj+aJAR7jHapSSAOO1RoOmBzj1qUlR/Du4oM2z1BdTSyibcW6Z44/Hn8qxtU8XyyEw2u7B4JBwcVzBludTbykLnDcYGcDtXY6D4VUqJLoMQDjB+UH8Kix77qyryvBWj3M7S9L1LWZDJcTS+WTk5BH8/rXpnhzQbfT4gCNxx3xk06xtooQERQNvHGKuLMQOoz1x0pNkuKSsjSUqg4YMAfvYxz/KozksD1zyTnt6VFDnAbKk8GnRxv5JDvvYk/MOOCeP6VBny2ZJF9485GR/KrsRyOnFQRpg7sYyozxxUyY/Tr2oE9Rty+EOM5x1rmtQf96zqBtB5GeMfWuhu2Kr2H4cGue1BhvwrHJyOSOP8APvVxRdK6Zg6lKvCyEbec7+o9PrWFM5clTGzNyuNxDJkZI9O5wf8A9dauoNg53N5ZPPfb6Af4VzOoTqYsF2VQCVznj15HBI4/OqsexhtUQXsnyOiMHVF6Hrj/AA/z9eeupSMAHnrmrd1OQSN4KqeABgfXHSsO7uSvG/nHGD3qW7aG2IrxpwZXubjnC5yRxg5FU3kZgefmHPoDUchOSeTnOc9fxNAPB45z60RR8zWrSqSuxGbnt179qZnrt+hofPPAGPQ0nfg8HjOe1MxEPr059aTrx6ccUdc8k8UvOCCBgnpVDGnO44NAz+OexpSDuI4J6Y9aUIWAAU89MU7XAYOeT1+uKB26juanFs5wdp565FK1u6MAy8HjOOtPkfYXMiDBxwP6U3H94HH5U9lP5/pTW9MipasUgHAGQaUbhng/59aQdetA6frx2pAxcE9ucZ+lGeDwM5zR0J4+uKN3APP50xC9+w+tKCdw4AJNHIGMdOKAfmAA6c9TxUgHO7JyG9qXpgEYAHakyf15/rS8ZwOn50wGjOAAQB6jnFLxnk4xS/3eB9KMYyOpzznjFACp/P8AzxQpJ29c/T3pV6HHB6/WjkZ7dhz9aBAp6fX8qB0IPPH6Uo4JySCOvHNKOAQTmkAufmPqfXtUiMAfr6fjTPTcST14Gaerfj1pktCqc8EFuOdo+gpy4yABxgjjJ/8A100Yzkk8jr0p2V7gZJyM9v8A61USPQgMBz/nvUsZ+VdwCnoMimKQCM5xzyfwqRAMg4yD7dfr61JDQqMO/fvzz61MMFgeMd81GhG/t6AY61IhyDjHTpt96dyGiWIhccHBHGKlUoB82WP+8BiokOR1XB9OlSEknjPHH3qZnJHqXh7QorMB3BZ8YLY5P09P89a6yOIKgAUN6gdPoKZaoEjDKp9T6fn9c1ciX5sCMknBx1rJs+pl5EcZfBHO709KnjRs4B6+o4P/ANarcEIZMDgKeOOKspEqqAcn26ZpNo5ZyIoI+vAyR1/DvUowG4BweMVIoxj68e1RTMVGT06g9aRje7HFxzycD24p6twRis+ScqWVuRnk5p6z/LgkDjI9MetFiuUdeuRGVU5PoPT39KwbwxnjHU44Oc1evJXDdMj2OOaxLiR2Zl2DH95h161olY0pxuYOtkYdd5A5+Yeh/lXIX0qmMOHct02+n19uldTrAJXByxJBcYA3HoMn6cVyd6Am4AncQSQ38PPQ/rTPbw8PdMa8lB+YjnGMDjHPbPSsOdgej5OB2xmta+wUbI4IHbP+e1Y0vJJ5Y+uRxWa1Z5OYN81nsQkgkHj/AD/9alJ+U/ngGkLDJ6+vHel3AKcLjtg/zrRI8lkT9T35zwM0KRu9/rSv15GBnvUsERkbaq5yaaV3ZA3ZakSruzgHOPzq1DZSSvgK2Md62dJ0N50DtHkHj8cZru9G8MhY/wB5ECuAc54P0Nd9LCdZnnYjHxpu0dWcFY+H5Znw0ZbGAfat+x8Lbm+YE5yQD3H+ecV6Jb6MqYJXK4wPT8Kuw2CwcgfMwIBA/OupRpwWiPMnisRVdtjjYvDUZjKbSZAoIxgj68/5zXL6/pUdquUUqpwML93HfGfwPWvW5YOAcqeOQOmP8c5rjPEtixWQhc4AC4Hf6+1Zt3YUqkqcld6Hk10gVyAeQfT86qtwevc9K09WjCXLgexxn26VmsAB1PFefWVpH0dJ3imIueMevalHJ7g0nTHr7d+Kfgfnxg1kWxoHLDrx1p3U++O3akwMnOenWnY+XH1oEJjOe2f0owNwHOR0px5HB7/0pMDdzke3ekAdSMYx09qMHsADjJpxGVySenNGATjpnqAPagBq8EYyR70LgL14HcDg0oXOTuz2pwH3c9j/ACp9AFGenfHemgE4/L8KcBjGDg4PApAuGyBgnv3pBYFBJA6Z9+KB909CQAaVRyCD3zTlUkgdWPTHP5UCFAJzkjjtj9KcM88ZBzx6elWYdMvpsGO1uGB4yE4J61eh8Na5Ifk0i/YcjiE800i3RqLVxf3GSM5yANo74p+cNgDjpj2z+tTXGn3lux+0W1zDkfxxMufxNRLjLDcM9/zFFjKcHH4lYeTnc2c+3QCnD5hz6AcDp7dP84pmCWyeMDGe30FOXkjI6DJ9aLGdiReSRtxz/OpVwRzk4+tRqpBPAz0yR70+PcWAxk+uMU0iGWE46jk9s9TT93rtBPUE9KhTOFBxyPT/AD7VIzYbBH6UWM7XPoK2ztwSwPGWPatGGIlwWPXnJFU7IFgAcDAx6D862LcA43HnHSsGz6SrLUlgiwowPwqYx4J/xp0WPXp79KexGM5xgdaRzPXUgc7e/wBKzbqYKAFPJzn2q3cSdeoz/OsW+lOXDZAzwM9atK5K31IzKZANpyzdyeaWNnKvkr0JIUZ/yarIGY52/iorSggwAcKeOoOQBjr9abaRsiIAPtJA4x16iqN3CDwWJbpweS1a6xqEIDLlsDgVSukXY3zKc8Z9R71HPqaU0rnFazHgu3RfLKjBznPauU1IqqbYgBgHnP3Vz6Y/Cuw16PkGMkOMhQD976fjmuHv3XLnLH2Vs49/1oTvse3RaUDEvSS2TgkDBPTP+cVhyjMhOBuBB/z61s3Zzk4XjOee/vWRLljxjBx3qoo8HMJJz0ICOcg8cnrTirAtnqM9eooRdzAqBn+tXrGxknbCIeDk4Nawi5OyPLnJRV2V7Sze4mVEU7icda7rwz4VMpQyAF2A4I6/X2q94Y8NfJHJLGORnBGfTj/PrXpel6WkMa5VeMjgcc9ga9OnTjRV+p4+IxE675YOyMrTtBit4IyifMB6DpnkfT8q14rXZtygJzkg9+K1hFgYHH0FRvGNjAfQCm5t7mEaaRUWNioBU8fhgY6U8QgEqo49untU+31zgcDJqQINpCgnB/Oo5ilFFOaIOuCu49s9jisDWLNmjbI+Q5wcDofX17/pXWlVJZTng56+1UbyEkE7iBxwTnIxUuVg5ObQ8D8XaZ5UgZdx/iIPJ5rkXjIPbGMdOlexeM9ODwsdpLIckkcden8q8qvYGikYOp+UkEd6wr66nrYKTcOV9CkF9RjJ70bevXH8ql2kc9z1/KlRGwccGuVHZYiCjJ7+9KqHIx3qaOJ5HCRq7uxG1QCSfwrp9K8B+Ib9VkFhJbxEZEk5CZHrjrQXGlKekTk8YOe1WbKznumxBGSP72cDH1r02x+GrRBWnkFzKTlskqoOOR6ntXaaR4Ts7RVaQhjjMgxgICc4U56mockjupYGC96tL5Lc8k0jwXPebC3zb8kHoqgdST/nmtOfw3a2QjXCyOzE4VccZ4685P8AnNeqxWCBZZUjaG342IBzt9M/5/Wo4tPtnvEjJTByyAcgY5x9f896jn1PZo+wpv3IK33v7zz+08ENcJv/AHSK2CCR29/ftUw8IQRsUDqzKQFwnDd/0HPX+Vep7Yo4+AW2gKO/JwMA9hWZfPGqrIwxvY/Oi/dXt/LrQpXexdOv72kV9x5hqOh2qAlGjljBIVm4L47genb+tYF5pFmuQQARx1xg8V3ev3WxNsYKshKMAAADk5zgfTj681x08ZJJbgnkKOcEjv8A4VodzoU6sbzgn8jF/s2FSHAZkH3Q3r9fSr1hZeWw2AKR3HBq7ZwK88Xm5CM2CQN2B9O59q9F8PfD6/l+e6MQgcAqRwwz69xjjIqFd6mFPBYbDP2lRJHIaVJcwB9spKSYDhyDn8D/AErtdM1mEWxdwWkUElOIhgc9D/SujfwX9n+eGTa4BUFRvXr6e3t19qz5PCl4nkZjsrvCKG+0SmMnaTg5wfXpyKu6JxFfC1la1vwLOk61BcZieKeSJlO3cmc+oHqPQ45rD8Y23hed5FvIoI7n+JsbXGehGOT+PFX9QsJba3lEdmbKf7peC5Vo8euTjgYxx9a4aTw5rWr3sn9nWfnKWwWDhlXt97PpVJX1PNVOjdzvZdtP+GOZ1Hw8Fdn0p5pogDxIvI/HPP4ViTW8tu+2dXQ4zz0/OvTbTwlrtu5STTCk2PvyLkd+VIz+gzzXVeHPhzYXd6x8STyzln+WCF/JGO5Y4yT7DFO3mebjaFD4oaP8DwZVIY8kduRT0zxknkV1vj7QNL0vXpl8MXDXWlszLGHOXjIOGQnqQD0JrlEGB2xj60I8mcOV2ZKhBA+Y5B49R/nrUglKAbdxB5ztzTIwSwDLn3p+3PQdOOlPcxaXU+gtOfjoCBjBJ6VtW8pYhcADH+c1xmn3YC8nDZI9Sa27W9BAwxOeAV6Vi1dn0NSB0sZ+QdvSoppdqk8e9U7a/DbkcYIAwT0b3B/SluJ1JJyMY6ipSOdxd7EUsm4MQSR7d/x/Ksm6+Zjjj68/5FXpfmBztLN+GPSq3l7skKcZPU/pV3saRpoZZoFQEjjPfnNacW10BBycZ/x5qKGIqQSAWxxz+eKtRjavAyT0IGOayeupbaGTKVzhQeM/4msy8yN4xuPAznArWnPyA7sjrWFqcgVt21ivOenB9c/57VFjSluYOsSBYmICkp0GOpI4+mfXmvN9SOC5UZj69MDrzXXa9ertHGABxhv1B9OnNcPetubIXJHbritIR0PSuqdN3Mq8LHllHc8fhWax4BUe3Azz/WrtyBgcgjHr+tMt4DcShUU5PYelawjfRHzdaXNJti6fZSXMoRVZu3TOa9R8K+F9irujPB3cjoP84o8GeGguySSP5sA5z90duO+a9O0+zWCFQiYOePavTpQVJeZ4mJk6r5ehUstOjjAUIvA6YFasSDsOp/OnBMHoM1KuRgkYxzxxine5iodiN09uvWoiuOnfpVoIW6c+gxnNOa1lYYEbDn0pNpFRpOWyKSrkE56dDT1UHIx0q4NPuCoIjbjt61PHplwdv7vPrU+0j3LWGm9LGayjOcj6dKhmjJXp0HGTW/Ho1w+Adq9qtxeHkOPNYt7Cs5VIm9PB1G9jy/X7FZkYOCcgg/Lj9K8d8T6U8F+VWJ2z0IX8AMevrX16miWsKMywhiATk85rlotMtIZ2mS3jEpJJfAyATWE61lY9ChhXTldnzfo3gHxDqrKIdOkiibkSz/IuPbPNeh6F8G4EAfXL9pjx+6tvlGfQseT+GK9ZQfMAAB9B1qfnbz6dc1zOoehGn5GFo3hvStEtzHplnFAO7dWb6seTV6aMGNiOABwfSrW1STzwfWkdRsB5Cjmsm2zVU23dmL9jZ8ZA2e/H4fSrUVkD8gACL3/vY7+3bitAKrMPMzgHketMnuBGo2KWb0UYH/6+aTZrZvQzL61dwyEAxHG4Hjpzx+lZkFp/phVfLhTYCcnJCj6Dqa1r1bi4gIVvLyOcjoP6n2psUIhtLiNndFl/izkn39cjHrSi7G8JcsbFGWeO3ldXVmb+GNhz0z9RXOaxO7Wsm/GWwdp4H146nt+Pert89nb3yklyY0DMCRufOecn+Vchq9/Jc3LRD5Yd7ICxAJwT25reEep6GHo3dzBupVd7aIAAKSckkggnuO3Oc4qGCEybstypJIzz+v8An9KbcRzC2gcKfn3Bcjg84wP8963NDt1nt0BLR+YTwCMEgdznJwMnFapXPSlUUdTV8AeHXudXtpbhYzArbihOd2MHkfiOK9tLpEoQcAc5Fec+C5EhjmaEFVJPJPB+TscdcqK71HG05wFPP4+tYzdmeLjpyq1Neg2UySbl27UHTjmsfUrE3CETp5kZOQm38v8ACuixuUbCuDjjtTv3XKtkEcYI6mktziScVdHkWs2JhlcQWRmll2orSbmUE+i9B0HNd7pVuNJ0mK0iJ83bvkY45J5wMcAenFaD2cAkYlF2o/mAn1zjNNuBmWTcFHJ6Ctr3MMVWc4xgZN1qVwGCxtyehPzcUmj2Utxq8V1PcAlB93BGQaluLSKXdnZu556Z96zotYfSLny5EiaPOVO3n8/8aTT6HMrOLUdzh/jT4aGmeKF1K3UCy1EeZJt/hkHDDj16/nXmV5bmGYgfxDI4619Waha2fi3w5LaXMcbrLGTE/wDcfqCPxr5h1qNYxEjuGkAKuBnh1+U9enSnG6MK0Izg5dTLXBXGeAOMcVJnHR1H0yKjC8hdoPpn6U4tt4zjHHTNVdnnNHoVlfZUkFhkjAPAz2rdgvVwoaTGeCvXHtVa30dBGZfK284K5xnn/P51YXS2DjkHJyD2Ax7dKjlPp9L2Zs2Golo0w29eeeAPStMTcHgdOD1yPeueWwljQnLAsMhv/rGpQshLJ5hUnouOh9aOUzlTT2NgzqcLzweSDT4p4wOgHOMdMfX/ABrAljldnw78rnI6ZzUUdrcvAzbxyemSKfJcXszrYbmFVHzDbn1GPzpkt7AAfmDAAd+tcw0G/qSx68nv9PapxA8gxtA6cH+tT7NdwVPU2LnUbdUcK+Nx6rg8+ma57Vrr7QHSHOD1IHH4ZNXk0xt0btgKD6A8f0qeLTCZDvbORtIA6D0/KlyRRrG0XdHAahpt3eFim4qckb8BR68+vPpVD/hELyc8umMZzuzj6+tesR2QVwcKOm1gPT86lSzBY7AvJ6hcd/T8ad0tjf2ikrNHkqeAGkBY3AU5wwx39j3FbukfDyKFw8k8jORxtX9PpXpS2xYq+Bx/wLr/AFq6YFHC9enSl7Tl2MJRhaygjmrDTpbZFCs2R1BGfz/WtMJc5xnhiBkDr/n1rWii25BXn2/lU6xqdpI6elHtp9zneGpdIL7jHSK4OAXY5/KrSW0pGWY554H861EiA5xxT9ueFHA70vay7kvC039lFfSbYtfQ7vm+boa7IWgB4H5Vz+ngC+hP+2AK7EJz0wQce9XCTkrsFRjHZGeLZevYU77OB/XNXSv+FJgeg/CquVyIrCEehxiniH1J9asAeuBQMY54PpRcOVEJjG0gAZI6etcTNCEkI28gntXfKwLAd65C8t2W7nAOAJG7dOayqbFxhdmZjbncMe3Whw23JHAqwYW446fzpHjxjgEntWJ0qkioEA4O7PrS4znrnrgVZEZ5x1OR7UuwZyMcY7UXL5EUed4BXKk4I9KrsXcnj5RxyO1a6xjcuAR3zUTwohJQEKOce3pUvUTSRiXEExRxvJYAk9cj6e3NVHX91G8j5EbtvXOAwC7vw4z09K2JmAZcbueCB6Y6Vg6hp9xPI8UThN3Vgc8joTnr1PHcGqjG71LjNehzniG4i+yWzokLfaY2QA8ASocHJ7HBUgeneuW86CJ5nKSiUN9oi24AD45XaMjBPHHQCukuNDPzwTnME+CyqMlHB4kX0I6Edxx7Vg3eh3dsXtJlEkiAmGTkLIM9j688DOeua642R305Rty3/wCG/rRmBNc77O1g8o7oncbmY8BsED8PapLHUTEEY7DNC3Xb0A4OD/ntTo4vNmmtfm3yoCiqC2XBBHbPrVW6ikDyjIcIwG5QeVPINXex0Qu3ys67wnrPkahE1ww2yNsPOM5DLnHbhq9L0vU0v9OiaJwSVCtjJw4GD19Oa8CwyJ8wYEEA+x7Vq6Xq1zazo6TtGQw5DHGPwrGSUmb1cBGv7ydme4LcSKwxkhv4sZAGcD9Tirf2rA29GYdzwTXLaZrepX9uGtdNtr5FPzeTMVYf8BPb3qa51SdPln0nXrTbgBrTEin/AIC3FZcrTseXLCy+F2v6r/hx41wPq8gLI9tIChYclT25HGOlapl8yNZo2BLjqG4B6Vy17pInaOeYyRBnL+ZLA9u4PuVBGfwxWlpSG3ha1e4jlJJMcoOARjkHng57jj0ra66HBjMPBx5oPVE0tzhpFJG5AOnXNcj4uuLoZMRVufUCtXUjLb3ZwDgZyQec+9ch4q1MrYMF3FySmeMjufxxW8Umjx6l4SO18B+JIrbQrppZA0VkjSMQM4AXOK8Gu7prqeaUk4kZpCMd2OeB+NbA1ea08LXcavh9QdYQw6+WnLfrgfnXOK2MjjLdATUNanNVlpp1JR1yfmYfSpA55wxIz64/nUMfUdB6AYPNPaQg/KFIPPUig5Gj6E2OsfEW4FcDPGasWumoV3Z5BO5ex64rUiCyKFIyc45qby0iOQVUnvXO5vY+ocuxjzxKH2MpwRgAZ4/KqjxQ7RkErnjk/wCe3Stm6wA2eMH/AD/+qqckDhmIJG3kDH5c+ntVRZN2yjJC7cOAEJIIHAY1BNaArjPDcjJ4OOla2zCngsTgHA5Ofeowm0EuABkYz9etVzDje5RjtR5rHBx03ED/AD+frRHCAzKASMdO5H41f2l8NtKrztYdP1qzAsartOBnHJH6euKlzK5GihGrABSCTxnjkf54qztUABlwu3kfWrMiAe+DkgcdvbtSQxt5ZDDJDd8YNS5XGkhoVW6qD8uQe35dqmYGRFQ/Kc84HX2pApVHYDazZ6jv6io05G1WJK/Mozzjr+NTc05S2o+Urt2bRgbcn9DU6RjHHXr7/nVUh+i56cGnmGXySkDIkmc7mTeBzzxkdRmoZahdFpIgOQAcCpEAUHLc9cVAYy4B4weqk4/l3p8EZUZDE55yeoqblKCJt54A+QD2pwc5+U7aYqZAOfm6GlVWIGOh6jHQfWmP2aH2suy5iYnkOD0969BPXrxivP4YT82Gxz685rvLWTzLWFwc7lByOlbUnoc9eNnoOYE47HPOPSmkfMKcxJB9egpmRkY61qc4oXHt+NOCn/6+aUA7eARn3qRQQckZoEhoU444Hfmuev0xeznsWyK6b04rA1lTHqAz92RQQc9COKiexpB2ZlMuCxOf5VXYMQSR6Y/pVuRecjnP86Zjp6D/AD/SsToUirgknAOBwOafjphSSB+RqYIOhBXilC4HHelYbkVsYJGCSf5VHtOFBGRjp7VeaMDkDrUTIpU8e+aCGrmZJbgkFgN3+eDUT2yyKuB8wGB9K0WQkAfp0zUciYOc8jHfFAchg31n5rfIiYIwT+f86zLuGb7M8F15TwuwZ0YADf2dT1BB/OuunhDnPr37YqrLbxkZKgnIx+NWp2KZyWoeD7PUSJ/k89hmVki2RyMD95l9P5965zXvAGpsGnsDCUH3bcycKPTJOD7e3HYV6oqAPuYkn1bkip5CihSm0c8Z6VSqMKdarSejPmnWdO1fR2H9r6bcQgnHmkBl6dNw4/Ws22v493GDjp719M3l3Z28bLezxRxkEFZOh479jXnXiPS/h/fljJJFazkZ8y0bbknsVwR+gxSu3qd1LH1+iv8AL+v1PPLK+VCjo9xG45BifBFdPBrFsy7m8U6rFMAcLNK8YAPbcpY5/CuR1vQrbTpVOka3Bexv0AR0dP8AeBG38jUFtp0jrueYAlfmAXP5U730PQjiK9da0n+H62PS7XxLoUEThPEPiBpmC73Sckbh3wev41Laa1o4uB5XiESAsDv1CzDNnPHzryByc5NcVp3hu2mDPeSXbIQVjaIKvzD29P8AOKgutCMEO6LT7iSVmwu98j+Q9qtRZyzhJNqS/Ff/ACL/ADPVJZbC8dkGtaNcMQDGouGiAHPUnJyfc/hXH6tpvhiJwNauJ7XerktY3S3Ybn5dp7fjiuYPhbWbucq9mLZM8sm0kc9+QPbrT7nwKdPhla+llSVQDhEVgOBgnBz/AJ7U4qR4mIlvGEbr1X5f8A5SeRTMQjOyrlULdl5/DPeo1PGecdPf8annghSQCGVt38W4dP8A61Mji5YFlynU+tWkfP1HeTuCFQBwfwHX8PSpVj3DlP0BpoGQM5z6H60qbQvzcnr6U0jFs+mElCREEhWA9/8AJNIZyVVixwTjB5OelVYnd+NjBevTofr37GpoYssQ7s3fJIPHYe1c59Q4W3JlLrubhs89en41IFLqFIB4zvxx/n/GhMRAnnaT7/5/GpI+oAVUX174/wAaVzJlTDoGUMSrHrn9KRI/MyRhge386tko8iruBYc49aYCS55wRz79elNyKincb1RV4B6cnv8AT+lKEcgcZOM8Dr71AreZO6jI29eBj/PSrEckZZ03cqQQc9qhmxG29UDE/dIHtT0LOoKMhLcHHtUj7ipOQjbgAO2KcEKruVSB0IHNS2WrFeaHLkhyWJz8xyAelCIFZFRwfUFs5P19faryqA3LY/U06OBdwwqke+M470uY0Ulaw1F8xRgZI67atJEM9O/1pY4l+cjAPf8A+vViNcnjr60g5hix7TyAcdOM0sUZ44AXkD3qxGnPXgdM9qmWMgjA46igOZECxnLMwOD0wBUoiIOQAcDjIqdFAGMEsDzTlG4k4+hzTE5kCQDJHXPT0ro9JOLEJnOw7ePTtWXCuCcKoz71o6exEzqcYZN2R65rWnoYVXdFuQ8YHAp9tH5hDN93sKikHbsOKvwDCLjoBitUznZIoAA4HQ09Y0ZcdD2zTO2e1Abn/CquS0JjDEN1/nWT4lgX7HDMpG9HwR6gj/61a0zZbjriqOpxm5sJo++3K/Uc/wBMVMtmilfc5O4bgYOdxAA/z9KcVyM5BxxTEcMQT2HSn/w8nI9+1c9zVSuKm0AgkYNPXB5x049KbgDGefWjdjofxNO5VxZDg98fnz6VGw4JAxTsk8Agj69aYWOADgZ560ikxjIoznByO9RMuAeKlGDjJ6dKGHB6/wBKRVyswwCDyT0qGfgY68girMmdxwOSO/FVZxuPc4P0zSuC1IWdVyRwOgrkfFuutaRssDSBlI+cNgMD05rq51GCD3449K868VWUNxOQz+WoBbBGeo7+g9z9K0pWctTpwsISqe9scTfX895LuuG3uW6Hmsy5jCEAMG+hrVuEjWJGUgSg4685/wD1Y5rMm28Akbieg71s30PpVypWWhd0XQb3VnZbNFIRSzOzgAD0ye9af9kLbP5cpUTKqsFckDk85z0x0x0PrWn4N1fT4dGurG7BzIAVCZDHnBwfpg1Ttr6yfxAILiWeSxkkbcAxOSMhW568Hn1pwSXQ55VqilJW0X4m1YF0hfIjES7lRCOOgIJ9BtGecdKmd38maK6uBb244DwrlnPbnHuOnf2rA1yMJbym0kMKLhmRn+8vIUgDp3/SuXh1O9s5Ckdw43cHBz9KqTszzqtCNT3+ax2thp9zruvtZ2d6LdAFJNwhkY453c9T+Q6VU+IPhd/Dj2oL7lutxRudxIxyfc8fnXN6Rq9xZahFdW0i/aUOVbr+BrpL3XpNSuVvfELNcypHst1XAVME5O0e+Oahu+2xoqTjaUWnC23Vs861SBku2X5i5OCpOSO2PrXqmi+D9N0vQYLnUtOt768mI4uSdmAMscZGP/rV55pz283iu1a/RpomlG5N+CSemT9a918RQLci1ik5jwd30yP8KuDvofG4qMfaTlHu/wAP+HPLPiP4VTTRDq2mQNHp852yRq2RBIeij0U9R+VcSM456/Q16VPJ5nhDxlGXcwZidctkKwkGMV5sQDySf8/Sml0POqaWZ9IQqhTcwACDABI5P0FN87y5XIRgAASXAP0rFt5ZigCZjBHAHHHf61YtoNkpMspeXBHzHhf856fSsHE+pcbN3NiF1C8ksmO46fWpl4I4OF9MH8DVBTnGcnOFJzjBqzyY1wxJIx2xUMjlHy4VsbiQeMjvQzPGdy9AOAR155x+dICWYCTGByd3X2qTywwT1z2H+elK5SVtxIwXK44b1AqZrdCVOThD6ckU3ykI2ggD6VZiTEQHt35xUsQxETfkjHpx1pzxBz1x7+9PK/MMD8zTjgAEDmkO5FEvlj5nLHnn0NXI1Ckd88VCF2gAZHvUq9O359KA5tSYLkYA4HHSrUY+9kCq6N8mQcH09amRweeST2pBcniHP1x1qwqg9jk1RE3zhR9etWlJABPAxn3NVYSZLjg4AwMinAgL8vYcUwNkEkjHuaQthu2PzoKRMH2t71bhkCXUDHgltmPrWerMW+Xj1Oasbgqhs7mBBznoAauLJlsbWDuA429avRHp64qsASwPbrVhCQvAPtzWyMWiQ9Dk0zOO/TpShuOuPaopJAT/ADpkobI4Jxzik3Yxxz1NR5yB347dqVfwxSKPPtQD2XiiaFj8hYADsVIyOPatQZZQOncntU/iuw82/sb1Oq5jf8sj+oqupwAGOM8YNKu4vlt2MMNCUHNPuPAI64z+dKRtGSOnPHao8kjpx7cYFOY8dAR7kVgdYjEZHzKBg004ycn25prbuijcc8YBpqsyg8jOeeaRSY7cCSPm/rQ78fLg89cdKaCS2fSgZOeD9TRYbkRPwSSD9c1UlZvlxjqegq6Yz3wcHp0zUE0eSgyec+2KTC/YxbqR2VmwcAZOD1+lcB4pllKyO4LKMfP90oR36df6V6oYlZSWXcPQ/wAqzrnTbW4UrKgdcAMGGePQjvThLlZ0UKvspXaueG32qpLFNGYoy0vJIG0g7s5/mPfNYNxICDtPHQE8V7H4g+HNtqKs1lcmGfbgEnIJ9+P/AK9eT+KvD2reGpkXUYMREny5kOUcezf0PNaXuei8fT5bR/4P9ehUspmWdSsnzdj6VejEk07SzThc7juxls9q5v7Wu75gVHGTjP41P9vTAPmkY6euc/5/Kri3FWMVmVCStKW3mdb58TIkdzOGXKl9rgjgnJxn0qlJCHBMSDy8g/pWFDqkKtu3bsHtHu9881oprVnOBE7W5HYvBsIP1XGavmutTanmGFTspr7xxIV27celE07MhAx05GM/57VXuLmDAZJlbnGA2QO3fkf/AF6qSXcDNgOB+mD+VZWdzLF5lRhBwjJFeGYxXwlZfmRw3I9PX16V6lf+MUMMdxE+dwYbBxjrgZPT/wCvXkrNkscKST+Faelaitk8nnWiXeVZYw8jL5TnA3jHeuiGh8Q62ji+50eral9i8LNpYmZ73U5UurpeR9nRfuJ/vE8kemK5bKgnIHtmowxMhZuWP3mJySfU5qRFDIuOwxRZdTmlK9j3+0jkaMMwLsMZLEc/XsPw9cVaERwGbGcZ646+v5UyOZYyjSKowccEYX9OPxqdbhCR0Vm5IHXjisJXPsZXbvYaWYoozzkDIH+eKkhlVI0j5VsFs+me/wDjTBKAQGXcDwCRkdOOn160sTonIIHcHpn0+pqRSjpsSs2SSmWXocHnj/8AXSRyOcffyTk47+2PSk8xcZXsTyf71KCQh/h56lvmP0xSJW2pKkwdgD97qB61fXJXk8/zqjan5cFVCntjv/hVqIbCQckH/P5VLIehZzkcDH8qDjnjpTN6q4X5if0pdwKnPQ+tIXMIzkN8q5/CpwRsJHDVGqhjuXuPWniMgnr+FAtxkkk5IMSIe/zNUN1qf2S3ea4BUfw4PX0/GriN+7weQPbpVSaET3sTvkJGCQB0Y+p+mP1pq3UVtdSewuNiDcDvbk+1TnVMuQUbA6EgikjhTOSOfUVJsU4BHHSjmQ+Vk0NyXXO3HtUiS4z0zVc4XAXAJ74qGRiuDjOak1SNQOAASeT1p7S4RgDnI/nVCNyQM4OevtUobaDjBPUGhMGjrdNlFxY28qkElBk+4GD+tXf4fwrA8JTb7GaAn5reUj/gLDcP1zW5I4C54/GumLurnO0RySYPB+X34qHOTzwSe1DOCSMgg/r9Kj6ds/WmBIGzwcfXvSllJ5xjvUWemOaevJHbPfNMQzUI/PspkAywAZfXIrnwv8fAz710ynBGRzxyetcrcgwXUyDO1WwMY5B6cVnNdSloKdgOFxn3BoyD1PPsMVB5pHV2GR3GM0rSDGRjpjAP+NZMq9yQqA3+0e9IFUE8A4xUYYnJJxx3AqQNx1QjOcCkF7CkAH6H/PNJlR1PzfzoDDs2Me2KbyR97pjn1oACygHGOe+OtVpXCnPQgHH+e1SSvt+6AGGKzZZd0jjjIAyPz/wpMpMfLKihix4A5IPSsfUNXhtWzJKq/KQMNyT9PoM03U7krAw3beWYjHoOhrgL6V7u7KMd2zazLvGeecDPHHPy+lVCnfVnbh6Sq6t6GrrHiOZJHiR8q2RuibJX0Ptn+lYl/IL6Jk1C6u5oeTsecSLnoCB0PH0wOaoau7wTBkAxt42nJ9Tk89M9ff1zWVeuTbp+9AOeA2SRzkY9a6IRSWh61PDwjFSSKGr6FYploVO3nkHt6+2fpWPNpkIyF3KSeed2TWncXE0aNGzZ5OQOQPfj2rJ80SSgEnZ60nbocGNjhUvegrvySZd03wxcXcQKW8rxk7S+MZ9ceuMUl1pFnCGSWG9inVc53r39QR/Wuj8N6XJLpl9fLJcQwWsRZp0m2AMTwOhznHQfnXLaheTSwyrM85QMANzE9uP0rWySODFYfD0Iu8V/Wu5leTulKR7mkY7VUISTz6V0I8KXUsltFbNctezRl0gktWjLHjKgnr1rs/gbpsUmp3l9JzJBEFQkfdLnkj3wP1rqvHWlR3cM8pnJMR3xgP8Al057VUEn0PnKtFQ333+88L1HTrzTrqS2v7Wa2mHJSaMowH0qIAnngAnrj3r1/wAX2J8SfD+bULmMDV9EIJl248yE4BBOTng5/D3ryJVCkkZI6DvnpS2djmmrWcdiRfvggbgOMU7aw6Z9+O9NVWAB/LjipAQOucnnhaa7mEvI9whnlSTEgUgZIGeh/wA/zqSeR1LMqjeRk4Oe3THtTEi+baqL3+bPSpJY3TbscHAJxxwKze59oqiuKkxKq3G7ldzdPpwasmf7obkgnjP8j2NUgmRG+UCckENgjjg/r/npViFiykAkqSTyOfpxUtFNpl9XLghU2JggEDqe/wDP/JqZZG2EEAZYAEHp3x9aghIMWWxlsdv061Im4gALg7vvDg//AFzWbRhcuodx3YA4x9AO1WAwK5B3Z9arRrnnbwAR196lYDeGHQ9SO49aixi5dCZCWwQCMcUu75hnoeTnpSAnGRj8DUbMSQQuT6+tIncsJJg4wOlWBJlDtJ4GOapJgdCMfrT1JLbmUfnSHzWLKkEj0HXNBbDEkfhUYckH1PShWLHLY57g5pFqRZRuhPHsO9SL6ZGMY57ioUfoozn0xTiwxxkikVckZhnp096Qleg4461FnGOmM561Jyw6daClIcGCEAnJPepSSeuQOtRgBhnrz+dQXt0LWIkYMrHainu3qaC4Rc5KMdzd8MRhb69mEi42LG8f45DfhnH41uXMuCFzj0FeT674h/4RWy86QqLrO+Rd/LN12j/CvRrC8W+tLe6ibdHPEsqnqCGAP9a3he2ppi8L9Xcdb3/r/hi4rZHOME85FOJ46nHpUasenQY7808HJGeo4rRHFceDjoc471IOB1+YevrUS5Oeef8APNPBA65A6YpiJDjnjB6jFYPiGDFxFKAMuu3PuP8A61bmc9ao65F5mnOQOYyHH9efxqZK6C5zIHHybhz/AA8igEkHBJTvgfoR2ppIHDOR6H2pXOUywbA75+7+PpWLKQ9SV6H5T6dKkU8dyPTrUSjkk5x9MZp4baw64/nSAm5P8+DTGPI/h79Ov4UhkUjAHGOKjZum4cDnilctK42Vd6nccjPGO1Z91FJ+8CHJzxn6VdkYEZxycjrVT7QIxJu+6GIOfwqWzRQPOfF97e6Zmc20scXKmQY+RsEDPse341wNzrUsgyhAGCcY4HPY/lXsmr+LNHtJvst7FJJvU718sONp7EHrXkXjKz0S7vFl8NfaLdXz5sMkY2K3qpyTzzx+tbxcrbHr4Z1FGyp6/wBdzJmu2uHMjk5JyT71E97hAhkbb1xngfSqU0UsCkvyozyM4/Kqk0oKjcRx0/L+dCkwxGOlSi1JWfmWruQfKVOd3GB371SM5Yg5ZsHJHTI/yKqy3PzFkygOM49KbvzGA2F5yDjtWiXU+VxeOlVk2tDobPWpUsGtfMc2xbe8Jb5HIPcf/XrLvr77SiKsKxhSSdnGfeqsTxiMkkFwOPb6VEvXOSRnt1NUm9jHEY6rUjytnZ/DvX5NHvpY1f8Acz+XnccAYb+fJpdW17UNSvZ4muJ3aS4ZRGnUru4XHeuQiJUhiSMH+E4Iq/ZalLaXRuYYoDKAceblwG/vdR83v9a0UrI4JzclZ7HqGun/AIQ/wBdWVyz/ANua5x5e7mKHPzEj6ce+a8sRcJgZ44GajklmncvcyzTyY+9IxZiPqeacrMS2QTzn+XFRq9WRUneyRMpx15z6dvrUyrkcbj9M1AGYggEDnnH5Z+lKQP8AIp9DGyPfLIq6AAH1yDyT/hTyiTAeYikqcEZzj/OaSAKIirkgMOSOCB7VJBEsZA5JA6elZt6n1ctGyCWNtqJ0UKSDnHHX+dEewkIysQO2OW9/pVqeA4JCKQByCefx/wAKIotnK5BAwKLh7SyHxAyBgQQ3fHp9Kl2kH5Vy46HHT049KIEZWGQCP4uM7v8AP9atBPMQZC56tjvU9TN1RIzj5SpBz+tXQoKcDacjoelRRx54ONpHTHvU6ZAGF6dvX0rNmPNdkbIwJI5A6jFCbVPzZ54xnrU2RkZIAI496iUHge+eBUmiY7aA4zjpipQefrxx1zUZbpu7+lLuGB2HuKTRSdxWHoCR/nmlB+bORSZBzkkep6Ck4yOeTnvSsMkjmweeR9ak3ZGeOe9Qds8c96fuyeOg7UWBysTK/HBwP508MB0I/wA9qqHIbk/hU8EbyyBIUZnPRVGTiiwKY+aZYRlyOvXufauev9XW0Cald4LNn7NBjoR1cjuBx7ZFafiO0utJtBqGrwFbZXESxB8ZZs4zjPXGPzrxDxJrd14g1URRuZZpWCFUGFUZwEQZ5Uev+TrTp31ex9DgqdKhS9tNpt/1b/N/I3tMil8d+I/3rMunW5MkrJ1lY92P94/y6V7b4MH2PTm0wHKWTeXFk8+UeV/LkVyfgjQ49B0aO3AVpm+eZlOdzV0lhKLfVIZMkJKpib8eh/P+dVza2PFxmLliKjlfQ6leCBxnGKkVsjtmoFY9TgY9KkVjjnp34rRHK2TKTzSq3PQ8VEG9en8qVW6j889KdguTBgO9KwDqYyR8wwaiySO/pxTgxGDx+FKwXOSkTymaM/wkgk/WkC4OOgx1A7emKv6xEEvXPdhuGKpLwwPUADn/ABrCSsWmN28fL1Hb+tKOQwwBSgZHyjjuv+FJxgEZPv0I+tSUNJ3HBwG64J60wSIvPHJ4B/UUSFZBtbBOMDHSszUJJIEMiBiq4LYGSoHcetIpXvY0vlIbrgdv1rnNbu2tLeV+CTkgqfmUZ5P07flVefxHbxsizP5NywwitkCYd8H1Hoea5zVtciN5LIJkZd4AZRkqvBOB69Ov6U4023qduGpylLVGDr3m3ksl2Y8CR+ETB2nGOfrXMvu5IbCdgf6102uavaylooJGYkAE5OM98+v+elc3DLFvcSk5IwCRXStEfSYZvl1VitcuUVPLUtxk5xjOaZp0Ok3LouqWuAThnSQoO/YA9M1d1IWssUslvIFkV+I1PABHJHt1/SuejeU3CK+3BPGDRdp9zgx043UZq6ZrX+neHRIYoba8RMN+/jk3HcOhCkjj61yl7Ym2umiCkZPyq2NxHauiuJpIlaaSUIZAAePvAdPr61zt7OrTs0LNg4+Ynn61Tb2Pms1pUaaXKkmMjtLl1k2207CMMzYQnao+8TxwB3qzo2j3+sXIi061eZuM7eQoJAyR1wMjOOgrsPhtqWnW2n38Wr3f2UI/2iFyRtkBGyRMHliQ3THakmh07wrp7XmneJtN1e9kYpbW1vCzGEFSDLIT90gE4Xn5j7VpZJXZ4LTfwnFTwm3uZoWdXMUjRl0O5Tg4JBPUHGc0idSRnPemKoXavIA4GRntUqZLYyM9MY5qLszlboC9M8/nUy8ZOCCMdDUaSE4y2BngntUgOT24P+TQrktk5G08uccn/wDVTiRk5yTnv/8AqpqkAnJXk5zj+dKcg/OcH8KEZn2DN4Yt7hnWIIGQ5JYYwTjvWZN4YkV3WJJGCkZx0ya7SG3liB8ufcWOT5gz+tTB5lBDQIf9xuf1puKPeV0ecXGkXEYIkXCjjBGKhW0ZABtII6YOa9Bvp42ZjJFKi7MDMeck/wD1qX+zra5hjIWIyn7xX0/xrN010C8noef/AGfAC4Bb3ODSmHgdyCRxXb3Xh2EgtC7L65GeKyX0RjxE6sWG4KRgkUnTZLcuxz4AXPcZxyelSq2eD/k1el0udNwMTHacHjNVHtXyFYkEd/X86zcWJSGkE85x+FNIIz1Ht1oYPGQpDDtk1GJgec//AF6ixrGQFWLA5JOM81IOc7iOSM1CWO35j+ANG4ZGef1oHzFjoeG5pMkA5A9etMVgz7cnr0p6sOrHnPU0rFcw7cec4A9aVTnGTgfyq5p+mXV6cwxsIv77ggfh610+n6BZ2P7y/cTSDnBHGfXHT8TVqm2KzZgabo9xfsGAMcGf9Yw7ewrpQthoVmXLJGAMs7HBb61T1bxFDbqYbcIzL3A/r/SvGviR4vnlVrWB2aeQ8sAf3Y9vetIxS0W5cNXyx3KPxd+Ilxrkp0nSW8vTs5lkwd0pGeB6L/npUHwv8MgFdUu4xu2/uQf4R6/XFc/4P8Mtq90JZhttlO4lv4j/AIV7LaxJbxqkKBUUAADjH+fSqm+XRG1eqqcfZw/r/hy4jBQCTT5cuDgkkcjtg1AH469OOelL5gzkkAdK57HFzaHV2Vz9otYpiOWXn6irS+/p+Nc/oFyAZbcnB+8mf1raDc8HntXQtUOLuiyGyPfpRu4z1H0qDdwSD070hfIzniqHcsB+pPX+dP3fNwec9u/4VUD8YBH1FPEg7d/ShgmyrrifuoZPQlTzisgtluT0PXpmty/XzrGZF67crgdxzXNLL93OCD71hUWpcZWLfI9Rxyfb3phORgZyO/PHvUSS/h75pSQxIz17HHFZNnRGwpKkjeuR1yvWmyRK67g556djTGAycYLHrnvUMrtjhmUAY6jFRc25U9jn/EugWGoW7xzsw3c4Tkg+3484rzO68C6xBeSfY7uEWrcL9obBf1H4V6fqdxdiIhXs1A4LM5GR65HP4VyupT3hjIbepOXU8YLr91s9V7n8Pz3hdndh1UStGWh5rqNlqenkteWjhATl0G5R25NUVvgRuR1YdODkV2k2qyxwufNAODuwM8H3xyMDv2NcXe29lK7EK8TnAPlOOT9P/rVq6d9mdNarXormTuVLm/UnDBRuA59KpfbpBJlySORjPGKc9kgYhbiRSORuTJJ49Dz36VRmjWJ2CSb8D+6VwfQ+9EYWPmMVjsTOXPJ2sXLu/aVDGSdv1zj3AqjuIUYH8XAA610PgPQrTxDrYstQupraEqNvkgM8jEgBVzx0JPfpXsnwg8GW+l6jc6m9jPLKrNBA91GcgbvvgEfKTjr+tWo8sbs8+pVniJ809T56QFlztOc8fWng5bBDYGSQa6P4ivBL8QPEcloF8lr+XGwjGc8nj3zXOjHUYxk/w0IwmrSa7DkOMDA4OenftUgJIbk8Z/P601emGznPTt0pyHbgc45PHNBmx+TnuTnBPXipEBBIB4JxgDio0PY4yMnrxUw7E9PemiWyUY3Fgc45yO3FO4PPA+uKQE7txPPYjtTyc9VX8xQjNs+2LPUMKPOUBzghDweT0H5ZqzFqMbkbkkQ4zkjIxnr7U0lnOXjgY9jk5pskQkyPJ2jI5VvTpTue+oyLlvcxXEO9GBAOPmpxt4pOWjBPqKyJ7WR0QI0gcHk4GCBxVq1Hl/M7S7+APYAelO4JS6osNakoVSeZN3GM5qGK2uYbjzfMWUFduCMGrQmXPUj8DUc87LEzQxmSXsuMY/Oi43Hqx3nlB80LjPJK/NVS+ktXcbkDYBYrjBPoOadYyeUjCRpHmc7nbbxn0HtUEtgxvlnQSEZO9ZGyCPQDtRclptbDf7Ktrq0FwseJGHAU8VRuPC6PudJFx2yOlbf2cAfIqxf7rH88VIo8pf3ty7KfXAqXYapd0cPPoLDGxwp6AbvfHGarw6HqEuBBGWXPO4beldm11YW/KhGOMf3jTpL24dgsdvsTsz8D/GpcUxqCW7OfsPC8zlmupgiZwdgz+p/wrYhsNM05QzKrsBnfIcn9aW4kZSpmvA3GSqcfqeaZLpFtcwCU7icEkbicn05pqFinJJe6rlbUPFMUYZLYCRh6dPzrnL/V5rnPnzEIOdq1oajo9pbW5kkdFfGcZxj8RXkfjHXZYZhbaW0khJ2+p9wPXik4tmXPKcuVm14i1xlheC1BMvQMpHB9K5PS9DfU7wyyZCE5OeSeeg9Bx+pq14f0nWtRlD3em3CRYyHdQn5A139nYfY4wPKZWIwfl4H/ANan8CsX7X2ekWN0+1js7aOCMABV2gAdKuYIIxn06UgYb8Z2kDvxxT1H3RjHFZNGXN1FxjABOcY4Pejp3Bxx060o+8BznnmkILbhtPPHHepsFya2nNvcRSdlOCB6eldUsmVBU8da4oncCxOF7mui0a6823CMQWj4/CtI9gi7M1ieuc9OlAbknJqEP7/lSbjkjvz37VZVyYnJppfkZzUe/K/09KYXOMnrjrQFy1HLhueexxXM38XkXbxn7gO4H2PStovtIzjGPTpWb4gJWCO7VQ2z5ZBj+H/9dRNXWg73KSzYOWJ59aUyFzkNlexFU1dZV3QtkEAkE8j2qus7AED5iDyM9PSudo1hJo0/PAO3dtYg4I71FKVPBYZx97PSqi3aS5jlO4HJyBVG9SWI+ZBNlT0BAz9KSjqbxqNE1z5cSv5h+XcOo4z2IrntcIMTGMhEwA46rjvgev1q5JqETxSrdsGjA5ZOCPwrhfE/iMWE7W86rNZSKwimhPzKe24enHUc1pGDR10K6jK8tCDUryFbmQzxQTMHz8ykK3Trjtz9axtQu9PuF/d2qwMMnarFkyfTPI6cVmalqtjLJ+5uJJAFyGkUhs+h6/hWPNqKuBsDN+HUnvWynKJ0YnHYdQ+K/wA/8i5dTwGMr5abgN289fb/ACPWsKQ/MwIIHpiiaVpGY85Hamfw5HbPQ0Xb1Z8xicR7Z6LYvaXqE+lahDe2LKlzEdyMV4B9avat4l1rWLlrjUNSuGdl2fI5jXZ/dCqcYrEY4GR9Pb60/PB4HXpiqvfQ5LtbAuNnQAZxgCpEGX4YAZJ47D60zIYAk896euCOfXIouSxydTySM9qkTBA2/XHSmAjC9evp/n3qRARyUK+x7e1FyJMkX7oGe/PH6VIvzAckAjB9qhTjJ5J5AOQe9TJ9RtzjOaaIZKmdw+Y56Z71KkbOuQDxxwcVGnAz7Z+lSIPl+Xp7UrkSZ9g2Wp6Jdhfs2qcY4Al5/WtREjcZiv35/wB04FeQz/CLUIJN1lqcLgA4Doytn3INVv8AhBPGdgWa0mDADAMc5BPvz/nrVNM9hVJLdfme2C3n27o7sMCActH1H4Gq9xcy20yRSXMG9ug2tmvGlm8faYf30V6QO+FkH14yaVfH/iOznBvLEsyjhnjIx+Pai3kV7a+if4ntjtdxY3vagMO7EZ/SpFF62MG3x1+8ef0rx2X4sXbNGJ7CN0Dbm+Yc8dv8KU/GW4gSSSXTmZAcKiuvT60Gim33/A9hEV5u/wBbbjJ5IUmo549Sx+7mgbnHKkcV5gvxlhygbTZdxAOQykD9aH+MUWwOLKXJOBkj8c0Kw3L1PRL5L1Xj8t5WU9d2B+WOeKsWFtAF3XDrcTMf4znH0Bryqf4s3Uhxb2qDPTc461Vm8V+KNWGLOydMn7wj6D6mhLsZufK7v8T0u/0+3fUWgt53hUkSXAU4A+lSa/4gsNNtooDdIskjCNMnJx615NbeG/GV5K7+dPbmVsyEzYJrSsfhPqdzci41LVt0nIxt3de3NOwotO/L1N3xh8SdK0uz8qxjW6uG+RcDge5P+FchpPxC17U2Nnp1nvZQCZUzgZ9jXYQ/DCzgszFJFHcOeshJBA74Hauqh0nT9F0R4NKsDEVX5VRckn1PvTsim7pto8u0jT9f8S6pNb391JCi8AlMqT6Cu60bwZYaI0T3SRSOpz5jcFm9cVv6WodLdliSCCH5juPzse9F/rVtJEBLbM8cmdh65PrimQkkuaX/AADRgW1UZ2EAgDJXg1WvIrJGyqpzyQDzVjSFC6ZFucMCvr09s1QuEENwhE4mSR9pjPOM+lI3ey0GS6Fb3UAmWMK5PAFVZ/CmOYJNox0z0rpRaIgHlFlUdgeKXZOBhZQ3H8QpWQ/Zx7HCy6DdoMxsGPT61SktbmMMskJABwecYrvRDMJkdlBVeuw9an/cO7b0ILc4ZanlRDpX2Z5jIwBIcMG6Yx+VT6ddRwXIdWABIBGcZzXbahaWTSgKkZGP1qm/huCaNJAnPcY6e4o5DN0pIgLhkBH4dqYXyeen8qmOh3lrCypKJUHIDdqrTW19GCRbiQezU7CfMt0OZ8nt0pjynptJOOK4jxdqniq3jKaRpaBc8yA7m+mP615drGseL4sm9l1GPHJxGQPzAp8pUIueqZ9CM5PTI9qR8Okkciko/Bz618vv4l1nCg6redMECU5qdPGniOHCpql1gDA3EH/PNLlG6U11PbbxHsLtkLfOPujGQ47VVa6V0G4hJB0O7t9fz4rybUvH3iC+sYIZrhf3J3eYiBWY+9VI/HGrxoUMqOAeroDj8ankTKi2lqepzXJGEL7GIJGD94/X8qY+oxw25WaVokGTktjOOo9sV5ZL471IoUeK3K47x9PesHVNfvb3KySFU6bF6Af/AK6XKupTrwWtzu/EniPSbhHibe5JPzxMVzj09jyK861O7ilmYQFmyQcv6VnMxYcg889KGb5vr/OnboY1sa5x5ErIYxDAEZ59qMAA9wPQ9aVj15IGe/amk5Xc3BzRY4bisxIbLcZ5wetAGCQTxzgk4/SlPysfTuelIpwPTr2oQri8hWJP096kwNuC/wBc1HjkDHNPHGQcE57+tMTHIeoOOwp0Z7DjnnH+f0pExs7cD8P8+1PU53fLnPYjFBDYKQW5IycgjFSr8qlWPTJ9f8mox90AHPP51IhBUbhzgjpyOaBNkik7Vwx54x61ImdwOT9aiXuB1B5PpU0ZLKCVxz9AP8/1oRm2TITtHfr26e1SovB3KCQeoXNQoMZAI556f54qVRkcA4HA6jFBDfY+3kHGB+VSgkAD86iBBB+nAxTl6AE4HvVM+hRLweoGP51llw9xKWgDQh9vMfGMcnNaWf8AJprojIY/4DnIoG43M6XT9ImCmayiXcMgPGATUQ8M6DMW26fbMVbDfIODWlNb+a6vvZVC4K9jzUMttLt2qoZd5cjO3ORxRqTypbopDwjoQcsdMtgPXyxwaQeD9DAIXTbYE5ziMfWrqmaKOQyb2ZRwP4SMen1p9pPK7RIzE4bBJGCRjqaEw5Idig/hiwWVHitYAAScBMcnFWhp4t43EcQDMpztHXntWuvA4GB7GiRlUMzHaB3Y9KBqnFbIpRSlbsQjAQKAMr2x3pftLCZgCoQNtxjqa5bxULu5m8/T9RgEUIy0Ybk/iPWui0RHk0+CW6hCzleeMEUCjPmk4l+O4jZRk7M5PzelSgowzlffB71m6iYLcRMUaSUcRxqeSTTbC28y1Vw2MklgfX0plqWtjTkgjf76jHfI61VXS7SM+ZHEEc8ZBxip490MQ3biQOg5zT0uImJy+P8AeGM0DaT3M+TTZBZzQQzlVk5yeSCazINCkhPmyO8k6fcdSVx+FdMjAg7SGH1oOQjYPzY7ii5LpRZVtLphbJ9s+SXocjg471cSWNz8rqxODx3rkNdgZfJllu2kumlAEaN8uM9MV1SIAFJUBsDn3pFQk3ddiZmIGe3cVBDcxyE7gFPUEkcipHXcuD3XtxVCXTy8RVJDnoC3pSLZceG3kYhkQsRkgUn2ZVI8pmQegPFVDbTQo/l8uEwDVqzMiQjzzhwOaBK1x0kc7JhZA3TqMmqT6jFYysl1gsf7gzge4q7c3UUUDSbg2BwM4OawrC1upb25SV41R/mJXk4PbNMiTtojYjazlTcFGxjksV61m3lnZzOwVUI3AAeta0IEX7gxARoBhj3rH8UOsKxiMmORumOh+poJmly3kjJ1b4e6JqShZ9Pt2DDBOzBH0IritZ+Cuj/MbczQhsj5JSefxr1yFClrEXnIfAG7PWq+oedHCXaVSF6AincXIkrrQ+e9U+DF1Epk0+/LgdRInT8RXIap8NPEdiSfsQnA/ihbOfwr6n028ja3mWSMkIfmLAirMd7p84Crg+mV9u1HqZ8vMviPiPUdE1HT2/0zT7qAYPztE2PxOMVjyBeAMfTNfcT2tldTiCWFHD5LbhkGvKfj/wCF9G03wlJeW9nbxXSzII5I0Cnk4wce2aTSsYzpv4j5uYADIbnpnNMOA2ASOfWlOcE5HWkIyeoPaouc7FbBAO7jNNXB7nHBpWBYccc8epoznkj260XEAwBz9PpRt5ye/wCtHQfXpzilA49+5I4FJMB20BRk8A8n+lPAwRjJBycD0phBycg/hTsYXnt2GTmquSKgH94biOKfGvzkAjP17UinIX6D/JpyZJORg9+P0ouJjo06fmTUqhsYVsmmgZC5GB1IxT16FcNyeMcUXM2OTtnoce3NTRbuMDJ6dP6VGnCgA4OfSpI1J2jBI6E+o7U7kskjyB97gD8amjTK/eIxxzUQ6Yxx79M/Wp4o9y/Nt/EUm9DOSPtqDon4f1p/8Y+lFFW9z6GJI/8AB+NNH3F+tFFC3DqSH7q/Wl/j/Ciiki2Kn3R9RUJ/4+U/65H+ZoooYuhJJ/rF+grN8Uf8eB/3h/SiimRU+BnGXX+sj+v9a9Mfp+NFFBz4Xr8jOuf+QtY/Rv5VNpP/AB4/9tGoopHTH4n/AF0RfPR/xqpdd/8Acooprc06MpL/AKxP96na9/x4J/nvRRSe5C+BnBn/AJD1j/11P8q9S7D/AHT/ADoopMjC7MZ/d+lOTp+FFFB0McOopp/1ooooQPcytV/49DVHwv8Afl+hoooMv+Xh0r/db61ka/8A8erUUUdCp7MS7/1dl9P6CjXv+Qa3+8P5UUVRm9mZVn/x5X/+e1Ptf+Pyz/3D/OiihGC6f11L83+t/wCBV4z+0v8A8ipY/wDXzH/7NRRSlsXU2Pmz+P8AGmN1H1/pRRWb3OKO44/d/EfyNIPvUUVIkKP4vxof73/Af8KKKI7gP7J/vf4Up++Pw/rRRVoTHt/rB/nvTo+g/wB//GiimRIcnV/qKsRf8e8n1NFFQthVP8hYf9QP94U6D7q/X+lFFWtzOXUtx/f/ABH/AKDSXP31/wB0UUUQ3Rmvi+R//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gangrenous toes developed secondary to prolonged hypotension and tissue ischemia in this patient with pneumococcal bacteremia and septic shock. A splenectomy had been performed years earlier for the treatment of immune thrombocytopenia (ITP).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Lippincott Williams &amp; Wilkins, Baltimore 1995. p.264.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1601=[""].join("\n");
var outline_f1_36_1601=null;
var title_f1_36_1602="Intussusception lymphoma CT";
var content_f1_36_1602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75825%7EGAST%2F64048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75825%7EGAST%2F64048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception of small bowel lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography&nbsp;scan of the abdomen demonstrates a large mass in the lumen of a distended loop of small bowel. Note mesenteric fat in the center of this intraluminal mass (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception of ileal lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema shows a large soft tissue mass in the cecum (arrows) caused by intussusception of a lymphoma arising in the terminal ileum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1602=[""].join("\n");
var outline_f1_36_1602=null;
var title_f1_36_1603="Sodium tetradecyl: Drug information";
var content_f1_36_1603=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium tetradecyl: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/53/40786?source=see_link\">",
"    see \"Sodium tetradecyl: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sotradecol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trombovar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F222262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Sclerosing Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F222241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Sclerosing agent:",
"     </b>",
"     I.V.: Test dose: 0.5 mL given several hours prior to administration of larger dose; 0.5-2 mL (preferred maximum: 1 mL) in each vein, maximum: 10 mL per treatment session; 3% solution reserved for large varices",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F222242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sotradecol&reg;: 1% (2 mL); 3% (2 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F222230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inject slowly.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F222268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chemically",
"     <b>",
"      incompatible",
"     </b>",
"     with heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F222229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of small, uncomplicated varicose veins of the lower extremities",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F222260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration at site of injection, sloughing and tissue necrosis following extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain, itching, or ulceration at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (including hives, asthma, hay fever); anaphylactic shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F222232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium tetradecyl or any component of the formulation; arterial disease, acute thrombophlebitis; valvular or deep vein incompetence, phlebitis migrans, cellulitis, acute infections; bedridden patients; patients with uncontrolled systemic disease such as diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, and acute respiratory or skin diseases; huge superficial veins with wide open communications to deeper veins; allergic conditions; varicosities caused by abdominal and pelvic tumors (unless tumor has been removed)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F222217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Observe for hypersensitivity/anaphylactic reaction; emergency resuscitation equipment should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred following treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arteriosclerosis: Use with caution in patients with peripheral arteriosclerosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboangiitis obliterans: Use with caution in patients with thromboangiitis obliterans.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Valvular and venous competency should be evaluated prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F222233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F222245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sotradecol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (2 mL): $39.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (2 mL): $62.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F222225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for DVT or PE (up to 4 weeks after injection)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F222234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fibro Vein (PL);",
"     </li>",
"     <li>",
"      Fibro-Vein (AR, AU, GB, HN, IE, IT, NZ, TW);",
"     </li>",
"     <li>",
"      S.T.D. (ZA);",
"     </li>",
"     <li>",
"      Setrol (IN);",
"     </li>",
"     <li>",
"      STS (IL);",
"     </li>",
"     <li>",
"      Tromboject (KP);",
"     </li>",
"     <li>",
"      Trombovar (FR, NL, RU, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F222216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts by irritation of the vein intimal endothelium and causes thrombosis formation leading to occlusion of the injected vein",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10330 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1603=[""].join("\n");
var outline_f1_36_1603=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222262\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222241\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222242\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222227\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222214\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222230\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222268\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222229\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222260\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222232\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222217\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300071\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223031\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222222\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222233\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222245\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323881\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222225\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222234\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222216\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/53/40786?source=related_link\">",
"      Sodium tetradecyl: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_36_1604="Femoral artery puncture site and position";
var content_f1_36_1604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Positioning and pertinent anatomy for femoral artery puncture or cannulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 589px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJNAgYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNNJPtQA6iojIw7LTDO4/gX/vr/AOtQBYoqp9rYdYx/31/9akN8B/yzJ+hFAFyiqP8AaKD/AJYy/p/jSf2nH3ilH4D/ABosBfoqiNTg7iQf8Bpf7Tte7uP+2bf4UAXaKqDUrT/nr+akf0pRqFof+XiMfU4oAtUVXF9aHpcw/wDfYp63UDfdniP0cUAS0U0Oh6Mp+hp1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaDTSaAAmo2ahmqCR6AFd6rvJTJZKrSSc07CJXlqFpKgaSomemBYaSmGSoC9NL0ATl6YXqEvTS1AExemF6iL0xnxTAlL0xmB61A8oHeoHuVHegRaO3+6Pyo3KOgArOe9UfxCoH1GNergfjRewJGyJ2X7rsPoxFO+2zL0uJh/20b/GudfVF7En6DNR/bZ5P9XE5+vFQ6kV1LVOb6HTf2ncL0uZv++yajk126iGftTge+DXPCO9m6kIPzq3baaAQ0zFz/tGs3WXRGkaD6sv/APCT6kx/cSs/uUXH8qeviTWx2iP1UUkcUaDAAqTC+lZOpJmypwXQVfE+tD/ljan6qf8AGpV8Tax3t7P/AL5b/GoQF9KX5falzy7j5Idix/wkurH/AJd7P/vlv8acPEernrDZj/gDf/FVSaRFHJFVZb5Vzyopc0u4ckexs/8ACQaqf4LMf8Ab/wCKpf7e1Q9rUfRD/jXK3etwWw3SXMa+xIqpH4utCTlgwHcA0KUmPkiux2T6xqjjHnxp7pGP65qu1zeNlpb65P0kK/yrIh1y0niDxTIc9s8ioLvV7YIRK6Ffc0nJ9WVGn2R0NrrVzZvlbg3Cd45myfwPUVsp4s0osqSyvDIR910P9OK8qmurB33xXTow6Yk4H4GqF3rHnaf87AyxuOR9f8KdOq00mOrhk4uS6HuEevabIPluR/3yf8KmXVbE9LmP8TivI9Jvw0akntW0l4uByK7bHnXPRRqNmel1D/32Ket5bN924hP0cV519qU96UXCnuKOULnpAmibpIh+jCnBgehBrzYSofSpFkHajlC56NRXnqTuPuuw+hqZbqbtPKPo5o5Qud5RXDreXH/PzP8A9/W/xqZL65H/AC8Tfi5NKwXOyork01C7HS5k/Q/0qVdSu/8An4b/AL5X/CiwXOnornV1O6/56g/VRUi6pc+sR+qH/Giw7m9RWINVuO4i/wC+T/jTxqkvdIz+YosBsUVlDVX7wIf+B/8A1qcNVPeEfg//ANaiwXNOis3+1V7wv+BFL/a0XeKX/wAd/wAaVgNGis7+14O6yD8B/jSHWbTuzD6oaANKjNZR1q0J4l/MEVDPrdqikmeMD3YCgDYZwvU1C9yqnqK4+68StcymPT0LgdZGGF/Csa9utQky6Tzk+iDC/nxWUqsUbQoSlvoekpcqx4IqdWzXmWi69cm4aG7PK4wemf1rudMu/OUc5q4yUldGc4OD5Wa1FIpyKKokWiig0AIajY05jUEjUANkeqcslOnkxWPqF/Hbxs8rqiKMlmOAKYi1LLVV5h61yN7410xXKxTmdh/zyQsPz6VQ/wCE2s2fDLcJ7tH/AIUuePcr2cn0O4MmaaXrl7TxDa3WPJnRj6ZwfyrQjv1bvVKz2Jaa3NYtSbqoC7U96eLgHvTEWy1NLVEJAaN1ADmbAqheXixELgsx6KBzViZ8KaoaUFnllnfnLYH0FZ1Z8i0NKUOd6leSS7l+4gQf7VQG0uHP7yc8+nFa11cRxE5xgVh3V491Jsh+UD+IVySqt7s7IUl0Rbj0sMMu5P1NSiwtovvsoPuaqRQXTY3TyEegOP5U8aYCSxXLHqTyam9zTlS6lrzLCHrJH+Ypj6vaRj5Fd/8AdWq504LyaYLLcwAFK7DlRKddZjiG2P8AwI4pr6nen7scYHuTVqDT1QdKnFoKLMLpdDNGp3g6pGfzp39tyoPngP8AwE1ofY19KifT0btRZhdFL+3s9Y5V/CoptdVQT83/AHyautpanpUMmk8cUah7pgXfiO4bIgtLl/QlCBWRPd6pdHEm+FT2VSP1rsodNKsTJuCjsOpq3JZQPbkwBhKozsY9a0i7dDKa6XOCt9MZ23Orux7tWpDpMhAwgFbVo0MwzHgnuO4rSgIXAxVe3k9hfV4rfU5lfDbycklT6in/APCJbj88spx/tV2cBUnpV6ONTUuUnuykox2RwieElxgySkemf/rU4eEY9u07ymc4JrvxCvpR5S+lRyluq3ucZFoLRDEeQB71L/Zk46Oa60otNKL6Vd5dzO8eyOSNjcr/AB0nkXa9CDXUvEpqFoR2pqpNdQcIPdHNGW5j+9GxHtTk1EA4bIPvW+0IPUVBLZQyAhkH5VarSW5m6EHsUY75T3qYXq+tN/siENkDj61ZGnW4jxsGav2/kR9X8yNb5fWpkvFPesm9sRGcplR7VRkinQZjkb8aFiF1Q/qz6M6tLtfWpPtajvXGxzXZOC6/lVgx3DjmZ/w4oeIj2BYWfVnVG+Qd6adSjH8QFcwtgW++8jfVjUiaandaj6x5F/Vu7OkGpx/3hT11JP71c6ulxf3akXTIfSj6w+wvqy7nQjUk/vUv9op/erBGnQgd/wA6Q6dD3z+dP2/kL6v5m42pxjqwqCTWIV6yL+dZH9nW/wDdFTw6fCOiil7d9h/V11ZYOqPMcQRu/v0FKIr6bq6Rj25NWII0iHAAqVpQo5NS6kn1KVOK2RROms3+tuJG9gcUi6ZCp+5n3PNWWvIh1YUw38XqKh67lq62HxwOmBD5aj/aFVr21lkVvNunx/dT5RSXGqQxKWZ1AHvXMXV9eahdkW0kiQHjjjNCi5OyG5KHvSLDMIpYbaHBKNnI7fWvQfDm7y13Vy2gaJhlZgc9c13+mWoiQcV1QhyKxy1qvtZXsakf3RRSqMCiqMhaQ0ppjGgBjniqk74BqeQ9azL+YRxszHAAyTTQHNeNvFNp4c09ri5bdI3yxQqfmkb0Ht6ntXis+qal4juzNqM7GMnKwqcRp9B/U81n+M9bfxN4ouLlXY2sZ8uBT2Ud/wATzWpoFvnANclWo3ojqpU0tWdDomlxTHZzgdcDrXQw6JAoysSg+oWneF7YB3JbtwCa6QRgdqzSOhzscxNotuql2RQFGScdKqyWzW8SuGkAbkKM8Ct/X1b7B+7OAHUv/u55pn2u1GmTzMBJOq/u48gFm7D86a0egOV1qjBhspZlWeKYkHPJ69emR0qc3Fxaj5xIcevzD8+v51c0Nfs9lBayMJJUH7xx0LE5OPxJrUns1ZTxQm4u6YS5ZK0kZOn6xHcLkNyDgg9jWxFMrgYNYF9pmCXjG1/Ud6q21/JbS+VPw3Y9jXXTqqWj3OKrQcPejsdRcN8hrA0a7xa7c/MCRirn29Hj61j6Ihae67r5rY+mazxPQ0wttUzQnVp2yScVZsrQBhxUiRcgYrQhURrnHNcyR1OWlixDEqp0pxRarNNL0VDQjy55FVczsPeMHoKbFAAelTpnHNPosFxgQelLtp4opiG7arTNMJQscJZTj5sjHvmrdFFgREy4HFRjrgirNKFBHSgLkOFPYVHLbh0Ozg9iKsGMVDcTLbR7nP0HrQK19jMm0+IyeaECOepXjmlEDqMhtwHrTlW51BixbZbkFSOn4j3pYNLeIDdNux14o5epfMlo2IkpQ9KtQ3vPWmvattxkn3FVTDLESCgkx3UgfoaWwtGbcVxuFPMlYlvfQq4jkDRuf7wwDWgJfQ00xOJa30heq/m+uKTzRRcLE5akzUHmj1o80etK4WJjimsBUJmAppmHrRcdh5OKjaYCo5ZxjrVCabLdaVylG5YuXEgqJYhtwRTI5BinGUClcqxE8ADcVPGoAqvJcqvUimrdKRwaVwsy8CKeGArP+0r60x7xV707hymmZB60xpgO9Yk+pIoPIrNudaRf4qXMNQOnku1X+KqsmoqOhrk5NUkmP7tWP4Uifapf4W/OqUJy2RLnTjuzrkv0PLyKv1NXoNTtYo9zyxn/AIEK4pbW4K8xg/UmrFnEkDg3Fsceo5qvZTXQj2tN9TqY9Ra5kPlqQnY4ptyJmQ/MRViza3aANCVK1U1XUIbaEtIwHoO5qTWKTOa1m8mhmFtA7eawyT6Cls9NmucGV5HPuxNS6ZYS6hevdzIVDngHsK7WxskjUDArspwUVruefWqc0nZ6HP2ugg43Ln610WmaMkePkH5VqQQqO1aVsgGK0Mr3J7C0WNRhRWoigCq0HarS9KkY+iiigBDTGNPaonNAFeZuDXnnxc1ZtM8H3zxttklAgU/7xwf0zXoE54NeMftBuw8PWIB+U3Yz/wB8tSlpFjjrJHkemKNoYda7TQwcZwR71x+i4YJjmvR9Btd6KqpkntjNcLO5HY+EI5DC7tu2npk8V0DriotEgNvYRxsoUgVeePI4q1sQ3qZtxCkqFX6Ec1ztz4bBfMN1IidlyDj6Vo6w9z9qEMDBEC7mYcn2Fc+GvVmYrNIcdm7ipNo+ptadoJWHL3coVTyqELn8etS6JPJLZ7pThcnGWLcd+Tz1qK1hu3i82EsyupV03469x71oxWaLYLCUUME2gjtQhSfdlK3vob24nSMfu4uC/wDePfFY/iXTPOtiyZVx8ykcYNWNAsZVSVHG0ibD/gwz/KtfxGVEbYwKN0VtKyOQstPlmiRjPJsYZwDW7pdmlsFjQdeah0gbdPjL9gTWlaIVAkf77/oKV29waS2LscIyOKsrGAOlSQJlQTUjDFXYxbIMD0oxTm602gY00mcUpqNzikBKDS1XEmKkWQHvTAkoqMsD3ppPvTAmprzRxj5nAqjNIRnkiltYopgS5DEds0DshLjVFXiJdx9TUENvPeSiS6JVB26flV2Wygkwduxh0ZDg1LbweSCPMkkz/fbNC0BvoiVVCqFUYA4Ap0Y/eNxwB81NyegGTSXEkUdsSz4Y8FiOD9D1xTXcyl2M241F4iVVVYj88VRlvraZszqUf+8QV/WnF1G7BHs3BqudUSA7LqJCvZwvB/wrNnRDVbFLWpkhhUiYyK+cZOSMDIINWdO1FngQyNzjmsbxBd2bwNHZpGGbrt7VzKa+Y2KKGODjgUopt6FycUvePSjfD+9SfbvevO/+Eib+64+oqGTxSUzkSflVezn2MvaU+56Sb33qKS/x3rzRvFxzgJJ+n+NWoNbnuFyEI+pp+yn2D21JdTvP7S55NH9oj1FcR9qun6DFSJ9sf+JvwFNYebE8TSR1z3xPeljk39TXMRwXh/5aPU8cN8vImb8hVfVpi+t0+zOqR1Udaz9Q1KODOXANZBt72Q4e5lx6A4/lU8GlJnL5ZvU801hn1ZEsUuiKsup+afkV2HsKb/aEqjHlP+VbkVjGo+6PyqcWkf8AdH5Vp9WgZ/W5nMtqNyR8kL00NqM/RAo966pbNP7o/Kp47ZR/CKaw0EJ4qbOVi0i5mI82RvoK0bXw9EMFgSfU10KRgdqnRa0jTjHZGUqkpbszrfR4EA+UVoQ6fCuMKKnQVOlUQRLZx/3RQ1hEw5UVaU1IKAMObRwWJid4ye6nFRQ+HoRKJJ2eVh0LnOK6PbmnBM0uVXvYrmla19Cnb26xgKigCr8SYxQiAVMooETRCr0FU4xV2AUAX4e1WVqtDVlakY8UUUUANaoZDUrVBIaAKs54NeV/G+xN54PndRlrd1m/AHB/QmvUpj1rmvEtol5Yz28q7o5UKMPYjFNq6sCdnc+Y/D0m1l9K9V8K3aJNEWPFeTzW0uj6xc2Mv34HK59R1B/EYrp9Lv2ZQAcEVxSVmdsWe7w3S7RzUwuVz96vNdM12RY1SXJ7A1pjUpMZB4pXK5LnSzFHvpnIH3F59RzWdJtu9aAhUCOG2Ib6swx/6C1VLe/804c4PTNaNtcQwKQuOep9aEO1jSs08mFVqR3ArLk1JF7iqFzq6gHBFFxWbNmW5SLOMAnk4rmNbvjdTLDGTkn8qoanrRAKocsegqrZyeV+8mOZn7elS2bQjy6s6BmASC3Q/eIU/TvW3D+9nGOgFcpp83m3ykn5gOB7muvsI9i89aFqTPQ1ohhBVPUvMaHEP3gwJHqM1bRvlqGU9atmC3IUJ2DdwaUmmswFML0ih5NQuaR3qJnouVYRzTfMxRnNMIpXCxMs1TLL71R5FOVqLhYvllYYYAg+tZd9ZyxkzWLEMOSoPP4VaV6uKuAB/Ee1NahflOOOqwkSnUJLlpl+6gO1fz7Vsabqpjs917A1pAvyo8h5c+gHU1oT6bYy3HnT2sUk46krx+PqakvYLe5iJvEV1HQkcj6elVd9RylTeysRR6nZSXQt/tUBm2eaIPMG9l6bivXH6VQaeDWIDcW11FcRPkLJDIHUY4wCOPrXm3xW8L6l4gu9Os/DFtNBdxRzSNqTOY1jjKFTCGHJLkgH0HNbvhZmsPD2mR3fh19OiWJY/I5Vo2HBGc8+ue/Wno1qzOMW5WhqX3hubScqeVPbsfpV2GNLgdOe6mrcBtbtdkUswz0Vxux+J/xqNoGikxjBB6is3G2zN1JvdWZk6lpStkoMH2rjL7SHtbppQMxk5PqK9ODhxtk4Pr61RvrJZFPHNOMnB3RM4KorM4hLJHiyADWTf2aqTxXS30D2LFlB8s9R6ViX0qyDIrvjNTV0ebOm4OzMFbbdKBjqcV22jaXmFSRXO6fF5l3EPevRNPjCRLgdqpEshi09FxwKtJaoO1WAKeBTERLCo7U8Qj0qUCnAUAQiEelSLHUgFLQA1UFPC4oApaAFApw4pp4qF5Tu2opZvQUm0ldjjFydkWgwqVWFZrm4QZMRxTI77DYbg+hqVOMtmVKnOHxI2VNTKazoblWA5q2kw9aZJbWpVNZ7XSoMlgKjOoovVuPWk2luNRb2RsqakFZEWoIe4q1Heq3emBoqKkUc1XhlD9DVuMZpASxirsI6VWjHNXIRQBbiFWFqCMVOtSMdRRRQAx+tVpDViTrVaWgCpMetZl6m9CK0ZqpTVQjxb4peFnuX/tGxizcxDDqo5kX/ABH+e1eb2V4YmGSQRX0zqNqJlIxXl/inwJDdzPPbE28x5JUcN9RWVSlzao1hU5dGczp+oFwNzflWzFqDxr8jAj0rnm8J6tZufLkicfiP6ULpurqQGRf++qxdJ9jZVkup10Gqxj73yn3qy2qZGAT+dc3pOmTzahbrqIXyN2WA7+1dbcXdveRxeTHHAi8LCsR5HoSB/KspRcdGdNN+0V0Z7Xs8hxHHI+f7qk1RurqZSyyERHvvOD+XWuqtb+3t28yWMB0GFVSSf15rFvrNtT1Brlo9oIAAPXFXTp87Iq1fZowPtjocwxtI/wDfYfyq1pct9e3HlJCSx/i7CtsaWsacgV1Xg3TI0tPN2jc5zWlWnGC8zGnWnOV3sRaNpC2igsN0h6setb8K4FWJIAp6UzGKxSsauVxdxAqGWTipGOBVK4lUZGaGJEck2D1pomyetUppMmoTPt70ijSaXjrVd7gDvWbLdgd6ozXoz1qblpG6LketPE4PeubW9GfvVINQQfxUrjsdEJAe9IZAO9YY1FMfeoTVIlmjMhygYFvpTCx0lvhXLSnYqjcc9qjlvnYn7N+6BGNx6ms3U9RtljUQSeaHbLc9fSqUc0lwRubavoKu9jFRctWaCtfqf3d8p9mQf/XpXl1UgeYqTKDn5R/Tg1LZpGAORWpEYxUmm26M+31Qr8lxbYPtwfyNXZLi3u7ZoThdwx+8HT3qyyRSrh1Vh781XawizmIlfbqKepOm+xVW2Dgh1DOvSWPqfc+tDo+0CT5wOjjr+NWPs0icgZ91pctuBzyPWmVe5RaIEcVGQV4bketXmQ7iQAM9qYyA9RilYdzHv7RZkIIFee6/p8llOWUHySfyr1OSEge1ZOqaetxEwZQQR3pwm4O6FOCqqzPP9FGb2L6E16Ba48sVxQspNO1EEg+V0B9K62xuFeMYNehCSkro8ycXB2ZoCniolapFNWSSCnCmA07NIB4paYGFG4etAEgpaiMgHeopLlEBJNICS5kCITWjpYgt7dWm2+YeTXO+a9zKAgO0HJJ6VeW3adh5rnb6LxXHXqczsjuw9Nxi29Lm3Jd2suQGXNZ13ZRTjOB9RTv7Nttn7pcN65q7awnywr8kd6xWpve2xzxsLmN/3UgK/wC1VyCxvHwDIoHrgmt5LMHqaspGkQ5xWnPLuYuMN7FOx0+KFQXXzH/vNzUs8EcmQUXHpilub6GEHcwrMfW4NxAaoKV+hLLp9rGhJVF/SsS8aJJGFpKkboN33sA/41cnvNPeMmZCTnqZAP61zV9svZTDZwLyfvLnA/Huf0oScnaJpzxhFuR1fh+/N0oNdbb8gVyvhzTmtYEDde9dbbLgV3nmFmMVbiHSq8Yq3EOlJgWIxUwqNBUgpDFooooAik6mq0hqzJ1NVZaAKctU5auS96py1QinKM1RnhVuorQkqtJTEZE9lG38Iqm+nR5+6K23FQuooAw5dNiIIKiqh0tVzsLLnrg9a6JkFRGMelDSe6GpSjszEg0uKM5281dW3VRwKubBRtpkmbdxYibA7Vp+FLxRaJGTyOKhmj3KRXP+dJpd6x5ELHOfQ1hXi2rrob0JJNxfU9GkcMMiq7daybDVFmQfMPzrSSQMM5rmR02sRXZYIdtcxfXdxDIS6ZT1FdWcE89KrXVlHIpyoOaTRUWupyxvVZNykEVlXmqKhIyK0de0OYqzWbmNj6DIriZbKeK4K32889exp0487sFSXIrpFyfWCxITLH2qAXF1KflQ/jWlZWkAUbVWtOO2UDhRXUsPHqcrxM+hzwS7b2pRbXR6uRXTLbD+7Ugth6VapQXQzdab6nL/AGW5/wCejUn2a5H8ZNdX9l/2aX7IP7tP2Uewvaz7nKILiM561K2rtaKGm+Vc4zXRvZqe1cx4xtlSyjRVJkeQbQO+OtZyw8GaxxM1uXrfxRbrjMy4rZs9einGY5lb6GuKttH3wKSvUelQvpEsbZjJUjoRxWbw3ZmixV90elJqpXBVsitOz1RZgMnmvI1k1O2+5O7D0b5v51ND4hvrVgZYlcD+6SDWbozRqq1OW57RBMGPWrZRJR8yg155oHieC9UBZNsg6o3BFdhZagrgfNUXtoxuPVF2SyX+BiPrzUDW8idQCPar0UysOtScGgm7RkMg7jFQvCp4xxWxKgPUCqcka59KLFKRz2p6Sk0bcZzXOG0ubJz5YLJ6V6AYz25pjWaSdUFOMpQd4jmozVpHGwX3Z8q3oaupcqe9bsuixSdYwfwqrJ4aUgmMsh9jXQsR3Ryyw/ZlJZx6017lEGWYAe5pl3ol9DxHID7kVDa6XIrZuF3t6tzRLEpbIcMK38TBtQDH90rOfYUnn3T/AHYsfU1qQWg6bQPwqz9kA7Vi602bKhTXS5h+XdyfecL9BUsVgMhpGZz7mtcwqo6VG5C9KzlJvdmsYxj8KIERUGAMVYjNVncDqar3GoRwrlnVR6k4qblWNuOQLjJqYXiRjJIrh59cklbbZxtIf7x4FMW31O9OZ53Rf7qfKK2jSnLyMJ1YR63OxuvEVtbKd8ig+ma56+8V3FwSllCze54FR22hRKcyDc3qea17exhjA2ov5VvGgurOeWIf2Uc55Wq37ZlfYD2Aq9beHC+DPI7H3NdJFGB0Aq3ElaKEVsjJ1JS3ZhQeH4lI4zWxY6bHCRtQVoRRirkSgVQh1rFgCtGIVWiFWo6QFmIVbjFVohVuOkxkyCpBTV6U4UgCiiigCKTqaqyVak6mq0lAFOUVTlFXpRVSQVQilIKruKtyCq7igCq4qFhVl1qFhTEV2FMIqZhUbCgCI0lPIppFMQxhVG9tVnjIYVfNNIzTA5Jo7jTZN0eWi9O4rX03XEcYZufQ1engWQEEVg6jo4Y74sqw7isJ0U9Ym8K7WktTsLe7SVQQatI2fpXnEN9eae+2UF0H8Q610Wna5HMo+YVzSi4/EdMZKesTpJIlcVk6ho8VwDlBk+1WY75WAwRVuKZXHJqbXKu0cHdaJPZuWtzlf7ppsNyY22zKVPvXfSwrIORWVe6THKD8taRqyjo9TOVGE/Ix4ZUccEVaQA1RudKltyTCSPY1Xiu5IX2zKR710wrRloc06MoG0FFO2Cq0F0rjrVpWBrUyEMYrlddkhGqgzkCK3jySfU//AFgK67PFed63m9127Qn93E+W9yOB/KgRFe+InCn7JbhYx0aQ4z+FUYdY1K7/ANVAjD1wcVbgsY76VmuDttIjjA/iNXGud/7nS7dSo4LdAPxoAqrPeAZntAR/sHn8qike2n++DE3o4xVp471Pv3MKn0xULPdAYeOGYf7PFAzMuLFoXE1u+1hyGU1uaJ4meFlhvvlboHHQ1lSNAM7o5bZvUdKrTQl1yuyZfUcGs50lM1p1ZQ2PWNO1dZFBV8ityC/DAZNeHafqc1i4SNyVH/LN+o+ldfpXiRJcKzbW9DXFOnKB2QnCpselidWHWmsQTxXN2upK4GGFacF2GxzUplONjSUc1agjB61TikBqzHJtqiWXPKUConO2kMxIqJmzQQglKuvIrOeIbzxVw1WlYBuTSZcRmxQOBUMrBRTpZlUHmsm8vQAcGpbNErktxcBc1lz3eThapXt+iH943J6KOSapFbi9BBHlQ9wOp+ppwpSnsKdWFPfcW61Ny5jtR5knQnsKba6TNdOJbtyxPY9BTbG7tYjbPCm63kBLu3BTkY49PmH4EGr9zqzLY3ktpFmW1b5o5ONyBsEj8m/Ku6nSjDY4KlaVTfY0bWxihACqKuooA4FZ8OqWszRJAxkmcgeWv3l9Sw7Y960xWpkKoqZBUa1ItAE6VZjNVUqeM0hlyM1ajNUozVqI0gLsZq3FVKI1dhpDLkNXIxVWGrcY4pDJV6U6kFLSAKKKKAI5Opqu4qw/WoXFAFSQVVkFXZBVaRaoRSdarutXnWoHWgCi61Cy1ddKiZKYFJlqNlq2yVGyUCKhWmFatMlRlKAK5FIRUxWmlaYEJFMaMHtU5WkK0XEZtzZJKDlRWDe6QyMXgJRvauvK5qJ4gw6UOz0YJtPQ4yK8urRsTBiPUVr2OsBsfN+tXbrT0lB+UVh3ekMjFo+D7VhKgt4nRDEPaWp19nqKSAAsPzrRWRXHUV5os1zaN82SB6Vu6XrauAGPNc8k4/EdMWpaxZ012nynC5rBvYEkBBj5+lbEF4kg65qxsjl7CoauUnbc4WS3lgbMeQPSpoL50OJARXXyWEb9hVG50VHzgCtI1ZxIlSpz8ihBdK44IrjtVha11XU2/wCeoEqe45z+tdRcaTNAcxE8VjaxFLIqM64ljyBnowPUGumnWjLTZnLUoShqtUYoQbbG33ERuCz4P3u9N1XUJYHWz09EQBc5x0qJySyCNlV4m3KjnBHqPcU2aSOWYMcxTrwNw6/41uYFG2glvTI13K5dDjBOKZcRSWvMU7BR2JyKuTMwYsQys3BKDINVXihPLyTSH024pWC4yPUphhZI/M4ycdqa88Mjfuswy/lmpw4iTCW2F9m5rJ1N8kFI2Vu2cZoAvuwuIiJQN68Gs0TvC+CSwB/EfQ1Layu1uxfqDtJ9aS0tZrmXMcZekxo07XW7mywdzSR+55rrtM8QCWNWO5Sex6iucsfDl5cyKZlCxjtXTJoflRBQORWE6EZbHRDESjo9TpNO1dJGUFxk+9dJbvvUEEEGvMTYXEBzGTxWnYa5eWPyzRs6jutYujKJt7aEvI9GHTmmu6juK5BfF8BTDB1PoVNU7jxXGfuCRz6Kp/rU8suw049WjsZrhEUnIrAvNRUynDCubudav7wbbeHy19W5NV4tMurg7riVznrzirVGUt9BOvCO2pqX2sIMqJNx9F5NZNzdzyDODGh6n+LGeT9BmrH9kRPfw2zrmPy2ldf72CAAfzz+VPu7drPy7ZEMshfNrnnP95GJ7AHr6e4rWNCK1epjPEylotDJnnSC+S2hI+0+YoZph8rZDYXPYkgfgc81qyXoiRjbj94Y/NQSNjeA3zpjswA/Wq9tpD3+GmiAIHluMkZjycDP99GXr6Y9a2xotvJIst2omfbhlYfIzcZbHY8CtznZzzWq3Mki6YpuIZIcrtIVoGP3Qc9sFhjrjjpitez0ImXzr+QM5RY2SHKrIF7t6k8fl3rdVABgACnAUAMVFDEgAE9TjrUgoxSgUwFFSLTAKevWgCVamQ1AtTJSAtRmrMZ5qpHVqPrSGXoavQdqowVoW46Uhl6EVbQVXhFWkFSMeKKBRQAUUUUAMbrUTipmqNhQBXcVA61aYVEy0wKbLULpV1lqJlpiKLJUTJV5kqJkoAoslRMlX2SomSgCiyVGUq8yVG0dMRSZKYUq4UphSgCoUppWrRSmlKAK22kK1Z2U0p7UAVilRPAGB4q9spNlMDDudOSQH5axLzR2Rt0WQfau2Meaje3DdRSavuCbWqOFivLm0bEgJUd617PXASMsK1LrS45QflH5Vg3ugkZMYIPtXPOgnrE6YYjpNXOmtNTjkA+YVoJMjjgivNWivbNuNxFWrXW5oiBJuB96wcZR3R0RcJ/Cz0JkVxyAap3WmwzDlRWDaeIAcbjWtb6xE/Uj86m6ZXLJGLqfhS0uc74hn1HFYVz4IG0+TcSj2f5hXoqXUMg6inMIyOMVanJbMzcIv4keUnwdqCEqlymPxH+NXrPwJdS4NxqDKPRVFehGBWarCRhRVe2m+pPsaa6HATfD2MocahdFv+AgfoKyLr4fTxZ8qcEHqSOT+NepXMDSx4SRo2HQqa5zVF1yAhrZknAPKkYJFT7Wa6lqlTe6PKNT064sZRaNAUOflPUH3zXd+ENIjtrZWdctjvUuopeahB/pNj5TjozEcGpPDl2ZYlB4I4rpo1fabnPXo+ys1szoVhUDgCl8lfSp4hlRTttbHMUmt1PUVBJZI38IrTK0FKAMNtLiJ+6KRdMiB+6K2zH7UnligDMjs0XotTrCB0FXNg9KNlMDLu7SUzRXFts86MFdrnCspxkE9ugNQSaZJcETzyqLtMGEoPliPt3Oeh9R6Vt7KTZSAgC4HvRtqfZRtpgQ7aNtS7aNtAEWKXFSbaNtADAKcBTttKBQAqipUpiipUFICaMVbiHNVo15q7AtIZbt16Vp268iqdunStKBaTGWohxVhajjGKlFSMKKKKACiiigBGphFPNNNAETCo2FTkVG30NAEDLTCtTkj0P5VGzL7/kaYEDJUbJVgundgKYWj/vr+dAisyVG0dWjsPRl/OmlR2IpgU2jqNo6vFKYUoAotHTDHV0x0wp7UAUjH7Uwx1eMdMMftQBSMdJ5dXDH7UhjpgU/Lo8urfl0nl0XEVdlJ5Zq15dHl0XCxV8qmNAD1FXfLpfLouFjGn05JByorJu9AR8lVFdd5dIYge1AWPObjw+6nKZH0qqbG9tz8jbh6MK9Me2VhyKrSaejdqhwjLdFxqSjszgob64gOJomHuOavQ65COGk2/Wukm0lG6rWfcaBG2fkrN0I9DZYiXUWy1RJcFWDD2rWiuUcdea5SbRpbJzLaceq9jUtrfBm2S5ilHY1hOEoehtCcanqdZvXGc1nXuoeVkCJm+hFY19qpt0OZ41A67hXPXOrS3DkWzSSN64AWoV5aRRraMdZM1/EOtJHpsgeOVXk+WMberfWqfhS0dIVLDk1BZ6Vc3sqS3sjPt+6vYfhXZ6dYCJVwK7KVPkWu5w1qiqPTZE8MfyipDHVpYsDpS+X7VqYlPZSGOrhj9qTy/agCmY6DHVvy6Qx0AVPLpClW/LpPLoAq7KTZVox+1Hl0AVdlJsq15dJs9qYFXZSbKtbKQp7UAVtlG2rGyjZ7UAV9lKFqfZ7U4JQBCq1MiU9UqVI6QCxJzV6COo4Y60II6Bk9vH0rQhWoYI8VcjWpYyRRxTqBRSAKKKKACiiigANNNOpKAGkU0ipMU0igCMimkVLikIoAhIppXPapiKQigCuY17qPyqNoEP8C/lVorTStMCoYE/uL+VNMK/3RVsrSFKBWKRgX3/M0wwL/tf99GrpSmlKAKJgHYt+dNMJ/vt+n+FXilNKUwKJhP8Afb8h/hSGJv735irxSm7KAKRif1X/AL5/+vSeW/qv/fP/ANeruyk2UAU9j+i/nRsf+6v/AH1/9armyjZQBT2v/cH50Yb/AJ5n9KubKNlAFLB/55t+n+NGPVGH4Vc2UbKAKfHo3/fJpOPRv++TV3ZRsoApbVPt9Rimskfdl/Or+yk8ugDKlgiYdU/MVj6jo0Fxk7Vz6iutMee1Ma3U9VH5UAedTeGw7jzGd1HZmJq9ZaAkWMRgfhXZGzjJ+4v5UCzjH8C/lQklsNtvVmPbacsYHy/pV5IAo4FXPsyD+H8jR9nX/a/76NAir5ftSGOrRgHq3/fRpPIPZm/OgCr5dIY6tGE/32/T/Ck8lv7/AOYFAFXy6Qx1a8p/7w/75pDE/qv5UAVfLpPLq15b/wCzSeW/91fzpgVfLpPLq35bf3V/P/61IUb+7+tAFQx0nl1b2t/cP6U3af8Anm36f40CKvl0hjq1t9VYfhSED0b/AL5NFwsVfL9qPL9qtYHo3/fJpPl9cfWgCt5dKI6sfJ/eX86coX+8v50AQrH7VPHF7VKkeemKsRxUhjYYuavwR02KPpV2JMUMB8S4AqcCkUU8VIwooooAKKKKACiiigAooooASilpDQAlJinUUAMIpCKfikxQAzFIRUmKTFAEe2mlalxSYoAiK00rU2KTbQBCVppSpytJtoAgK0hSp9tJtpgQbKTbVjbSbaAINlJsqxto20AQbKTZU+2jbQBBso2VPto20AQbKNlT7aNtAEGyjbU+2jbQIr7aNlWNtJtoAr7KNlWNtG2gCtso2VY20baAKxSk2VZ2Um2gCtspNlWtlJsoAq7KQpVrZRspgVNlGyrWykKUAVSlIUq3spNlAFTZSeXVvZSbKAKhjpPLq3so2UAU/Lo8ureyjZQBV8ulEQ7irISnKlAFdYE7qv5VPHbp/cX8qmWOpkSlcBscCDoKtouBSItSAUhigUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGKKKAEopaKAExSYp2KSgBMUmKdRQAzFGKdijFADMUhFPxRigBmKTbUmKTFADNtJtqTFGKAI9tG2pMUYoAj20bafilxQBHto20/FGKAGbaNtPxRigBm2k21JijFAEe2jbUmKMUAR7aNtSYoxQBFto21LikxQBHtpNtS4oxQBFtpNtTYpMUARbaTbU22kxQBFtpNtTbaNtAEOyk21Nto20AQbaNlTbaNtMCApSbKsbaTbQBBso2VPto20AQbKcEqXbShaAGqtSqtAFPApAKop4pBS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGKMUUUAJRS0UAJRS0YoASkxS4oxQAmKMUuKKAExRilooATFGKWigBMUYpaKAExRilooAbijFOooATFJinUUANxRinUUANxRinUUANxRinYoxQA3FJin4pMUANxRinYoxQA3FGKdijFADMUYp+KTFADcUmKfijFADMUYp+KMUAR4oxUmKTFADcUoFLilxQAgFOFAFLQAoooFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFYvia+vLJLBdPa3SW5uRCWnjaRVGx26Bl5+Ud6ANqiuY+0a/wD8/wDpX/gBJ/8AHqPtGv8A/P8A6V/4ASf/AB6nZhc6eiuY+0a//wA/+lf+AEn/AMeo+06//wA/2lf+AEn/AMeoswudPRXMfadf/wCf7S//AAAk/wDj1H2nX/8An+0r/wAAJP8A49RZhc6eiuX+06//AM/2lf8AgBJ/8eo+06//AM/2lf8AgBJ/8eoswudRRXMfadf/AOf7Sv8AwAk/+PUn2rX/APn+0v8A8AJP/j1FmFzqKK5f7Vr/APz/AGl/+AEn/wAeo+1a/wD8/wBpX/gBJ/8AHqLMLnUUVy/2rX/+f7S//ACT/wCPUfatf/5/tL/8AJP/AI9RZhc6iiuX+1eIP+f7S/8AwAk/+PUfatf/AOf7S/8AwAk/+PUWYrnUUYrl/tWv/wDP9pX/AIASf/HqPtWv/wDP9pX/AIASf/HqLMdzqKK5f7Vr/wDz/aV/4ASf/HqPtWv/APP9pX/gBJ/8eoswudRRiuX+1a//AM/2l/8AgBJ/8eo+1a//AM/2lf8AgBJ/8eoswujqMUVy/wBq1/8A5/tK/wDACT/49R9q1/8A5/tK/wDACT/49RZhc6ijFcv9q1//AJ/tK/8AACT/AOPUfatf/wCf7S//AAAk/wDj1FmFzqMUYrl/tWv/APP9pX/gBJ/8eo+1a/8A8/2l/wDgBJ/8eoswudRikxXMfatf/wCf7Sv/AAAk/wDj1H2rX/8An+0r/wAAJP8A49RZhc6eiuY+1a//AM/2lf8AgBJ/8eo+1a//AM/2lf8AgBJ/8eoswudPRXMfafEH/P8AaV/4ASf/AB6j7Vr/APz/AGlf+AEn/wAeoswOnormPtOv/wDP9pX/AIASf/HqPtOv/wDP9pX/AIASf/HqLMLnT0YrmPtOv/8AP9pX/gBJ/wDHqPtPiD/n+0r/AMAJP/j1FmFzp8UYrmPtPiD/AJ/tK/8AACT/AOPUfafEH/P9pX/gBJ/8eoswudPijFcx9p1//n+0r/wAk/8Aj1H2nX/+f7Sv/ACT/wCPUWYXOnxRiuY+0+IP+f7Sv/ACT/49R9p8Qf8AP9pX/gBJ/wDHqLMLnT0VyU+p65aSWrT3OmyxSXMMLqlm6Nh3CnBMpwefQ112KQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPeLv9bon/X//AO0Za6GuV8f3X2ODR59hfbfj5Qev7qWk3bVjSbdkW80Zrn18Sw/x28o+mDViLxBYyHDO8Z/21oVWD6lOhUXQ2M0marw3dvOP3M0b/RqmzWid9jJprcdmjNMzRmmA7NGabmkzQIfmkzTc0ZoAdmjNMzRmiwD80ZpmaM0WAfmjNMzRmiwXH5ozTM0ZosFx+aM0zNGaAuPzRmmZozRYLj80ZpmaM0WC4/NGaZupN1FguSZozUe6jdRYLkmaM1HmjdRYCTNGaj3Uu6iwXH5pc1HmlzRYB+aM0zNGaAH5pc0wGjNIY+im5pc0ALRSZozQAtFJS0AZ2t/6ux/6/wC1/wDRyV2NcdrZ/d2P/X9a/wDo5K7Gpe40FFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXI/EgbrLSR/0/D/ANFSV11cn8RBm10j/r+H/oqSpn8LLh8SOUMQ9KYYQe1XSlN2Vw2PRUjOa2GcgYPtUkc93D/qrmZcdtxI/KreykMdCTWw7p7iR61qMX3mjlH+0uP5Yq1F4kkH+utPxR/6VTMIpjQ1aqTXUh0qct0bUfiK0b76zR/Vc/yq1Hq1jJ0uYx/vHb/OuXMFRtb5q1iZrczeFpvY7NLq3k/1c8TH/ZcGpQc9DXBtbe1AWVB8krr9GNWsU+qIeDXSR3uaM1wa3N4h+W6m/wC+jU8eqX6/8vDH6gGqWKj1RLwcujO0zRmuRXW75erqfqtSL4huh96OJvwIqvrMCHhKh1WaM1zK+JZB9+2B+jYpx8Telqc/7/8A9an9Yp9yfqtXsdJmjNcrJ4iunz5UEafUk1Vk1PUZus5UeigCk8TDoUsJPqdmWAGScD3qCS+tY877iEe28VxTpNMcyyu/+8xNC2lZvEvojRYRdWdVLrlgnHnbz/sqTVZ/ElsPuRTN9QBWCLWni1qHiJs0WGpo1W8S/wBy0P4v/wDWqM+JJj0tkH1YmqItqUW9T7ap3K9hSXQtnxDdnpDD+v8AjTT4gvf+eUP5H/GoBBS+QKXtZ9x+yp9iQ6/fHokI/wCAn/Gm/wBvah6Q/wDfJ/xpvkCk8gUe0n3H7On2Jf7evh1WE/8AAT/jR/wkF6P+WcH5H/GovIFIYBR7WfcPZU+xIfEN/wD884P++T/jQPEN/wD3IP8Avk/41F9no8gelHtZ9x+yp9iceIb4dY4D/wABP+NKPEl33ghP0yP61XMApPIHpR7WfcXsafYvL4nlB+e1U/R8f0qZPE6H79rIPowNZJgHpSG3FNV6i6ieHpPodBH4jsm++Jk+q5/lVuLWLCT7tyg/3sr/ADrkvs/tTTb1SxM1uQ8LTex3MVzBL/q5o3/3WBqbNeem254qaKW7g/1VxKo9AxxVrFd0ZvB9md5mlBrj4da1CL77JIP9pf8ACr8PiMY/0i2YH1Q5/nWqrwZlLDTR0VFZlvrNlNgeb5Z9HGP16VoI6yLuRgy+oORWikpbMxlFx3RR1r7lj/1/Wv8A6OSuzri9Z+5Y/wDX/bf+jlrtKT3BBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxA5t9I/6/h/6Kkrqq5bx/wD6jR/+v4f+ipKmWzKh8SMIrTStTYpCK5LHdchK03bU+KCtKwXICtNK1Y20hWiw7lfZSeWKsbaTbRYdysY6Y0VXNtGylYOYzWhqNogOtaZjFTxRR20fmzLukP3Uo5bg6nKjHjsp5RlIzt9W4ok0+4jG47T7YNa39qSRt89uAnfackfpWhDLDcoChVgfSrUEYurI5NIwxIIww6g1IIBWpqVgcPLABvUZUHgMfT8ayrO6iuUBjOG7oeo+tQ4WN4VOZEqQAdqmWIelKpqRaVhtiLEPSniIU9alUVViGyERD0pRF7VYApwWnYXMVfLpPLq0Uo2UWDmKvl0vl1Z2UoSiwXKvl0eXVrZRsosK5U8ujy/areyjYKLBzFTy/ak8v2q5s+lJsosPmKhjppjq6UpNlFg5il5ftSeXVzZR5dKw+YpeXR5dXfLpPLosPmKXlUhiq95dIY6LBzFEw+1IYAe1XjH7UhjpWHzGc1sD2pqRyQtuhkdD6qcVpFKQx+1Fg5iq1/dvc6bDM4dGvrbkjn/WrXqleWzoBdaacf8AL/bf+jVr1Kuqk21qcVdJS0CiiitTEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArl/HozDpHtfD/wBFSV1Fc/4yhMtvp5H8F0G/8ccf1qZbMqHxIwMUYqXyz6Unln0rlsdZHioXlVWwetWTG2OOtZNwLmGbeIi34ZpPQqKuXldWOOh9Kfis62S6uLtZZE8tFHTua1NpoWoS0IsUhqUrUZFMAoApDUkKbyc/dHX3pCegsahcOwz3Vf60jIWYs5yxqwxyaQLmqM3qU2gz9KgWzaN98LmNu+Oh/CtbaKYyelKwiqbpvlhuAAzfdYdD7f5/+tXKa/pNzbaiz2yMQ3zgqcEHv/n3rqdQhzGHxnacn6d/0pwjF1D5Dn94nzRue/t/ntVv31ysqEnTfMjibXWbmBtlwokA6hhhhWzaavazEBmMR9HH9atXNlDdKRPECRx6FT9aybjQ3QZtpN4/uv1/Oue0kdfNCXkdFEwcBlIIPQg5qda4yI3FnJgmSFvTsf8AGta21acY8xUkHqODVKXciUH0OhFOFZ8Gp28nDExt6N/jV5HVxlGDD1Bqk0ZtND6KBRTEFFFFABRRRQAUUUUAFFFFABijFFFACYoxS0UAJto20tFACYo20tFADdtJtp9FAEe2m7KmxRiiwXKF2uJ9OP8A0/23/o1a9Lrzm+H73Tv+v+2/9GrXo1b0tjnrbhRRRWpiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5R8SviHrXhPxSttJax6d4dW2Ev9rXGmz3kUkpJzGWiYeSAB94hz32kVJN8WNCvb+LRmtr19W+221osMSIRL50RkWeMlhmHaCdxwcY+XnFdd4g8D6D4gnnl1S2uZDcALcJFezwxzqAABIiOFkGB0YH9TXN6z4GsLP4j23jItAHjsk0y0tIrcIIsbiX3A8nblAMDC8c0pbDjuczZfF3RL1LRrfRddYXkNzNbZjgHmi3J80D97wQATzgEdDnipLr4s6DHFHLbabq95G2kLrbtBHEPLti5Qlg0incpHIGfbNaln4H8L2aWC22l7BYpcR24+0SnYs+fNHLc7snrnHbFYcvws0GXxBDcuZRosWkrpKaYksqAqJTIC0gkDOvONjZB4J6CsrxNrSMuz+J62Xi/wAVPqf2y88NRS6YllJbwxAWq3MO7c+SrkMSD0YjHQV0UPxN0GbU304Wmpi/jubq2mt/KRnhFugeSRgHPyEEbSMlicAVo3fgjwvdf2j52lJjUGt3uFSaRFc24xDgBgFCgYwuAe+aq6b4Ks7bxz4k8TTz+Zc6xAlsqwoYGgjChWxIrbtzbVO4bSMDHrSvELSMM/FTTNR8OjVdJjmgg+1W0G6Vbe5Y+a5UAxx3AaM8dXwR/dbkVu6B470nXvFF5odhBcC5tZZIZHmkgjO5OpERk84r23eXj3qX/hAPCz/aTNp81xLcywzSzXN7PNK7RHMeZHctgemce1XrTwrottrsesiG6n1OIOsU91ez3BiD/eCCR2CA/wCyBR7o/eOe8S/EfSNA1TWLO80/VJI9I+zm9uokiMUKz42NzIGIycHCk+1Mm+Iuire/Zfs2oGQ62NByI0x55Gd33/ue/X2qe7+HGlal4z1nXdake+g1AWxWxLPHGjQjALhX2ygnBwy4FX5/AHhibWDqj6c/2w3qaiSt1MqfaV6S+WH2bvw575pe6P3jz7wb8RZ201IfEIupLy7ur2K0vPIiMJ8nJ8sqrK2QAOoAP96tjRfippcw0WykiuZr+/to7gNtgtEIdiowss/Jz/CjOf5V0mnfDnwtZXf2q30196+dsEl1NIkZl4kZEZyqluhKgGg/D3w39nsrY2dy9nZbDBavf3DQIU+6fKL7CR6kGjQV5bHSKyszKrAlThgDyD15/OnjisDXfD0st9/a+hXC2OtKoVmYEw3SjokyjqPRh8y9uMgu8P8AiGPU55rC8gfT9ZtxmeylIJx03o3R4z2YfQgHipsVc3gaM5phFICRSHYe4DAg9KolTE20krg5VquhqCAw56UBsVLpQ+2dAAG+WQejdjUBWom1fTY7oWyybxKdjlB8o9yf8Kx9f1O60y8Nv5US4GVdmJ3D1xSk09TWnTm3y2Nt40ddsiqy+hGapy6TC3MJMTenUVzJ8RXzHiSMfRKU63fSIVNxjPHCgGs+ZM6fq811NS5T7K+2aSMn2cfy60RORzE5X3U4rDgkVHLSIsuezk/0NX4Lq1B5tAp9Y5SP0OaRcqLS01NmHULqPjeHHowq3Hq4/wCWsJHupzWE91FjdGJcejYOPxp0dxG/fB9Kd2jF0+6Olj1G2f8A5abT/tDFWEljf7jq30Oa5kbT0NGznI4PrT5jPkOporm47i5j+5K2PQnP86sx6pOo/eIjfpT5kJwZt0Vmx6tEfvxuPpg1Zjv7Z+koB/2uKq6J5WWaKRWVhlWBHqDS0CCiiimAUUUUAFFFFABRRRQAUUUUAFFFFAFW+/1unf8AX/bf+jVr0avOb7/W6d/1/wBt/wCjVr0at6WxzVtwooorQyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vxwxWDSwP4rwD/wAhyV0lcx46GYdI/wCv4f8AoqSplsyofEjLoyaSiuY7Bc0ZNJRQIduNG402igB+80hc4ptKOo+tAFleFA9KM0gNGaZA6sfxDoNprkMQuPMhuoCXtruA7Zrd/wC8jfzByCOCCK1s0hNAHKafrt3pt9DpPioRx3Mp2WuoRrtgvD2X/pnL/sHg/wAJPQdMah1OytdTsprPULeO4tZl2vFIuVYVyMl3feCVb+0ZJ9R8ND7t0cvcWI9JO8kf+2Msv8WRlgbjWh11xPHbxGSVtqj9a5fV9TlulKklIe0Y6t/vf4VFeaoupbJ4XV4GAaIo25Sp6EEdc+tFjZvcSgAZc8knoo96mMXN6bHV7tBc0tWZf2Sa4YDDDPREHJrqLrS5tT0WAXce28tvlDSc7k9Tj/PFa1laQ2iYjUbu7nqatBtpDdcdR6itVKMdIo5qk6lTWTOUTwpLjJnhA9lJo/4Rwo5Vpk9vk/8Ar11GRDLs/gb5kPqKkkiEiejdQap1p7GKhHdnJy6AyRlkKSEdgMGqsFjZSqY53kt5+gJ+7XWqTkqwww6imzW0M/8ArY1Y+uOfzpe15laZoouL5oM5O3stkjW90Qh/hbGQfxqyNJVuCUDDtk1sSaTD/ASv15phsnUYyGA6e1Q3bbU15766r5mcukyp/q5Bj03VMthcj+5/31T5IbhOjuB+f86iaS5j6OT9Rn/Cocu6KUW9Uxs0UsIzLHgf3u1MDo3eobiW4lP71g4HYfL+lQqQTgEhh1B6isrmln1LuwHpSFBVYNIOhzUizMPvA0wJ1Ug5UkH2NWI7q4TpKT/vc1VWdT1AqZXU96aEy4moSj7yKfpxVhL9D95WX9azxg9CKeFp3JcUaiXMTdHH48VKCD0OayAopwBHIJH0p3J5TVorOWSVejt+PNSrcyDqAfwp3FYuUVXW5B+8pH0qVZUb+L86BWH0UAg9DRmmAUUZozQBVvv9bp3/AF/23/o1a9Grzm+P73Tv+v8Atv8A0atejVvS2OatuFFFFaGQUUUUAFFFFABRRRQAUUUUAFFFFABRRXjfxJ1W1tfjn8PbCXX7mzt7tbr7daR6tLBG5VAbbfGrgfNJkDj5/undjFAHslFeBaZ8YfFDzaRPcafpd5bahcarbLaWsEiT7rRC6bXMjBi+AMbRz354oWnxs8Tz2l5JAvh6/mj8NPrgitbeUm2mE6oYJf3pJKqSW4U9OgHIB9GUV86658XdR1ObVYLQadPY2Vxo3kTWk88Zc3IBlDPFKuQrZAXpxhg1bWn/ABW8RSeI4I7m30ltMk8WXXhwxR28omCRgFJQ/mEFueRs5xxjPAB7hWN4ntjcwWeP+WdwH/8AHGH9a+efEPxevvFGkeJtE/0K60u70PUJI50tRbTRvECCrR/aJSOP74jbkHGK7D4s4/4Z10XPZNK/9DipNXQ07O53zWjelJ9lb0ryWH4i6nYX91Zxiws4J/FV/pr6lqEk88FtHEqFdweXhmLEBVZEGOFFZNz8b9XTwTpOphdMTWLq1ubprVrJvJdYpnT5ZXuUwcJ91RI2eQMVl7M29oe4fZW9KQ2relePa38XfENumr3dlaaQLTT7fSrnyZoZGeQXaqXXeJABgtwdp+hqfWfix4g0t9Ts5LHT5JbPWv7Ok1FYikEURQMrOkkygMSSPmlVf5FezH7Q9ZNuw7UxoWHavJf+Fo+KJ7XT1jt/D8N3Jo97qMzI32yJnt2OAjRTbQrAc/MxUnvjBPAPirV9a+J9vNqep29pZapodteQadIH2yMyEsIAZMbgQSWCn5RjAxupcgKoerlSKQfeFYsPiiGPUF0/X7V9Hv5H2Q+cwaC5PbypRgE/7J2t/s962yMNUNWNE7kmaM1HmoZruCAfvZVX2zzRcEr7FrdSZrDuddRQRbxlz6twKybvU7m4BEkmxf7qcVLkjaOHlLyOivtVt7Ulc+ZJ/dTn865nUL+W6kzKeP4UHQVVG9+EGB61asbGS4fEK7vV2+6KuNOU9XoinUp0NFrI5hNFvtIujc+G4PPgcl5tKyFU9y8JPCN6qcK3+yeT6B4VvrDUdLE+nTeZhikyspSSOQdUdDyrD0NX9Pso7NCFyzt95z1P/wBasjXfDrT339raJcDT9bVQpl25iuVHSOZR95fRvvL2PUG5SVuWOxy+83zS3OhzSisHQPEC6hPJYX8B0/WoV3S2cjZyvTzI26PGT/EOnQgHit4VmVuDR+dEYcgSD54j/Mf59aks282EHuOCD2PpVe5do0WRfvIdw/wqeOOQTGaHBSTBdW4z/tD3q1qjKWjIb4iKVGY4HQmlBBGQQR6ioNVIkO3096xtgDEZOKiTsbU1dG3JKnI3DNUbiFpTkSMPo2Kyp7rySQOCKiXVeeTWbkupsqb3RpNBeJ9ycsPRuaYZJFH76L8U5qCPVh/eFTx3ySdcUropRa3RDI0D8B1DHseD+VZl2jI25OWXp7+1X9QMbRtis9JTLBljllO01DZtFaEsUwZQQMg81Or57Gs6xbEWBjAYgfmauK/uKtTXVGMqb6MnG09Qacqr2BqNW9xUisPWq510RPI+rJQSBxUiSEVErCpFalzXDlJ1l9aeHBquCKdkUCsWAR2p2aq7hS7z60xFofSnCqqyGpkZj/CaAJxx0qQOw71EA3cUBsdaYiwHPelDioA1KGouKw29OZtO/wCv+2/9GrXpFeZ3JzPp3/X/AG3/AKNWvTK6KWxzVtwooorUxCiiigAooooAKKKKACiiigAooooAKKKKAGyIJI2RtwDAg7WIP4EcisHQfB2i6FqtxqdjBcPqU8Qgku7y8mu5TGDkIHldiFzzgEDNdBRQAUUUUAFZPiO4+z2sHON8wT/x1j/StauZ8cttg0vH8V6B/wCQpKmWzKj8SMLXLG31q3WC9kvFjBJxbXs1sTxjBMTKSPY8UaLa2eh6VbabpNvHa2Nuu2KFOijOfx5JJJ6k08k0wmua7OvlRdN69NN+w7VRZqYWpXZSii+dR9Qfzph1JO+4fhWexzUEpPalzMtU0yzqc1lqFnLa31ql1bSrteKVAyMPQg1x7Q6zoO4+HJ/tVgP+Ybfylig9IZjll/3W3D0K1uu5qJhuPzNjNVFSlsJ+zjuZVh4qh1WZ7d5p7a/QZksrgeXKo9dvRh/tKSPerTZb7qn61Yu/DGma5EqagElMZ3RvGSskZ/vI/DKfcVXih1nwucmF9f0sf8tEVRfQj3HCyge21vZjTcF1YLENL3UEltOqbzGwX1waqA7ZQJcqpPJxnFdbo2safrdobjTLlJ4wdjqMho27q6nlW9iAaddaXa3AO6PaT3XinHlTutPxB1ZSVpar7jOsI9K2qz3CyN6SfKB+FbEVxb8LFJGR2CHP8qx38OjdmO4IHoV/+vVmx0g20odrhmA/hxinK71cvzM1yL4U/wADWHNLmkHFFQBm6/odprcEa3PmRXEDb7e6hbZNbv8A3kbt7jkEcEEcVk6frt3pV7Fpfivy0klby7XU412wXZ7Kw/5Zy/7J4P8ACew6mq2o2lrf2M9rqEMU9rKu2SKVdysPQii4mixOpkjKIMuwIX8qsiVoI9s8bIMfeByv59qwPDOianpN39mluTeaL5RNu88rfaLY5GIif+Wi4yQxO4Ywd3WuglSWMHy33r/df/GrStuZN3MS7mBueOV9qrJbSzEsGUezHn+VWrmBdzPEpXH3kPb3HtRHWbWppCVirLYbxiUIffNZ82hK/wDqpGQ/UH+dat60ioWRdx7gHmqEV6HztbkdQeoqHbqdEbvYzpNBulHySq3+8P8ACqhhubSRRMhAJwGByK6Nbr1pkzxyoVkUMp7GpaRpGU1uc1c3bD5M4J7dzSRb4baWWUFd3zYPUAD/AOtWs8dtBkxRop9QKxtWuQUdc/ewv5nFZ2tob3bVyxZQzLbRjYScZP1qysc/aP8AUU2O6VI1BPQU8XqjvVIybZIsF0f+Wf8A48KkW3uv7g/76FRLfj1qQXwPeq0M7smS3ue4UfjUy20/dkH41VF9/tU4X3vT0FqXltX/AIpF/CpVtV/ilJ+grOF970ovvencVmaiwRDqSfqalVIl6Kv481kC996cLwetFw5Wa4ZR0wPoKXzB61k/a/ej7V70XFymoZR603zR61lG6HrSfaaLj5TV80UeatZP2n3o+0+9Fw5TRmkDXWmgf8/1t/6NWvU68bin36lpS5639v8A+jVr2Sumi7xOPEK0gooorYwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5fx7/AKnSP+v4f+ipa6iuZ8dLug0o+l6D/wCQpKmWzKh8SMUmmFql49BSYHoK5rnXYgLCo2de4q5hfQUbR6D8qfMKxmuVNV5GK98itkoh6qv5U1oImHzRr+VNuL3Q05R2ZgOQ3Tg0kFyYZQ21cj1HBrYm02CT7u5D7Gsq+spbcZYeZH/eA6fWpTcdtjb3aqtLRmzZ3EVwNyAK46jHIqzXIxytEwZWPHQg8itm01ZdgE+Sf7yj+YqrKWsTKUXTdpfeQa14as9RuhfQvNp+rKNqX9oQkuOytkFZF/2XBH0PNUP7d1PQPk8VWyy2Y6atYxsYwPWaLlo/94Fl7kr0rVudaijH7pSx9W4H+NZkmsXUrYjcj2jT/wDXRy/zOxKTesUdLa3EF3bx3FrNHPBIoZJI2DK4PQgjgipK8zOjXtndy3fhyefSrmVt8kXk7raZvV4+ACe7LhvUmuj0/wAV/Z5IbPxRbHSb2QhI5XbdbXB/2JcAA/7LBW9AetJpdHcfvL4lY6miigbnbbGu5/T0+vpS3BuwjsFGTn0wOpqVYNiefdssYXkKT0+vvTJJYrIMVxPcgcnsv+H8zRbwvNia8O9+oHZfoKtJR9TKUnLbYWKe5nbMSiOEcbnzz9B/+qkvbvyxgEb/ANKg1fUltUCR4aVuFX+v0rCnkuBb72LSAdT3H1pSmEIps2kniuuFOycds8//AF6jiG1irDBBrkpZ2b5lYgjuDg1asdcZGWO9BdR0kH3h9fWsue+50Og1qjp5IwwrF1PTfMbzYG8uYd+x+tbdvJDcRCSFg6H/AGs051GOgptXFFuJxTXMkL+XcLskH5H6Gmte46nFdReWkUylZEVgexFYN3osRJMbyJ7A5H5Vk4nVGqnuZVzejGQc1jMz3Fx5nPloc59TXQf2IgbMjPJ7E8flUV5b+Qu0JhfYVKjYuVS6sjm9R1Q2ib3BYZwAKqL4j3dIJPzFJ4iT9yDjo4rOt4wccV2UaUZRuzzsRXnCVkay6+f+eEn5ipk19f4o5BVOKBSOgqwloh7CtfYQMfrNQtLr8OOfMH/Aaf8A2/B/z0I/4Caq/YUI6fpTJLBPSl9WiP63PsXf+Egth1m/8dNIfEdqOs6/kax57FADxWbc2qg9KX1aPcf1uXY6n/hJrMdblfyNA8V2IP8Ax8D/AL5NcPJAM1D5Iz0o+rR7j+ty7HoI8WWXaYn6KalTxPbP90yH/gNcDBCMjiuh0uxLgHHWmsNETxc+x0S6/G3RJT+FSprJb7sEn40WWlAgZX9K2bXSRx8v6VSw0CfrVQzF1Gd/u25/FqlSe8bGI0H5muig0pcD5RV6LTFH8I/KqVCC6EvEVH1Ob003J1nSPNChPt9vnAP/AD0Wvd68tlsRDc6bJgcX1t/6NWvUqOVR0RLm5ayCiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVwnxZ8Va34V07Tp9D0uS7imnK3l2tnJdiziCk7zDGys2emdwA79qAO7ory3SfjBpDWMX2uQ6hOdPvNSM+nW7JEYrYncpSVg6SYH3DkZ/ixzRc/GvQorb7Qmk65PAmlwaxM0ccH7m3lOAzAygkg4yFz14zQB6lWH4ti82ztj/zznDf+OsP61xlx8b/AAhF4nh0VJbmV5LmGz+0p5QRZZBlQUZxKV6AsEKgkAmsa9+MVhrujWd1pWma1Z2smp29l9qvtNDQzF5HQpGwmUZBXlgW25Hyk5AmWqHF2aOr2mkrjh8UtBe4QfZdSWymlngtr4xp5NxJCMuq/PvB4IBZVBx1rQ8F+LrXxjpzX9hp+qWlr8ux7638oTAjOUIJDAdCRxmudxaOtSTOhopuaXNSULmlpuaWgBaPakzSk4GaAMq/0oOS9oArdSnY/T0rBlBV2R1KuvBU9RXa42j3qjqWmw3y5b5JR92Reo/xFS49jalWtpLY5S3eD7Sv2oM0XcKcZrq4JrKCzM0BjWFRyV/z1rjNTt5rKXy7pMf3XH3Wqi0wQZZ8j0zTjKKWu5rOhOo04O6Z0N94judzG3VUj7ZXJqt/wk0d1C9rqlpBdW0g2yRlQQw9CrZB+lU9D0ybWpZG3vHCvAYDJZvQV0ltoVhoEJvb8NeXUY3KirnHuB/U1rCo3vFWMq1ClD3VJ8xn2Oi6nplul14YuCmmHBbTNUdgijv5UmGaP6HcvoBXXGUsmy2Bii7ufvNXmuveK9R1GboI7VT8scZIP1J9auaP4tlISK6PnoOoY4fHpnvVwSqL929exz1aFWjrVjp5bHe2sAkKkDEK8gf3j61PeTLBCzE4CjNVrLV7S7iBgfB/uMMEVHdTRl1MzKqKdxLHA4rNpx0e5HxalGHT3uJmubpirv0QfwjsKti02D5Hz7MKgfWtPQ4Nyv4Amnx6rYy/duY/xOP50ezmtbMfNDuYur6UyM0tqmD1aMfzH+FYDoG5FegsUmTMbqxHQg5rC1XSvN3XFqP3nVk9fp71hKB006ttGYNjdz2Mu+Bseqnoa6rTNYgvsI37qf8Aunv9DXKbQRz/APqqN0wQc/QipUmjWUFI7yRc1TljzWPpuuPDthvsvH0EncfX1roMpIgeMhlPIIPBq73MbOO5SEQ71XurdXUhgCK0WXFRMuaLFJnC67o3mRSKvQj8q4yBWhkaOQYZTgg17BdQB1Ncjr2jLO3mINso6Ed/rWlGpyOz2Mq9L2iutzBgOQKvRDpWdHuhcxyDDDtWjAwIFd6dzzWrOzLAFMkANSr0pklMChcKNtZFyK17nvVCS2eQ/KKQGNNjNQY5rYk0yVjwpqIaVNn7p/KkUQWMXmSAV3miWeUXisPR9Il80ZU16Fo+msiLlTTRLLFnaAAcVsW9qABxUlrakY4rQSEgdKYEEcI9KsJFipVjI7VIENAGdqUf/HjjtfWx/wDIq13VcnNB5slqB/DcxN+Tg/0rrKiW5SCiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc54usvD13Np41+7+y3O50s2j1CS0mYkAusbRursSFGQM8CujrhviPpviLUNX8Kt4ea5FnDeSNqKxXIiVoTEwAdSw3jcRxzQBjaL4a+GHifTtIj0hLaRJLKdrSOG8mt7ia2kYpMzLvWR1Zsgl88/WnyfBnw/P4je7ujLJog0yDTItJWWZECxNuUu6yZlXp8rgjgHmuO8KeFPiBoGgaNaQ2Fw0dp4auLWSwGq+RE161wWQZjkBD7CcOpGOm5e1fSvDnxVjt9VjuX1YafJfWFwLUantuHtwji5hgla5laM7vL5MozjIK5IoA9iXwNoEWsPqlpbXVjdyNG8osb64tYpSnCl4o3VH44+ZTkcHIrP1DwH4ctPCtjo1rp2zTbK9W+gh8+Q7JgzPu3Fsn5iTgkj2qW8s75/hteWmkW/iDTL+SGRIUlu47q+iYsfm8ySdlY85GZeBgAggAeHa4PGOhr4WsfECa2i3ervCIoNZmFzfQiD+PddyLGxbJwsoHfA7p7DW53j+DfCEGvLG1vbpqU4mnitGu343jbLJHCX2qT3ZVH1rf0jR7TRdLttO02HyLK2Ty4o9xbavpliSfxNeUW2ifEdNJtI7i7v3uBouoRNt1EbkuHJ+zhm3jdIBgb+cf3u9RXfh/4iw2F5FpV9fo8+j2QY3Oo+cftilfPVCzkoxG7kEKexHBGDV+p0JtdD2RlIpma4PwbZeLNO0fUFlmmmuWuRLBDrHRYyvKLItxO4GcYLMcc8HNasXi6C1kWHxHazaJOx2q9yQ1u57bZx8vPYNtb2qGuxon3OoBpRUasrKGUgqRkEHIIpwNIY/NOUbnUfjUeantVJDOfoKEJ6DmFMxUr4qNmCkDkseijkmnYm5FcRRTxlJ40kjPUOMis2Hwxps8m9bNVXqWZmx+Azg/yraMKRL5t4wCjog5//AFmo5pXuOCNkXZO5+tVypayBVZbQYRGG0iEGnRoiDjeAMfh60wAAk9SepPJNJ0p0a+Ycn7nf3pNtjSUdTK1Dw3ZaqS5TyH/56xAAsfcdDXJ6j4QvLKbcEW5iH8cXDD6r/hmvRZ7lIYySQAKxbnVt7YjU7fU1EoI2pYupT0Tujy34iWmpp4Zmu9I1OfT7zTwbkHzNiuqjLK4PBGB37+xNYPw/8Raj401K613ULuS3sLZVto9OgmO3ftBZ3HfOTjP9K9L8Z+G08Zafb2N3dy29kJVkuI4VAM6g52Fuw+nt6VmwfDO0tPE1xq2gXjWIniEc9iUBhkx0YY6Hp+vqa1hUlFaPUiXs6s05Ky6mzpVx4clwkkOyU9TKxcfn2/IVuLoukXC74YkIP8UUhx+hxXmNho+qXV5qt4IWnso7g2sJhOQTESsjAdfv7h/wAVX1TU77SY7a6tbmSMRXUQlXOCUZthB9huz+FP6w29W0/wCv66mjwMXHmpNSS+/+vuPUW8PxId1rc3ELfXI/x/WoxBq1o5EUyXKjnDdT+f8AjWTZeLZYwBdxGQeo4P8A9etWHxNp0jBi0iEjoy9PypyrSW7T/r7zH6pLpFr+vuM7UmZn8yW1e3k/i4wre9VDtYZBxXX21/aXYxFIHz2IP9axdb05IpTNCu2NjyF6Kazl7KWrVvQqLqwfLv6mMy9fSprG9n098xkvCfvRk8fh6U14mUZU5H5YqM5Bwwx9az9l/I7m3tL/ABqx1lpdw3kW+Fs+qnqPrUjVx8bSQSCW3Yqw9O9dBp2pR3gCN8k4HKnv9KLNbonTdMtOMiqF3AHB4qbUtRsdNiMuo3ltaRdd88qxj8yawm8XaZOMaal7qR7GztJJEP8A20wE/wDHqVmx8yRnavpokywGHHQ1hxO0chRwVYdjW/dXevXq/wCiaClqp6NqF2qkf8BiD5+mRXPanoWtXPz3OqwwMOi2dsFI9tzls/XArWlU5NHsY1qSqK8dzSicEVn3+t6XZP5d1f20cp/5ZmQFz9FHJ/KseHRLR3K6g13duDgi4uHZf++Mhf0rcs7S0s4tllawW6Y+7FGEH5Cu1O55zVjIfWhO+LLTdRuefveT5K/XMhXj6Zre0i4MWnz3Wr28VmkQZyBN5mEAySTgAHrwM/Wqcz7STUD3zxjgmgaON8J+JdXtNbOqavDeS6brcU8llBJIGRXTLRpGAxK5X5eQMkjrUdr4puD4hl8RCOxvrtPDbSi2tVYLE32hfkf5mJZQct047DrXXNq8o6MasWmsTFh8xpWHc53RfE9xo+t+Ltbt5dLv2aXSUmnijb7OsbowdhhyRt6ZLdR07V21r8UNRlu54Yxotpp/9vXGmLrE6O9rBBGgZGkxIMs+cA7lXiun8OXkrKCSa7ayuGKinYVzyeXxZrWk/EPW7hNYsdWtv7BS8sbKBHWK/ZVYn7MvnMM5UsxXeSoIxkZpLv4va7a+GNdv7WPQ9VaxsrK6S8tYZBbRyzSIj28g8xiXUMTwwPHKjpXtsU7VOs5osFzzX4uR6uPgJ4hPiUacNW8g+aNPLmEDzht2l/m+7tznvntWTe/EzWbDxGdMhtNOxBqFrYR6VJG5vbuGRMtcxsHACD/cI45YV7GJz604TmiwXPGPD3xS8RXGqaA91Y6ZdWuo3mo2otraGRJg1qpZNrl2BLcDG0frxBp3xs8T3dq0kKeH72dtButVNra20pe1mifAgk/fEkgctwp5HTqfbWuvLeDJ+9KifmwH9abongzRNG1iTVbSC6l1N4fsxur2+nu5BFndsVpnYquecDFSxo8hl+NesXJ1UaQfDEqQadYXMMtxdLDGZZgDKpd5VQlTuATcp4wTkV3vhnxxdav8J9T8UxmOa5tre6lj32RtkZolYj5BNLuUlfvLIQR0xXodFIZ87SfGLxhFpd1dNF4fZovDdt4hUC0mAw7hGhP773yG7Yxg9a9q8LeK9L8RyXVtYT7r+ySBryDYw8kyx71G4gBuPTNb9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVznjeUxWlgB/Hdhf/Ibn+ldHXK/EE4ttJ/6/h/6KkqZ/CyofEjF3mk3GmZozXJc7h+aZKiSxtHKivGwKsrDII9CKC1IWpAc43hVbFzL4YvptHfO426DzLRj7wnhf+AFD70n/CRajpXy+JdKdYhx9u08NPCfdkx5ifkwH96uiL00yYP8gKd+4uXsGl39pqttHcaZdQXcDnCyQuHU/iK05JkhQKpAUcVzE/hOxvrx7yyM2l6o3376xfyn+jj7sh9nDD9K2NHgu9NtJE1e8t76dXPl3CQeUzJgffG4jdnP3cDpwKtIxlK7LEbSTPxmNP7xGSfoKtPLbafDu6yv0ycs5rDvNTV3dVcHA6AZ/QEVn3LTXEShYHY/7RH9ScVXOktAUOZ6s6EMZZPNmYM/YDov0p6kyfcxj1PSuJaxvQcrA4+jD/GmkajHxtvFA/ulv6Vi5vqjoVJdGd0Y1H32Lew4FIzkjjge1cG19eRHD3Fyp9Gc/wBakTV71fu3TfioP9KPaIHh5PqbuoO885TPyKfzpYbUYGRWJHqdwGJJick5O5cfyq/BruzAmtsj1Rs/oaFJMiVGaNmK3wOBWV4t1CXRtBu7u2XddhRFbJ/fmchI1/F2UVo2uuWEmAztEfR1I/XpWNqcsOt+NNJ0+GSOW206M6lcbWBBkOY4VP8A5Fb6otWmmZODW5t+GtMj0bQbHTomLC2iWMuertj5mPuTkn3NYXxF8KLr2gagLNNt+8Dqu3jeccfiDjBrr14qK6uVtoixVnPZVHJpPXc0puUX7p5x4PtrLxNoNrcRs1tevAku3OVcMAc4PP1qS50q70qXMkfyg8OOVP49qoeF7Oe00652gwvZX89uFTIMS7t6A/8AAHWu3s9ZIiWPU48qwwJlGUYe4qV7r00O+U5Sjr7yfQyNO1dEdRdQRsf720Bvz7100MtvfQuEIdGGGU9R9azNQ0O1u42n090U/wB1TlD/AIVg4u9NnAYSRsOgP9DV8yfxK3mc7pc2tJ/Jmjd27Wtw0RyQOVJ/iFVWT8u1XxqMWo2wSfCXC8o/v6GqwwR7Gs5wcRwnfR7mNqtpqE7RjT7y3tE58wvbmRz6bTuAHfqDWa3htpvmv9X1W7PdfP8AIX8ogv6k11BXt+RppT86SnJdSnCL1aKfhzS9EsZwU0uyhueguPKBkb6ufm/WuqcVzjxZ6dauWF80JEVwSU6Bu6//AFqOa+4uRLY0HXNZ95bhlPFahwyhlIIPcVDIuR0pMEzh9ZsGyZIh84/WsmK542twa7q+ttwziuO13T2jZp4Qc/xKP510UKtvdZzYmhzLniVZmDZrOuDmlSfPWo5mz0rsOArOOau6dHulQe9U+ta+iR77pOKEDPQPDkG2NeK7SzTCiud0OLCLx2rqrZcKKsRZQcVIopFFPFIBRThSCnCgCnqjFBZY73tuPzlWuxri9Z+5Y/8AX9bf+jlrtKzluUtgooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5P4i/8AHppH/X+P/RUldZXI/Ec4stJ/6/x/6KkqZ/CyofEjBDUFqg3j1pC/vXHc9CxMWpheomcetRs9K47FmMNLIETqe56AVPJstoztyznjPc+1Os18uxMp+9J39u1RWiG6ugT/AKqM7mPqewq0jCcruxeaZNOsAZSNwG5j6mubnmn1CQs7FYj0Ud/rVjWZjeX3lA/u4+o9TT4owi5PA96HqQMgt1jHyqBVlV9Kbv8A7gz7mnAE9T+FK5agx+4Dvz6U4MewP40KlSKlBfKkMb94NsiIw9+aqS6VZy58y3Vf9qM7TWgFp4Wi1x7bGBN4czza3HHpIP6is650y8tcmSEsg/iT5hXZKnORwfanjd6j8qnkTKVWSPP1dcZJwKxvBy/are61hvv6lMZo+xEI+WL81Ab6sa634iW0dxpEenxIi32qzpYxugwyhsmR8/7MayN9QKtt4YS3hSOwl2RxqFVHHAA4ABFHK0ilUUnqU4L27h/1c749G+YfrWjb67KpHnwo49VODWXPZ3dr/rom2j+JeRTEcMOxqbtFOMWNsL+0bxd4gs5d0UV/b296m4f8tAGifp6COH861rK1YQBrZ45UbiW3bkE+o9K5DWP9G8UaDd4wJvOsXP8Avp5i/rDj8feugC4OVOD6g4qnImK5U0jVfSXjbzrB2gf+4xyKje+Uj7NrVttz0cD5fr7fhUEV9dxfdlLD0cZqydTWaMx3tsrof7tF0O7+1r+ZRvNBOPO09xLGeQM8/ge9ZyStGxWZSpHB4/mK1BN9gYy6dNvgP3oJOo+laW2y1q33AASAdejIf8KqLa0RUmmrz18+qMIEMoORg9DSlc1A8UltK655U4YVJHMrfe+U/pRyxl8OjE1KOu67r/IUrn60ySPI6c1Y20Fc8d6zcXF2Y1JSV0RWly9sdrZaI9vT6VqgrIgZCCprLZM8GiCR7d8ryp6r60A0XZUyKyb+2zk4rbR1mTcnPqPSoJ4gRSYJnl+vaa1q5miH7onkf3ax/M9a9M1G0V0ZXUFSMEGvPtZ05rG44yYmPyn+ldlCrf3WcWJocvvx2K6ckV0nhiLdcg+mK5iEnNdt4Oi3Hd6mupHEz0TR48IOK6GBcAVk6YmEFbUQwtMB6inikFOFACinCkpe9AFDWfuWP/X/AGv/AKOWuzrjNa+5Y/8AX/a/+jkrs6zluUgooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK434nts03Sm9L9f8A0VJXZVxPxVVm0nTAgy325f8A0VJUyV00ioNKSbORNyPWkNyPWs10nXqhqBpZF+8j1yeyn2PQVWn3Nc3A9aTzs96xjdAdSR9aVboHoahprdGkWnszvtIuIp7BEbaSo2spqxcyJHCVTCgDoOK4K2vnhcPG5Vv51f8A7Xd1wwBPrmrU1bUwnRd9CaJsyOwGWLHk/WrC8nLEk+9Z8M6gACrCTj1qLmkYJF5MVMuKoLOPWpVmHrTTBovoKlAqG2dT1rifijrWrabrXhOx0W4vI11G5ljnSyS3M0iqgICmcbAc+uKuKuZSlY7zpS5rzTVPiLeaJqI0W38P6zrGoW1tHcXIlANwQ7YwBbxPGSAck5ReMAk0+8+J80OrTWsWhRvAmsRaMJHvCjmSVdyMU8o4Xgg85HoarkZHOj0oGnAmvMbP4qSXv2W1tNCi/tSSS8SSKa+2QoLYZcrL5ZLE8YG0e+BzUulfFOXV9Y0az0jw7JNBe6fHqVxPNepD9kiMxjkYhh8wXGeDlhjgdafIw50dJbq2qePriZ1P2bRrcW8eRwbiYB3P/AYxGM/9NGrqa8S8UfFWXU9A13T7S3+xzHSpLy01KwuZijbJAh2s8MR9fmTcO2a9I1XxInh/wVpeoTvbSTzJBEi3U0i+dIy9AUjkdnODgBSTQ4sSmjpSKp3Gm2s4O+FQx/iX5TXP+A/Hlj4p05ZLqOLS9Qa7ms1spp/nkeIAvsDBWOAQSNoI7gV1TMM1LVty4y7HBfELR3tPDsuo28u4adLFfEMOQkbhn5/3A4/GtGWCaAkTQsuO+OPzro9StYtQ066spxmK4ieF/wDdYEH+dZnga7kvvB+kS3ODci3WKfnP71Bsf/x5TUuKsWptMzVIPQ0/8K37jTbabJ2bG9U4rPm0iePmF1ceh4NQ4s0U0zPIU9R+dIimOQSREo46FafKskDYnjZPqKQMp6UiiO5Ek8pkdhvI5IGM1XaFu6/iKvD86pXt+lrfafasjM15I0akHhSqM+T/AN84oBPl2ERnjPt6dqsJIr99p9+lTMgbqBUTW4P3eKtTez1QNKWuz7jtvqOaQpkYxSKJIzjGV9KlR1bjofejlT+EWq3IU3QvuT8R61eRlmTI4PcelRbPUU0KUYMpwam1twunsRXUGQeK5/VLBLiJo5Vyp/T3rrOJVPGD3FULu3yOlTtqi009GeV3dm9ncmKQe4PqK7rwZDiCLjk81Bq+nLcxlWGGHKt6Vr+GIxGEX+7xXoUaqmrPc8zEUHTd1sdxYJhRWog4qhYj5RWgo4rc5xwpwpBThQAopRSUopAZ+tfcsf8Ar/tv/RyV2dcZrP8Aq7H/AK/7b/0cldnUMpBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy3j5BJDo6nvfj/0VLXU1zfjUZ/sUf9Pw/wDRMtCA56WxU9qpTaap/hrpGQelRNEPStSDkbjSVOflrLudEUkkAg+1d68APaq72qntQB5xNp9xDnYxI9+arGS4iPzofqK9FmsFYH5RWfcaSjfw1lKhCXQ2hiKkepx0eoAcE4PvxVuO+960brQ1Ofk/Ssm40Vkz5e5fpxWEsK+jOiOMX2kXVvR61Kl6PWuM12e70poAjBhJu+8PTH+NU4vEFx/Hbg+6sRWToTRssTSZ6XDqIXvRPNa3U9tPc29vNPbMWgkkjDNESMEqTypI9K8+j8QN/FBKPoQanj8Qp/FHKv1FLkqLoP2lJ9TsdWs9I1mSOTV9K0+/eMFUa6tklKj0BYHFSfY9KLlzpdgWM63RY26Z85RhZOn3x2bqK5e31uCTGJgD6Nx/OtKK9z0bNLma3HyRlqjSudK0O5tjb3Gi6XLb+a0/lPaRsvmN958EY3HuepqeNbOG7W6hs7WO5WEWyyrEocRA5EYbGduedvSs0XWR1pRcA96Odi9mkOg0Xw9D5gi0DSEEqskm2zjG9TjIPy8g4GR7Vr3UdhqViLLULG0urMYxbzwq8Yx0+UjHFY4k9DVi3k+brRzMORGhZaRo9o9u9npGnW727vJC0VsiGNnADspA4LAAEjqBWqJSTXC/FPWL7QvAV3qGj3BgvUlhRXVEcgNIqnAYEdCetVtQ8XXnhaPTrO503XNQ1PUpZvIi1AQ7gsaKxx9jjkyDngbSc5JwMGtFFtXMnJRdj0hJDWB4MP2a41/TeALbUZJUA/uTBZsj23SOP+AmuS1H4pXNkH/4pmWKSHRhrE8N5cNbyxjzjE0e3yzznkE4yD2pT8Srey1LUw3h9E1V5dPt4yl3lJxcKzRGR9g8sKCc8NycAmmoMhzR6quTTgDXl0vxXvPtVtp1h4WN7rEmoXWnNbx36pH5kKK2UkZAGUhu4UjHQ8Vow/FCM+MLHRW06CWC6vHsTdWtxLIIZlXJRy0Kxlh3CSMRRyMOdHoLIGGGAIPYiqM+kW0hyqmM/wCwf6Vw/wANvEGpQ/Au01yRJta1KGG4mZJ7k+ZMEmk43kMchRxwegFafg/4jad4miu7wJDY6RG8EEF5cXIUTzyRh2iCkDlSwXqST2pOA1M1Z9Jnj5iZZB6Hg1yviBZYvEXhsSoyEXM3Uf8ATCSvRyRmub8SAN4l8KBgCPtU/B/69pajlNOd21IQwNPBB71uTadbS/8ALMIfVOKpS6S68wyBh6NxU8rNFNFEU4xq3UU5reeI/PGwHqBkUit60h37AIyo+U5HoaXHY8H0NSKQRT8Aiqv3JfcrlSrbl6inFRKucc9xUpjqNlKnI60muw0zOu7bOeKz4XeyuBIoyO6+tdFtEqnHXuKoXVrkHipV4u6NNJKzOm0W9iuIFeNsg/pWyhBFeaW00+nT74en8S9jXZaTqsd3ECrc91PUV30qyno9zzK1B03dbG6KcKhjkDd6mBrcwF606kFKKQGfrX3LH/r/ALb/ANHJXZVxutf6ux/6/wC1/wDRyV2VQ9ykFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO+MvvaL/1/j/0TLXRVzvjD7+if9f3/ALRloQEJFNK1MRSEVoQV2SmMlWStIVpgU2jpjRZ7VdK0wpQBnPAD2qrNZq3atgximNHQB5R8SLQRTacMcMJP/Za522sgVBxXSfFy+U6jY2MQBeFTK59N3QfkM/iKz9FZJ7dT60CKgsl9BTv7PUjpWyYMHAFPWEelFgObm0sHoKgWG5tTmGRgPQ8iuraAelQyWwPapcU9GVGTjqjCj1SaPieMn3WrUOqQvj94AfRuKnmsFbtVCfTBz8tYSw8XtodMcXNb6mzBcg45q5FPyDmuNa0mgOYndPoaeuo39v1KyD/aX/CsZYeS2OiOKg90dvO9te2xtr+2gurdiCYp4w6kg5BweOCM1dvlsNYt1t9VsbW+hB3CO5hWVQfXDAjNcLB4iK8XFuw90Oa17DWLadgIphu/ung1m4zjujRSpz2Z0cekaIIzGujaYIzB9lKi1jx5O7d5eMfc3c7emeamk0zSZUuVl0rT3W5RI5w1shEqpwitx8wXsD07VUtbkMBWgjAjihTYnTQlrpulWv2T7NpdhCLMs1t5dui+SWGGKYHykjrjrSJo2ijUjqI0bTRqBk803QtY/N3/AN7fjOeTzmp0GTVkRqqM7sFVRkknAA9TVJtmbikLp0Vrp9mlpp9tBa2qZ2QwRhEXJJOFHAyST+NQQ6Lo0djHZR6Tp6WcconSBbZBGkgOQ4XGA2e/Ws7Q/Emka1NHHptxLL5oYwu1tLHHMF+8Y3ZQrgf7JNdCsDCnqLQnV81z/iE/8VN4U/6+pv8A0mlq7barYz69c6LFcbtStoVnlh2MNqMcA7sYP4HNWrvR0vL/AE67d3V7GR5EAxhiyMhz+DGmhNovA0tQrNGdRNjsuPOEXnbvs8nlbc4x5mNm7P8ADndjnGOauiA0rMLogNQy28Uv30BPr3q/9no+z0WHzGM+nqOY3I9jzULW0yfw7h7Gt1oaYYqXKPnMHODgjBoNa8sakYYA/Wqj2yH7uV+lTYtSM8rg5Xg0MQw+YY96svbuOmGqBlIOGBBqWi0ylcW4YcYNUPLlt5RJCxRx3FbJjzyKY8JPUZpW6lX6E+neIQuFvEKt/eUZFdLZXsNygaGRXHsa4qS1B7VGsMkDbomZGHdTiuiGIkt9TmnhoS1joejKacK4q11y+twFk2zL/tDn8617XxJbSECdHiPr1FbxrwZzSw84+Zf1v/V2P/X/AGv/AKOSuyrhdSu4LiOx8mVH/wBOteAef9cld1Vt32M7NbhRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArnvGH+s0T/r+/9oy10Nc94u/1mif9f/8A7RloATFIRUmKTFWSMIpMU8ijFMCMimlalxSEUXERFainZIYZJZWCxopZmPQAck1ZxXI/E+/Fl4XlhRtst2whXHp1b9AR+NMDyLULptX1a7vpc5nkLKD2XsPwGBV7R0eAtz8pPFUrSLAFbFuoXBNCEbEB3jmrSxAispb2KLqwFPGsQL/GKYGoYcConi+lUTrcB/iFA1aFv4hQBYeMelQvGpzxSC9jfow/Ol81W6GkMqyQKe1UprRT2rWOD0qN0BpAc/NYg5+Ws6exIOVGDXVtFmq8lsD2pDuY+marcWMgScvJCfU5K12mnaik0asjhlPfNcndWWR0qnbvcWEu6I/L3Xsa56tDm1judVHEuPuz2PU7aYMRzWhKPOsp40ETO8bKBKMoSR/EO49a4jR9XScDaSGHVT1FdJa3gYDmuVNxdmdjipK6OCsvh3rlhNejR5tO0yxks5YRpz3c17aXEjDAZopFAjXqcfP1xyODmW/wl1w6ZrFnNc6XHBfXljciGKUoqeUGEuBHDGqlsjG1R05ORk+vJMSOtSiQ+taqqzB0Ueb3fwrSz8QajN4cj02ysbvSzZQTFn+02Mu1h5iEqxbcCFJ3q2CeTgA5d18K9YufDmt2NvJo+mNe2dnaraWssht5JIZEZ7hz5YIdgpH3SeeWPWvXdxpCxp+0ZLpI818VfCn7U+oW3huSzsdMl0I6dBHNNLIyzG8FwSxIY7TzzkkE9MU24+Hetag3ieXUV09jrE9jKIbbUnjVPIjZWDM1u4cElflKEEZzjAz6YHI705HNHtGHs0czB4U1Q/B+98L3E2kjVLi3miD2sAt7dWckjhEA78kIM+lcdq3wi1Caz1iPT20eCa4ttPFowLr5NzAV82XhPlLAMNw5OecZNeuo59alDGjnYezRHpc2r/adR/tf+z/I88/Yvsu/d5OOPN3cb85+7xV5pqr5pp61NylEe7ZqM80tFIoaRTGUEcgGpKMUgKzQKeRwab5RHbP0q3ijFFh3Knkg9qabbPar20HtRtosHMZj2ue1QPae1bewU0xA0rBzGEkHl6jpZH/P/b/+jVr2CvMrqMLc6af+n+2/9GrXptdFFWRzV3eQUUUVsYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZHiPTbnUYrM2UsMU1tcCYeapZW+RlxwQf4v0rXooA5j+zdf/5+dL/79Sf/ABVH9m6//wA/Ol/9+pP/AIqunop3YWOY/szX/wDn50v/AL9Sf/FUf2Zr/wDz86V/36k/+Krp6KLsLHL/ANma/wD8/Ol/9+pP/iqP7M1//n50r/v1J/8AFV1FFF2Fjl/7L1//AJ+dL/79Sf8AxVct4v8AAniDxFcWrPqGmRxwA4URyDJPU9T6CvUaKLsLHi0fwo1xOmpaZ/3xJSTfCvxE4wmqaYo/3JK9qoouxWR4X/wpzXWOZNX08/8AAXqVPg9q69dS04/8Aevb6KLsLI8T/wCFRawBxqOm/wDfElMPwg1s/wDMT00fRHr2+ii7Cx4ivwi1xD8uqaeD/uyVPH8LfEKdNV00/VJK9noouwsjyGP4b+IQOdR0s/8AAJKkHw517vqGl/8AfEletUUXYWPJv+Fc67/0ENM/79yf400/DfXT/wAxDTP+/clet0UXYWPIW+GeuN11DTP+/clV5PhVrT9dQ0z/AL4kr2aii7Cx4ivwj12OUSRappyOO4R617b4f+IogN2oaWSPRJK9XoqJQUtzSFSUNIs82j8GeIU632ln/tnJ/jU48Ja+P+XzS/8Av3J/jXoVFT7KJXt59zz/AP4RTX/+fzS/+/cn+NH/AAimv/8AP5pf/fuT/GvQKKPZRD20jz//AIRTXv8An70v/v3J/jSjwrr4/wCXvS/+/cn+Nd/RT9nEXtZHBDwvr4/5e9L/AO/cn+NPHhrXx/y96X/37k/xruqKPZxD2sjhv+Eb1/8A5+9L/wC/Un+NH/CN6/8A8/el/wDfuT/Gu5oo9nEPayOG/wCEb1//AJ+9L/79Sf40f8I3r/8Az96X/wB+pP8AGu5oo9nEPayOG/4RvX/+fvS/+/Un+NL/AMI3r/8Az96X/wB+pP8AGu4oo9nEPayOH/4RvX/+frS/+/Un+NH/AAjmv/8AP1pf/fqT/Gu4oo9nEPayOI/4RzX/APn60v8A79Sf40f8I7r/APz9aX/36k/xrt6KPZxD2kjiP+Ed1/8A5+tL/wC/Un/xVL/wjuv/APP1pf8A36k/xrtqKPZxF7SRxKeGdYkurRrq70/yYbiOZhHG+47GDYGTjtXbUUVSilsS5OW4UUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient should be positioned with a towel roll placed under the buttocks with the leg exernally rotated at the hip and flexed at the knee as shown.&nbsp;The femoral artery is palpated approximately midway between the symphysis pubis and superior iliac spine and punctured 2 cm below the inguinal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1604=[""].join("\n");
var outline_f1_36_1604=null;
var title_f1_36_1605="M mode dilated cardiomyopathy";
var content_f1_36_1605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode scan of the heart is obtained by moving the transducer from a cephalad to caudal direction, recording the aortic root, mital valve and mitral valve annulus, and the left ventricular chamber. In this patient with a severe dilated cardiomyopathy, there is significant enlargement of the left atrium and left ventricle. In addition, the septum and posterior left ventricular wall are thinned and hypokinetic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1605=[""].join("\n");
var outline_f1_36_1605=null;
var title_f1_36_1606="Cutaneous polyarteritis nodosa";
var content_f1_36_1606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75391%7EDERM%2F58586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75391%7EDERM%2F58586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous polyarteritis nodosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerated, erythematous nodules in polyarteritis nodosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryoglobulinemic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcers are present on the lower legs in this patient with cryoglobulinemic vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1606=[""].join("\n");
var outline_f1_36_1606=null;
var title_f1_36_1607="Nerves of the female pelvis";
var content_f1_36_1607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Nerves of the female pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1607=[""].join("\n");
var outline_f1_36_1607=null;
var title_f1_36_1608="Nafcillin: Drug information";
var content_f1_36_1608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nafcillin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/32/17924?source=see_link\">",
"    see \"Nafcillin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"    see \"Nafcillin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endocarditis: Methicillin-susceptible",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      (MSSA):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Native valve:",
"     </i>",
"     12 g/24 hours in 4-6 divided doses for 6 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing intended for",
"     <b>",
"      <i>",
"       complicated",
"      </i>",
"     </b>",
"     right-sided infective endocarditis (IE) or left-sided IE. For",
"     <b>",
"      <i>",
"       uncomplicated",
"      </i>",
"     </b>",
"     right-sided IE, 2 weeks of therapy may be adequate (Baddour, 2005). The British Society for Antimicrobial Chemotherapy (BSAC) recommends 4 weeks of therapy with a penicillinase-resistant penicillin for all patients with native valve IE due to MSSA unless patient has intracardiac prostheses, secondary lung abscesses, or osteomyelitis, then extend treatment to &ge;6 weeks (Gould, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Prosthetic valve:",
"     </i>",
"     12 g/24 hours in 6 divided doses for &ge;6 weeks (use with rifampin for entire course and gentamicin for first 2 weeks) (Baddour, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infections:",
"     </b>",
"     I.V.:",
"     <i>",
"      Staphylococci (oxacillin-susceptible):",
"     </i>",
"     1500-2000 mg every 4-6 hours for 4-6 weeks (2-6 weeks if in combination with rifampin), followed by oral antibiotic treatment and suppressive regimens (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Skin and soft tissue infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Methicillin-susceptible Staphylococcus aureus:",
"     </i>",
"     1000-2000 mg every 4 hours (Stevens, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Necrotizing infection (Staphylococcus aureus) of fascia, muscle, skin",
"     </i>",
"     : 1000-2000 mg every 4 hours (Stevens, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F199193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"      see \"Nafcillin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     I.M., I.V.: 100-150 mg/kg/day in divided doses every 6 hours (maximum dose: 4000 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 150-200 mg/kg/day in divided doses every 4-6 hours; for life-threatening infection (eg, meningitis) daily doses up to 200 mg/kg are used (maximum dose: 12 g daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F199181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is necessary unless in the setting of concomitant hepatic impairment; however, manufacturer labeling does not provide specific dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Poorly dialyzed. No supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff, 2007; Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F199182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustments provided in manufacturer&rsquo;s labeling; however, dosage adjustment may be necessary particularly in the setting of concomitant renal impairment; nafcillin primarily undergoes hepatic metabolism. In patients with both hepatic and renal impairment, monitoring of serum drug levels and modification of dosage may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution: 1 g (50 mL); 2 g (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F199158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer as a deep intragluteal injection; rotate injection sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse over 30-60 minutes. Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do",
"     <b>",
"      NOT",
"     </b>",
"     flush the line); remove needle/cannula (if not using I.V. hyaluronidase antidote), elevate extremity.",
"     <i>",
"      Hyaluronidase:",
"     </i>",
"     Local administration:  Using a 150 units/mL concentration, mix 0.1 mL (of 150 units/mL) with 0.9 mL NS in 1 mL syringe to make final concentration of 15 units/mL; administer 5 x 0.2 mL (15 units/mL) intradermally and/or subcutaneously into area of extravasation (MacCara, 1983). If needle/cannula still in place, administration of 1-6 mL hyaluronidase (150 units/mL) through existing intravenous line has been reported in the management of other extravasations (eg, plant alkaloid agents) (Schulmeister, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F199204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, Aminosyn&reg; II, cyclosporine, enalaprilat, esmolol, famotidine, fluconazole, foscarnet, FreAmine&reg; III, heparin, hydromorphone, magnesium sulfate, morphine, oxytocin, phosphonoformate, propofol, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caspofungin acetate, diltiazem, insulin (regular), labetalol, midazolam, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem, meperidine, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections such as osteomyelitis, septicemia, endocarditis, and CNS infections caused by susceptible strains of staphylococci species",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal:",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, bone marrow depression, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Inflammation, pain, phlebitis, skin sloughing, swelling, and thrombophlebitis at the injection site; tissue necrosis with sloughing (SubQ extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis (rare), renal tubular damage (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions (immediate and delayed; general incidence of 1% to 10% for penicillins), serum sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): ALT increased, AST increased, bilirubin increased, cholestatic hepatitis, diarrhea, drug-induced lupus erythematosus, fever, hypokalemia, itching, nausea, rash (including bullous skin eruptions), vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nafcillin, or any component of the formulation, or penicillins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxic effects: Large I.V. or intraventricular doses have been associated with neurotoxicity;  use caution, especially in patients with concomitant renal and hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Contains sodium; use with caution in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic/renal impairment: Use with caution in patients with concomitant hepatic and renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in pediatric patients; elimination of drug may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Vesicant; avoid extravasation of I.V. infusions; ensure proper catheter or needle position prior to and during infusion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F199195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Nafcillin may increase the metabolism of Calcium Channel Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Nafcillin may increase the metabolism of Contraceptives (Estrogens).  Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nafcillin may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Nafcillin may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Information specific to nafcillin use in pregnancy is limited. Maternal use of penicillins has generally not resulted in an increased risk of birth defects.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5697164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillins are excreted into breast milk. The manufacturer recommends that caution be exercised when administering nafcillin to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F199163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nallpen in Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 gm/50 mL (50 mL): $17.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g/100 mL (100 mL): $24.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Nafcillin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $14.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $28.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $138.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Nafcillin Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $17.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $33.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F199152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic CBC with differential; periodic urinalysis, BUN, serum creatinine, AST and ALT; observe for signs and symptoms of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall destruction and resultant bactericidal activity against susceptible bacteria; resistant to inactivation by staphylococcal penicillinase",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed; CSF penetration is poor but enhanced by meningeal inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: &lt;3 weeks: 2.2-5.5 hours; 4-9 weeks: 1.2-2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1 month to 14 years: 0.75-1.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal/hepatic function: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (~30% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alam MB, Kadoura A, and Sathaiah M, \"A Fatal Case of Nafcillin-Induced Hepatotoxicity: A Case Report and the Literature Review,\"",
"      <i>",
"       Case Report Med",
"      </i>",
"      2012, 2012:953714.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/22844299/pubmed\" id=\"22844299\" target=\"_blank\">",
"        22844299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics. \"Antibacterial Drugs,\" In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds.",
"      <i>",
"       Red Book&reg;: 2012 Report of the Committee on Infectious Diseases.",
"      </i>",
"      29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary:",
"      <i>",
"       Endorsed by the Infectious Diseases Society of America",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3167-184.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Banner W Jr, Gooch WM 3d, Burckart G, et al, &ldquo;Pharmacokinetics of Nafcillin in Infants With Low Birth Weights,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1980, 17(4):691-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/7396459/pubmed\" id=\"7396459\" target=\"_blank\">",
"        7396459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blazes DL, Martin GJ. &ldquo;Drug Induced Lupus Erythematosus Secondary to Nafcillin: The First Reported Case,&rdquo;",
"      <i>",
"       Rheumatol Int",
"      </i>",
"      , 2004, 24(4):242-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/14658003/pubmed\" id=\"14658003\" target=\"_blank\">",
"        14658003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carek PJ, Dickerson LM, and Sack JL, &ldquo;Diagnosis and Management of Osteomyelitis,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 2001, 63(12):2413-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/11430456/pubmed\" id=\"11430456\" target=\"_blank\">",
"        11430456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang M, Koh ES, Kim MJ, et al,  &ldquo;Nafcillin-Induced Bullous Skin Eruption With Granulocytopenia in a Patient With End Stage Renal Disease,&rdquo;",
"      <i>",
"       Intern Med",
"      </i>",
"      , 2012, 51(3):287-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/22293804/pubmed\" id=\"22293804\" target=\"_blank\">",
"        22293804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cone LA, Lopez C, O&rsquo;Connell SJ, et al, &ldquo;Staphylococcal Septic Synovitis of the Sternoclavicular Joint With Retrosternal Extension,&rdquo;",
"      <i>",
"       J Clin Rheumatol",
"      </i>",
"      , 2006, 12(4):187-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/16891922/pubmed\" id=\"16891922\" target=\"_blank\">",
"        16891922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlgren AF, &ldquo;Adverse Drug Reactions in Home Care Patients Receiving Nafcillin or Oxacillin,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(10):1176-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/9161625/pubmed\" id=\"9161625\" target=\"_blank\">",
"        9161625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacCara ME, &ldquo;Extravasation - A Hazard of Intravenous Therapy,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1983, 17(10):713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/6628223/pubmed\" id=\"6628223\" target=\"_blank\">",
"        6628223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(Suppl 2):27-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/17278083/pubmed\" id=\"17278083\" target=\"_blank\">",
"        17278083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qua DA and Tan MJ, &ldquo;Hypokalemia Associated With Nafcillin Treatment,&rdquo;",
"      <i>",
"       Infect Dis Clin Pract",
"      </i>",
"      , 2009.17((2):130-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulmeister L, \"Extravasation Management,\"",
"      <i>",
"       Semin Oncol Nurs",
"      </i>",
"      , 2007, 23(3):184-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/17693345/pubmed\" id=\"17693345\" target=\"_blank\">",
"        17693345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al (Infectious Disease Society of America [IDSA]), &ldquo;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005; 41(10):1373&ndash;406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zenk KE, Dungy CL, and Greene CR, &ldquo;Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1981, 135(12):1113-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/36/1608/abstract-text/7315807/pubmed\" id=\"7315807\" target=\"_blank\">",
"        7315807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9674 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1608=[""].join("\n");
var outline_f1_36_1608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199199\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199179\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199193\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199180\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199181\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199182\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199154\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199158\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199204\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199157\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199197\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199161\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199142\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199150\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720663\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199188\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5697164\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199163\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323444\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199152\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199141\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199160\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/32/17924?source=related_link\">",
"      Nafcillin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=related_link\">",
"      Nafcillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_36_1609="Kidney disease following hematopoietic cell transplantation";
var content_f1_36_1609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Kidney disease following hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Chirag Parikh, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1609/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/36/1609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is the only cure for a variety of hematologic and oncologic diseases. However, it has been associated with the development of both acute and chronic kidney failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the requirement for dialysis following HCT is relatively uncommon (in the range of 2 to 5 percent), it is generally associated with an extremely poor prognosis. However, acute kidney injury, as defined by doubling or smaller increases in the serum creatinine concentration is common, approaching 50 to 60 percent in several reports. There are a variety of causes of acute kidney injury following HCT, and several risk factors that are associated with chronic kidney disease. In the majority of patients, renal dysfunction is temporary and returns to baseline; however, adjusting medications to avoid further damage is common.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology and causes of kidney injury following HCT other than sepsis or drug-induced acute tubular necrosis or tumor lysis syndrome. These include hepatic sinusoidal obstructive syndrome (SOS, formerly known as veno-occlusive disease), hemolytic-uremic",
"    <span class=\"nowrap\">",
"     syndrome/thrombotic",
"    </span>",
"    microangiopathy, and calcineurin inhibitor nephrotoxicity. The technique and other complications associated with HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and risk factors of kidney injury following HCT vary with the different types of regimens associated with HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both myeloablative allogeneic and autologous HCT require a high dose conditioning regimen, frequently in combination with high dose radiotherapy. Myeloablative allogeneic HCT also requires post-transplant immunosuppression, commonly with calcineurin inhibitors. By comparison, post-transplant immunosuppressive therapy is not necessary in autologous HCT.",
"     </li>",
"     <li>",
"      A newer form of HCT, known as non-myeloablative or reduced-intensity allogeneic HCT, is generally used for patients who are older (&gt;50 years) or have comorbid medical conditions. This procedure entails a lower dose of chemoradiotherapy and is frequently performed on an outpatient basis. The nonmyeloablative HCT procedure also requires post-transplant immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology of acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of acute kidney injury following HCT develop 10 to 21 days after HCT. By day 21, as many as 50 percent of patients have at least a doubling of the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. However, the incidence of acute kidney injury following HCT may be decreasing. In a retrospective review of over 2500 HCT recipients from the same center, the incidence of a doubling of serum creatinine was significantly lower during the period of 2003 through 2007 compared with 1993 through 1997 (33 versus 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66480158\">",
"    <span class=\"h3\">",
"     Type of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acute kidney injury associated with HCT depends in part upon the specific procedure used, with myeloablative regimens associated with a higher incidence of acute kidney injury compared with nonmyeloablative regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and allogeneic regimens associated with a higher risk than autologous regimens. In a review of these and other studies, the average incidence rates of severe acute kidney injury, defined as a 50 percent or greater reduction in glomerular filtration rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more than doubling of the serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the requirement for dialysis, were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      76 percent with myeloablative allogeneic HCT",
"     </li>",
"     <li>",
"      43 percent with nonmyeloablative allogeneic HCT",
"     </li>",
"     <li>",
"      23 percent with autologous HCT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of acute kidney injury is higher with myeloablative compared with nonmyeloablative allogeneic HCT despite the fact that patients who undergo nonmyeloablative therapy are older and have more comorbidity. In one study, the risk of acute kidney injury with a myeloablative regimen was nearly fivefold higher than the risk with a nonmyeloablative regimen after accounting for age and other comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66480165\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure requiring dialysis in the peritransplant period has a poor prognosis due, in part, to its association with coexistent injury of multiple other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/4,7-9\">",
"     4,7-9",
"    </a>",
"    ]. In one study of 88 patients who underwent allogeneic HCT, the requirement for dialysis was associated with an 83 percent mortality, with patients dying an average of 47 days post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2005 meta-analysis of six published reports of myeloablative allogeneic transplantation noted a twofold increased risk of death with acute kidney injury (defined as doubling of the serum creatinine concentration) and a sevenfold increased risk of death with acute kidney injury requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/9\">",
"     9",
"    </a>",
"    ]. Mortality rates associated with acute kidney injury vary by modality and have been reported to be 54, 48, and 11 percent at 1000 days after autologous, myeloablative allogeneic, and non-myeloablative allogeneic HCT, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology of chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide range in the reported incidence of chronic kidney disease (CKD) following HCT (zero to over 60 percent at &ge;6 months following HCT); this is related in part to variations in the definition of CKD, duration of follow-up, and type of HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation therapy has been implicated, possibly by causing a subacute or chronic thrombotic microangiopathy (radiation nephritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. The likelihood of developing CKD varies with the radiation dose [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/20\">",
"     20",
"    </a>",
"    ]. This was suggested in a review of 11 studies in which CKD was rare when the total radiation dose to the kidney was less than 17 Gy; most patients who developed CKD received more than 20 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Thrombotic microangiopathy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H6#H6\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Radiation-containing regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term renal prognosis following total body irradiation (TBI) appears to be relatively benign [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This was suggested in a report of 60 patients who underwent HCT in which 34 (57 percent) had at least a 20 percent fall in glomerular filtration rate at a mean follow-up of two years; this was mostly seen in patients who underwent TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the mean glomerular filtration rate after TBI was still above 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (compared with 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    among patients who did not receive TBI).",
"   </p>",
"   <p>",
"    A similar benign outcome was noted in a review of patients receiving TBI (estimated renal dose 12 Gy) in which only two of 33 surviving patients had persistent elevations in serum creatinine 24 months after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors other than TBI can contribute to the development of CKD. This was illustrated in a series of 122 patients who underwent nonmyeloablative HCT (with only 2 Gy of radiation given); 81 patients (66 percent) had a &ge;25 percent reduction in glomerular filtration rate at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/21\">",
"     21",
"    </a>",
"    ]. Multivariable analysis found that acute kidney injury, previous autologous HCT, long-term calcineurin inhibitor use, and chronic GVHD were independently associated with the development of CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF ACUTE KIDNEY INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of acute kidney injury after HCT are acute tubular necrosis, toxicity from medications such as calcineurin inhibitors, and hepatic sinusoidal obstructive syndrome (SOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/2,3,5,22\">",
"     2,3,5,22",
"    </a>",
"    ]. Acute tubular necrosis is typically seen during the period of pancytopenia in septic patients who may also be treated with one or more nephrotoxins, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (both liposomal and conventional), aminoglycosides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . Less frequent etiologies include tumor lysis syndrome, thrombotic microangiopathy, graft versus host disease (GVHD), and hemolysis associated with ABO incompatible transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, acute kidney injury after HCT may result from the overlapping occurrence of more than one of these etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"     \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hepatic sinusoidal obstruction syndrome (veno-occlusive disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hepatorenal-like syndrome due to hepatic sinusoidal obstruction syndrome (SOS) is a frequent cause of acute kidney injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Hepatic SOS is almost exclusively seen in the setting of HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\", section on 'Pathology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatic SOS is more commonly associated with myeloablative allogeneic HCT than with autologous HCT, which may due to the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    since GVHD is not a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/23\">",
"     23",
"    </a>",
"    ]. SOS does not occur with non-myeloablative regimens.",
"   </p>",
"   <p>",
"    The renal failure with hepatic SOS usually begins after the onset of the hepatic disease (as manifested by progressive hyperbilirubinemia) and a superimposed event, such as sepsis, often triggers the onset of renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with a plasma bilirubin concentration above 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (120",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    are at higher risk for the subsequent need for hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How the liver disease might cause renal dysfunction is not clear, but decreased hepatic clearance of endotoxin absorbed from the gut may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/24\">",
"     24",
"    </a>",
"    ]. It is possible that chemoradiation induced injury to sinusoidal epithelial cell leads to the development of portal hypertension, splanchnic vascular dilatation, sodium and water retention and systemic vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/24\">",
"     24",
"    </a>",
"    ], mimicking hepatorenal syndrome. In some patients, however, renal dysfunction is evident before the onset of overt liver disease.",
"   </p>",
"   <p>",
"    The fractional excretion of sodium typically remains below 1 percent in these patients, similar to the findings seen in the hepatorenal syndrome. The urinalysis often reveals many muddy brown granular casts; however, this abnormality appears to be induced by bilirubin toxicity rather than reflecting tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ABO incompatible transplants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive hematopoietic cells from a donor with a major ABO incompatibility are at risk for hemolysis and acute kidney injury due to hemoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/26\">",
"     26",
"    </a>",
"    ]. Nevertheless, these types of transplants are generally safe if careful attention is paid to minimizing the risk of hemolysis. This includes red blood cell depletion of the graft, vigorous hydration, and infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    if overt hemolysis does occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF SUBACUTE OR CHRONIC KIDNEY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of thrombotic microangiopathy in HCT is most likely due to a combination of factors that damage endothelium, including calcineurin inhibitors, chemotherapy, GVHD,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total body radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. The classic picture of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) induced by calcineurin inhibitors is a relatively rare complication occurring soon after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,22,25,28\">",
"     3,22,25,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instead, the most common clinical presentation is a subacute or chronic thrombotic microangiopathy that first becomes apparent 20 and 100 days after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,22,23,29-34\">",
"     3,22,23,29-34",
"    </a>",
"    ]. Affected patients present with the gradual onset of microangiopathic hemolytic anemia along with thrombocytopenia, a urinalysis that may be relatively normal or show mild proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematuria, and a moderate elevation in the plasma creatinine concentration.",
"   </p>",
"   <p>",
"    Histologic examination of the kidney reveals mesangiolysis with necrotizing arteriolar and glomerular lesions, and intraglomerular and renal arteriolar thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,29,30,32,34\">",
"     3,29,30,32,34",
"    </a>",
"    ]. The kidney seems to be the primary site of microangiopathy, since autopsy studies have not identified systemic thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The renal abnormalities are thought to reflect mesangial and endothelial damage induced by the chemotherapy and radiation that are given to eradicate the patient's underlying disease and provide immunosuppression prior to transplantation. In one study of 22 patients diagnosed with a TTP-like syndrome following HCT, all had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and 20 had received total body irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of radiation (as in radiation nephritis) is suggested by two findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial shielding of the kidneys during total body irradiation can diminish the incidence of late renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A late decline in renal function is seen primarily in patients treated with total body irradiation, not those treated only with chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the observations that some affected patients were not given radiation, and that high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    can induce mesangiolysis in animal models, suggests that an alkylating agent may also be pathogenetically important [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/39\">",
"     39",
"    </a>",
"    ]. The lack of cyclophosphamide nephrotoxicity in other settings is a probable reflection of the much lower dose (one-tenth) used to treat glomerulonephritis and vasculitis.",
"   </p>",
"   <p>",
"    It is possible that infection is an initiating or contributing factor. In a review of 35 autopsies of patients with thrombotic microangiopathy associated with HCT, infection was listed as the cause of death in 54 percent, with the most common organisms being Aspergillus species and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/34\">",
"     34",
"    </a>",
"    ]. This observation is consistent with the ability of these organisms to cause severe microangiopathic hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of thrombotic microangiopathy has varied in different studies (zero to 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,23,30,36,42\">",
"     3,23,30,36,42",
"    </a>",
"    ]. The diagnosis can be difficult to make as the presenting signs and laboratory findings, such as anemia, thrombocytopenia, and acute kidney injury, are common in patients who undergo HCT. Autopsy studies have noted a poor correlation between clinical criteria and histological findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/27,34,35,43\">",
"     27,34,35,43",
"    </a>",
"    ]. In most patients, the hematologic abnormalities eventually resolve, although hypertension and stable CKD (in which the plasma creatinine concentration is usually below 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 220",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    usually persist [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,15,31\">",
"     3,15,31",
"    </a>",
"    ]. Some patients progress to end-stage renal disease (ESRD) (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Management of patients on dialysis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/15,44\">",
"     15,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no convincing data to support the efficacy of plasma exchange in patients who develop thrombotic microangiopathy after HCT, in contrast to the beneficial response seen in most other forms of TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,33,34\">",
"     3,33,34",
"    </a>",
"    ]. Plasma exchange has been tried in selected patients with generally disappointing results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3,34,36,45,46\">",
"     3,34,36,45,46",
"    </a>",
"    ]. The lack of efficacy of plasma exchange may be due to the fact that TTP-HUS following HCT is due to direct injury to the kidney from drugs or radiation, and deficiency of the ADAMTS-13 protease, which is present in classic TTP, is not involved in the pathogenesis of thrombotic microangiopathy after HCT. Since thrombotic microangiopathy is often associated with calcineurin toxicity, discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a survey of the literature, no reported patient convincingly responded to plasma infusion or exchange and patients were not severely deficient in the vWF cleaving protease, indicating that these patients do not have classic TTP. In addition, the microangiopathy appears to primarily limited to the kidney, since systemic thrombotic microangiopathy was not identified at autopsy in the review cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/34\">",
"     34",
"    </a>",
"    ]. Instead, supportive care and withdrawal of calcineurin inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A, are the mainstays of therapy. Small studies utilizing daclizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/47\">",
"     47",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/48\">",
"     48",
"    </a>",
"    ] for treatment have met with moderate success.",
"   </p>",
"   <p>",
"    Given the current lack of effective therapy, prevention is the major therapeutic goal in this disorder. Studies suggest that the risk of this condition may be minimized by shielding the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/37\">",
"     37",
"    </a>",
"    ], by fractionating the total body irradiation over several days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/18,29\">",
"     18,29",
"    </a>",
"    ], and by replacing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with other types of chemotherapeutic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3\">",
"     3",
"    </a>",
"    ]. It may also be desirable to avoid the use of other nephrotoxins such as platinum in close proximity to the conditioning regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/49\">",
"     49",
"    </a>",
"    ]. Vigorous hydration is also likely important.",
"   </p>",
"   <p>",
"    Studies in animal models of radiation nephritis and bone marrow transplantation nephropathy suggest that angiotensin converting enzyme (ACE) inhibitors may be effective for both prevention and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The applicability of these findings to humans is uncertain, but it seems prudent to preferentially use an ACE inhibitor in patients who become hypertensive. Prophylactic therapy is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitor toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic calcineurin inhibitor therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , can cause nephrotoxicity similar to that seen in other settings, such as solid organ transplantation. The early renal vasoconstriction induced by these agents is markedly enhanced by concurrent therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , and a temporary reduction in dose or cessation of therapy may be indicated if acute kidney injury occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/3\">",
"     3",
"    </a>",
"    ]. Frequent monitoring of the plasma creatinine concentration with dose adjustments for rising creatinine values is also helpful.",
"   </p>",
"   <p>",
"    Long-term complications are unusual because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is given in full doses to stable patients for only several months. However, the characteristic vascular and interstitial changes of cyclosporine nephrotoxicity can occur with prolonged therapy for GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/54\">",
"     54",
"    </a>",
"    ]. Similar considerations apply to the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports and case series of nephrotic syndrome following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/11,55-61\">",
"     11,55-61",
"    </a>",
"    ]. As an example, in one series of 163 patients who underwent HCT, nephrotic syndrome developed in seven (4.3 percent) a median of 300 days after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/56\">",
"     56",
"    </a>",
"    ]. A variety of histologic patterns have been reported; the most common are membranous nephropathy (MN) followed by minimal change disease (MCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/11,56,57,62\">",
"     11,56,57,62",
"    </a>",
"    ]. This was illustrated in a literature review of 42 well-documented cases; 60 percent had MN and 22 percent had MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of MN is often associated with a decrease in immunosuppression and, therefore, with an increased likelihood of GVHD. A proposed mechanism is immune dysregulation from transfer of alloreactive donor lymphocytes with reactivity toward glomerular antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/63\">",
"     63",
"    </a>",
"    ]. In the above literature review, nephrotic syndrome was diagnosed 8 to 14 months following HCT, and all 42 cases occurred within two months following the diagnosis of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Remission frequently occurs upon re-initiation of immunosuppressive drugs (corticosteroids, in particular) or anti-B cell therapy (anti-CD20,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/58\">",
"     58",
"    </a>",
"    ], but some do progress to ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/56\">",
"     56",
"    </a>",
"    ]. The treatment is the same as for idiopathic MN, but success is variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PATIENTS ON DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients who develop dialysis-requiring kidney disease varies with the time of onset. The requirement for dialysis for acute kidney injury occurring in the peritransplant period is an ominous event since it typically occurs in association with injury to multiple other organs. Relatively few of these patients are long-term survivors. (See",
"    <a class=\"local\" href=\"#H66480165\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who require dialysis at a later stage (ie, ESRD), when they are hematologically stable should do better. Among patients with ESRD, using a kidney for renal transplantation from the original hematopoietic cell donor may obviate the need for anti-rejection therapy, since the donor cells have repopulated the patient's bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. By comparison, with an allograft that is foreign to donated marrow cells, antirejection therapy is still required, but perhaps at lower doses since reconstituted marrow may not be fully functional [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/50\">",
"     50",
"    </a>",
"    ]. Combined hematopoietic cell and kidney transplant has also resulted in the development of tolerance to the transplanted kidney and withdrawal of immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1609/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44135?source=see_link\">",
"     \"Investigational immunosuppressive drugs and approaches in clinical kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury occurs in approximately 50 percent of patients following hematopoietic cell transplantation (HCT). The incidence rate is highest after myeloablative allogeneic HCT and lowest after autologous HCT. Although kidney injury is usually mild, severe acute kidney injury requiring dialysis may occur in a small percentage of patients and is associated with a grim prognosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology of acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute kidney injury after HCT is most commonly due to acute tubular necrosis, medication-related toxicity, or hepatic veno-occlusive disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology of acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic kidney disease may occur following HCT and is often due to a subacute form of thrombotic microangiopathy related to calcineurin inhibitors, chemotherapy, graft versus host disease (GVHD),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      total body radiation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology of subacute or chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of thrombotic microangiopathy includes supportive care and the withdrawal of calcineurin inhibitors. Plasma exchange has not been shown to be effective. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nephrotic syndrome in association with membranous nephropathy or minimal change disease may rarely occur following HCT and appears to be related to graft versus host disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nephrotic syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Renal disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare patients who require dialysis at a later stage when they are hematologically stable do better and may benefit from a kidney transplant. Using a kidney for renal transplantation from the original hematopoietic cell donor may obviate the need for anti-rejection therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management of patients on dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/1\">",
"      Cohen EP. Renal failure after bone-marrow transplantation. Lancet 2001; 357:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/2\">",
"      Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/3\">",
"      Zager RA. Acute renal failure in the setting of bone marrow transplantation. Kidney Int 1994; 46:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/4\">",
"      Parikh CR, McSweeney PA, Korular D, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002; 62:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/5\">",
"      Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005; 67:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/6\">",
"      Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/7\">",
"      Parikh CR, Schrier RW, Storer B, et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005; 45:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/8\">",
"      Parikh CR, Sandmaier BM, Storb RF, et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 2004; 15:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/9\">",
"      Parikh CR, McSweeney P, Schrier RW. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005; 67:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/10\">",
"      Ando M, Mori J, Ohashi K, et al. A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT. Bone Marrow Transplant 2010; 45:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/11\">",
"      Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006; 17:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/12\">",
"      Kal HB, van Kempen-Harteveld ML. Renal dysfunction after total body irradiation: dose-effect relationship. Int J Radiat Oncol Biol Phys 2006; 65:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/13\">",
"      Ellis MJ, Parikh CR, Inrig JK, et al. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant 2008; 8:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/14\">",
"      Guinan EC, Tarbell NJ, Niemeyer CM, et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/15\">",
"      Cohen EP, Lawton CA, Moulder JE, et al. Clinical course of late-onset bone marrow transplant nephropathy. Nephron 1993; 64:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/16\">",
"      Cohen EP, Lawton CA, Moulder JE. Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron 1995; 70:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/17\">",
"      Lawton CA, Cohen EP, Barber-Derus SW, et al. Late renal dysfunction in adult survivors of bone marrow transplantation. Cancer 1991; 67:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/18\">",
"      Leblond V, Sutton L, Jacquiaud C, et al. Evaluation of renal function in 60 long-term survivors of bone marrow transplantation. J Am Soc Nephrol 1995; 6:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/19\">",
"      Borg M, Hughes T, Horvath N, et al. Renal toxicity after total body irradiation. Int J Radiat Oncol Biol Phys 2002; 54:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/20\">",
"      Cheng JC, Schultheiss TE, Wong JY. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 2008; 71:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/21\">",
"      Weiss AS, Sandmaier BM, Storer B, et al. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/22\">",
"      Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/23\">",
"      Parikh CR, Coca SG. Acute renal failure in hematopoietic cell transplantation. Kidney Int 2006; 69:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/24\">",
"      McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/25\">",
"      Fink JC, Cooper MA, Burkhart KM, et al. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced \"hepatorenal syndrome\". J Am Soc Nephrol 1995; 6:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/26\">",
"      Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/27\">",
"      Changsirikulchai S, Myerson D, Guthrie KA, et al. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009; 4:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/28\">",
"      Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/29\">",
"      Antignac C, Gubler MC, Leverger G, et al. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989; 35:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/30\">",
"      Loomis LJ, Aronson AJ, Rudinsky R, Spargo BH. Hemolytic uremic syndrome following bone marrow transplantation: a case report and review of the literature. Am J Kidney Dis 1989; 14:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/31\">",
"      Rabinowe SN, Soiffer RJ, Tarbell NJ, et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/32\">",
"      Cruz DN, Perazella MA, Mahnensmith RL. Bone marrow transplant nephropathy: a case report and review of the literature. J Am Soc Nephrol 1997; 8:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/33\">",
"      Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/34\">",
"      George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/35\">",
"      Siami K, Kojouri K, Swisher KK, et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/36\">",
"      Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/37\">",
"      Lawton CA, Barber-Derus SW, Murray KJ, et al. Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. Int J Radiat Oncol Biol Phys 1992; 23:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/38\">",
"      Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol 2003; 23:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/39\">",
"      H&eacute;bert MJ, Fish D, Madore F, et al. Mesangiolysis associated with bone marrow transplantation: new insights on possible etiogenic factors. Am J Kidney Dis 1994; 23:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/40\">",
"      Grigg A, Clouston D. Disseminated fungal infection and early onset microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/41\">",
"      Maslo C, Peraldi MN, Desenclos JC, et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/42\">",
"      Imai H, Oyama Y, Miura AB, et al. Hematopoietic cell transplantation-related nephropathy in Japan. Am J Kidney Dis 2000; 36:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/43\">",
"      El-Seisi S, Gupta R, Clase CM, et al. Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2003; 9:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/44\">",
"      Atkinson K, Biggs JC, Hayes J, et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol 1983; 54:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/45\">",
"      Elliott MA, Nichols WL Jr, Plumhoff EA, et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/46\">",
"      Moulder JE, Fish BL. Influence of nephrotoxic drugs on the late renal toxicity associated with bone marrow transplant conditioning regimens. Int J Radiat Oncol Biol Phys 1991; 20:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/47\">",
"      Wolff D, Wilhelm S, Hahn J, et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 2006; 38:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/48\">",
"      Au WY, Ma ES, Lee TL, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/49\">",
"      Silva VA, Frei-Lahr D, Brown RA, Herzig GP. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apher 1991; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/50\">",
"      Cohen EP. Radiation nephropathy after bone marrow transplantation. Kidney Int 2000; 58:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/51\">",
"      Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 1993; 27:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/52\">",
"      Cohen EP, Moulder JE, Fish BL, Hill P. Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med 1994; 124:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/53\">",
"      Paller MS. Bone marrow transplantation nephropathy. J Lab Clin Med 1994; 124:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/54\">",
"      Dieterle A, Gratwohl A, Nizze H, et al. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 1990; 49:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/55\">",
"      Ruiz-Arguelles GJ, Gomez-Almaguer D. Nephrotic syndrome after non-myeloablative stem cell transplantation. Br J Haematol 2006; 132:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/56\">",
"      Srinivasan R, Balow JE, Sabnis S, et al. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol 2005; 131:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/57\">",
"      Brukamp K, Doyle AM, Bloom RD, et al. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol 2006; 1:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/58\">",
"      Reddy P, Johnson K, Uberti JP, et al. Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/59\">",
"      Kawakami K, Watanabe Y, Mukai K, et al. Nephrotic syndrome with extensive mesangiolysis as a clinical manifestation of chronic graft-versus-host disease (GVHD). Int J Hematol 2005; 82:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/60\">",
"      Suehiro T, Masutani K, Yokoyama M, et al. Diffuse proliferative glomerulonephritis after bone marrow transplantation. Clin Nephrol 2002; 58:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/61\">",
"      Kemper MJ, G&uuml;ng&ouml;r T, Halter J, et al. Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation. Clin Nephrol 2007; 67:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/62\">",
"      Terrier B, Delmas Y, Hummel A, et al. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. Nephrol Dial Transplant 2007; 22:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/63\">",
"      Stevenson WS, Nankivell BJ, Hertzberg MS. Nephrotic syndrome after stem cell transplantation. Clin Transplant 2005; 19:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/64\">",
"      Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/65\">",
"      Butcher JA, Hariharan S, Adams MB, et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 1999; 13:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1609/abstract/66\">",
"      Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7197 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1609=[""].join("\n");
var outline_f1_36_1609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology of acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66480158\">",
"      - Type of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66480165\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY OF ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hepatic sinusoidal obstruction syndrome (veno-occlusive disease)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ABO incompatible transplants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY OF SUBACUTE OR CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Calcineurin inhibitor toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT OF PATIENTS ON DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44135?source=related_link\">",
"      Investigational immunosuppressive drugs and approaches in clinical kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_36_1610="Ablative laser resurfacing for skin rejuvenation";
var content_f1_36_1610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ablative laser resurfacing for skin rejuvenation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/36/1610/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1610/contributors\">",
"     David J Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/36/1610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1610/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/36/1610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/36/1610/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/36/1610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15356078\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablative laser resurfacing is used to target the cutaneous signs of photodamage that progressively increase with age and occur most prominently in individuals with fair skin. Through the ablation of the epidermis and portions of the superficial dermis as well as the induction of collagen remodeling in the deeper dermis, ablative laser resurfacing can reduce rhytides (wrinkles), dyschromia, vascular changes, and skin laxity.",
"   </p>",
"   <p>",
"    The mechanism of action, efficacy, adverse effects, and administration of traditional and fractional ablative laser resurfacing for skin rejuvenation will be discussed here. The basic principles of laser therapy for cutaneous lesions are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8009623\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technology for ablative laser resurfacing has continuously evolved. The procedure was first performed in the 1980s with the continuous wave carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ) laser. Use of this laser was complicated by an unfavorably high risk of adverse effects, and the subsequent development of pulsed CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers and rapidly scanning continuous wave CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers improved the safety of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/1\">",
"     1",
"    </a>",
"    ]. In the 1990s the erbium:yttrium aluminum garnet (Er:YAG) laser was introduced as an alternative device for ablative laser resurfacing. Advantages of Er:YAG lasers included more precise control over the depth of cutaneous ablation and a lower incidence of adverse effects.",
"   </p>",
"   <p>",
"    For a number of years, the CO",
"    <sub>",
"     2",
"    </sub>",
"    and Er:YAG lasers were the primary lasers used for ablative laser resurfacing for skin rejuvenation, with CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers considered the gold standard for this indication. However, in the early 2000s, the approach to laser skin rejuvenation was dramatically altered by the development of fractional lasers, which emit numerous narrow, microscopic columns of laser light. Fractional lasers treat only a defined fraction of the skin within a targeted area, leaving intervening areas of skin unaffected (",
"    <a class=\"graphic graphic_figure graphicRef53757 \" href=\"UTD.htm?38/15/39153\">",
"     figure 1",
"    </a>",
"    ). The reservoir of undamaged skin adjacent to sites of laser injury allows for rapid reepithelialization after treatment through the migration of viable cells into wounded areas.",
"   </p>",
"   <p>",
"    Aside from the repair of photodamaged skin, ablative laser resurfacing is used for a variety of other indications, such as the treatment of scars, actinic keratoses, epidermal nevi, and other cutaneous lesions and disorders. Nonablative traditional and fractional lasers also have been studied for facial rejuvenation; however, these lasers generally are less efficacious than their ablative counterparts for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18975495\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92421460\">",
"    <span class=\"h2\">",
"     Patient evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the appropriate patient is of critical importance in ablative laser resurfacing. The patient should be thoroughly informed of the expected treatment outcome, anticipated recovery period, and treatment risks. In most cases, treatment results in mild to moderate improvements in cutaneous signs of photoaging (",
"    <a class=\"graphic graphic_picture graphicRef81643 \" href=\"UTD.htm?20/42/21152\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The length of time required for healing after ablative laser resurfacing is a deterrent for some patients. The expected convalescent period after traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing is around two weeks and is followed by several weeks to several months of persistent facial erythema. Shorter recovery periods are associated with resurfacing with traditional Er:YAG lasers and fractional lasers. Reepithelialization after traditional Er:YAG laser resurfacing is usually complete after three to eight days and postoperative erythema resolves more quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Patients treated with the fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser can usually return to normal activity after 5 to 10 days, depending on the intensity of treatment; less time is needed for recovery after fractional Er:YAG resurfacing.",
"   </p>",
"   <p>",
"    The specific concerns of the patient and the clinical features contributing to an aged appearance should be assessed carefully by the clinician to ensure that treatment is likely to achieve the desired result. Although laser resurfacing can lead to improvements in rhytides such as those in the periorbital, cheek, and periocular areas, deep nasolabial creases, marionette lines, and severe skin laxity are often best managed with interventions such as injectable cosmetic fillers and surgery. Dynamic rhytides (wrinkles exacerbated by facial muscle movement) may recur within months after successful ablative laser therapy. Patients with dynamic rhytides may benefit from the use of botulinum toxin before and after laser resurfacing to delay the recurrence of rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link&amp;anchor=H4081882#H4081882\">",
"     \"Overview of botulinum toxin for cosmetic indications\", section on 'Use as adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92421453\">",
"    <span class=\"h2\">",
"     Choice of laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paucity of high quality data on the efficacy of both traditional and fractional ablative lasers in facial rejuvenation makes evidence-based practice challenging. The available data are primarily limited to uncontrolled studies and a few small randomized trials. In addition, systematic interpretation of the published literature is compromised by wide variation in criteria used to assess treatment responses and clinically significant differences among devices within the same laser class. The differences among brands of ablative lasers also make standardization of treatment regimens impossible.",
"   </p>",
"   <p>",
"    The relative efficacy of traditional and fractional ablative lasers remains uncertain, and the choice of procedure is heavily influenced by patient-specific factors, laser availability, and clinician expertise. The traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser appears to have a greater effect on dermal collagen remodeling than traditional Er:YAG lasers; this effect clinically manifests as favorable tightening of lax skin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. However, due to a relatively high risk of adverse effects (eg, scarring, dyspigmentation, and prolonged erythema) and a recovery period that exceeds that associated with fractional lasers, use of the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser has become less popular with the advent of new therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The traditional Er:YAG laser requires more laser passes (retreatment of the same area during a single treatment session) than traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers to achieve a similar depth of ablation. The more precise skin ablation feasible with the Er:YAG laser is desired in some clinical settings, but may also contribute to reduced thermal damage to underlying collagen resulting in a lesser skin tightening effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The traditional Er:YAG has been favored by some clinicians for the treatment of dyschromia and fine wrinkling associated with photodamage rather than for the treatment of coarse, deep rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"     3",
"    </a>",
"    ]. The Er:YAG also appears to have a lower risk for scarring than the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser and may be beneficial for the treatment of areas at greater risk for laser-induced scar formation, such as delicate periorbital skin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like traditional ablative lasers, fractional ablative lasers improve dyschromia and rhytides associated with cutaneous photodamage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/9\">",
"     9",
"    </a>",
"    ]. Although comparative trials are lacking, some authors have suggested that the efficacy of fractional ablative lasers for skin tightening may exceed that of traditional ablative lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/7\">",
"     7",
"    </a>",
"    ]. This assertion plus the relatively short recovery period and reduced risk for adverse effects associated with fractional ablative lasers have contributed to a near total shift away from traditional lasers to fractional lasers as the preferred devices for ablative laser resurfacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional high quality studies are necessary to clarify the role of fractional ablative lasers in skin rejuvenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H903511\">",
"    <span class=\"h2\">",
"     Dark skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although photodamage often is less severe in individuals with dark skin compared with fair-skinned people, patients with skin phototypes IV and higher also present for the treatment of photoaging. Laser induced dyspigmentation is a major concern in this population, as the risk for this adverse effect rises with increasing baseline skin pigmentation. (See",
"    <a class=\"local\" href=\"#H7559620\">",
"     'Adverse effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1449770\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hyperpigmentation and hypopigmentation may occur with all forms of ablative laser resurfacing, but is most likely to occur after treatment with traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3,10-12\">",
"     3,10-12",
"    </a>",
"    ]. Thus, we generally avoid the use of traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers for the treatment of photodamage in patients with skin phototype IV or higher. Fractional ablative lasers may be a preferable alternative in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Additional studies are necessary to determine the most appropriate treatments and laser settings for ablative laser therapy for skin rejuvenation in patients with dark skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693104\">",
"    <span class=\"h2\">",
"     Nonfacial sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablative laser resurfacing for photodamage primarily is used for the treatment of the face; however, patients frequently present with photodamage on other photoexposed areas such as the neck and hands. Due to an unacceptably high risk for scarring, treatment with traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers is contraindicated in these locations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk for scarring appears to be lower with fractional ablative lasers and traditional Er:YAG lasers, and successful treatment of the neck and hands with these devices has been documented in small, uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. Yet, treatment must be approached with caution, as the development of severe scarring after treatment has been reported in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832338\">",
"    <span class=\"h1\">",
"     TRADITIONAL ABLATIVE LASERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional ablative lasers used for skin rejuvenation include the 10,600 nm pulsed and rapidly scanning CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers and the 2940 nm pulsed Er:YAG laser.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H214349\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theory of selective photothermolysis is the basis for the efficacy of traditional ablative lasers in skin rejuvenation. The theory is based upon the following principles [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/22\">",
"     22",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999074#H31999074\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Selective photothermolysis'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The wavelength of light utilized should be absorbed preferentially by light absorbing molecules (chromophores) in the target and must penetrate the skin sufficiently to reach its depth.",
"     </li>",
"     <li>",
"      The light must be delivered in a period of time that is short enough to prevent the transfer of excessive heat to adjacent structures.",
"     </li>",
"     <li>",
"      The energy delivered per unit area (fluence) must be sufficient to exert the desired therapeutic effect, but should also be at a level that minimizes undesirable collateral tissue damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The depth of light absorption into the skin generally rises with increasing light wavelengths. According to this principle, one would expect infrared light emitted from CO",
"    <sub>",
"     2",
"    </sub>",
"    and Er:YAG lasers to penetrate more deeply into the skin than light emitted from the 585 to 600 nm pulsed dye lasers that are often used for the treatment of vascular lesions in the dermis (",
"    <a class=\"graphic graphic_figure graphicRef60561 \" href=\"UTD.htm?43/30/44516\">",
"     figure 2",
"    </a>",
"    ). However, because light emitted by CO",
"    <sub>",
"     2",
"    </sub>",
"    and Er:YAG lasers is highly absorbed by water in the epidermis, little light reaches deeper levels of the skin. At a setting of 5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and a pulse duration of less than 1 ms, light from the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser penetrates to a depth of approximately 20 to 30 &micro;m [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"     23",
"    </a>",
"    ]. Water molecules have an even greater affinity for light emitted from Er:YAG lasers, which reaches depths of only 1 to 3 &micro;m per",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    The absorption of light energy by water in the epidermis leads to the rapid accumulation of heat and consequent vaporization of the epidermis. Thermal damage extends beyond the penetration of light; residual thermal damage reaches depths of 100 to 150 &micro;m with traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers and 10 to 40 &micro;m with traditional ER:YAG lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"     23",
"    </a>",
"    ]. The heat transferred to underlying dermal collagen is believed to contribute to collagen contraction and remodeling as well as clinically evident skin tightening [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/6,24-26\">",
"     6,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excessive transfer of heat to the dermis can lead to adverse effects such as scarring and permanent hypopigmentation. To minimize this risk, the time the laser beam is in contact with the skin (pulse duration) should be shorter than the time it takes the treated area of skin to return to ambient temperature (tissue thermal relaxation time) (",
"    <a class=\"graphic graphic_figure graphicRef78746 \" href=\"UTD.htm?23/29/24017\">",
"     figure 3",
"    </a>",
"    ). CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing was initially performed with continuous wave CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers, which offered relatively poor control over the duration of time that the laser beam was in contact with the skin. The development of the high energy pulsed CO",
"    <sub>",
"     2",
"    </sub>",
"    laser (pulse duration less than 1 ms) and short pulsed Er:YAG laser (pulse duration 250 to 350 &micro;s) allowed the delivery of sufficient amounts of energy to induce ablation, while maintaining tight control over the duration light delivery and reducing the risk for inadvertent damage. Rapidly scanning CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers utilize a computerized scanning mechanism to limit the duration of contact of the laser beam with any given site on the skin and are an alternative to pulsed devices.",
"   </p>",
"   <p>",
"    The principles of laser therapy in the skin are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7559533\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally accepted that skin resurfacing with traditional ablative lasers is effective for cutaneous rejuvenation. However, data on efficacy are primarily limited to uncontrolled studies and a few small randomized comparison trials. In addition, the methods used to assess treatment responses have been inconsistent and often poorly defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146740\">",
"    <span class=\"h3\">",
"     CO2 lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of studies that have investigated the value of traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers in skin rejuvenation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study, 259 patients with facial rhytides were treated with a high energy pulsed CO",
"      <sub>",
"       2",
"      </sub>",
"      laser [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/27\">",
"       27",
"      </a>",
"      ]. All patients responded to treatment; the average improvement in rhytides compared to surrounding untreated skin was reported as 90 percent.",
"     </li>",
"     <li>",
"      In an uncontrolled study that investigated the efficacy of CO",
"      <sub>",
"       2",
"      </sub>",
"      laser resurfacing for perioral (n = 73) or periorbital wrinkles (n = 38), multiple pass treatment with a high energy pulsed CO",
"      <sub>",
"       2",
"      </sub>",
"      laser led to reduced severity of wrinkling as assessed with a nine-point clinical scoring system [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/28\">",
"       28",
"      </a>",
"      ]. The average wrinkling score reduction was 2.25 in the periorbital region and 2.34 in the perioral area. A subjective improvement in skin laxity also was reported. Patient skin phototypes ranged from I to IV (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a retrospective study of 47 patients with perioral, periorbital, and glabellar rhytides (skin phototype I to IV) who were treated with a rapidly scanning CO",
"      <sub>",
"       2",
"      </sub>",
"      laser, good to excellent cosmetic results were attained in all anatomic areas [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92421580\">",
"    <span class=\"h3\">",
"     Er:YAG lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of studies of traditional Er:YAG lasers in skin rejuvenation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study of 15 patients with facial rhytides (skin phototype I to III), full face resurfacing with a short pulse Er:YAG laser was associated with marked improvement (50 to 75 percent improvement in fine to moderate wrinkles) in eight patients (53 percent) and moderate improvement (25 to 50 percent improvement in fine to moderate wrinkles) in six patients (40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an uncontrolled study of 20 patients with perioral, periorbital, or forehead rhytides (skin phototype I to III), treatment with a short pulse Er:YAG laser led to clinical improvement in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fluence levels of 5 to 15",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are commonly used for ablative resurfacing with Er:YAG lasers. Microablative procedures, which utilize lower fluences and a single laser pass may also have some benefit for the treatment of photoaging [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7558968\">",
"    <span class=\"h3\">",
"     Comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;On a per laser pass basis, traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing is associated with more dramatic clinical improvement than traditional Er:YAG laser resurfacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/32\">",
"     32",
"    </a>",
"    ]. The use of higher numbers of passes with the Er:YAG laser may augment the treatment effect.",
"   </p>",
"   <p>",
"    The following studies compared the efficacy of traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    and Er:YAG lasers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single pass with pulsed CO",
"      <sub>",
"       2",
"      </sub>",
"      laser was compared with four passes with a short pulse Er:YAG laser in a split-face randomized trial of 13 patients (skin phototype I to III) with facial rhytides [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/33\">",
"       33",
"      </a>",
"      ]. No significant difference was noted between the two therapies in regards to improvement in hyperpigmentation and reduction of rhytides. Overall, improvement was modest.",
"     </li>",
"     <li>",
"      In a split-face randomized trial of 21 patients (skin phototype I to III), one side of the face was treated two to three passes with a pulsed CO",
"      <sub>",
"       2",
"      </sub>",
"      laser and the other side treated with at least two passes with a short pulse Er:YAG laser. Treatment with the CO",
"      <sub>",
"       2",
"      </sub>",
"      laser led to greater improvement in rhytides [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/32\">",
"       32",
"      </a>",
"      ]. However, patients who received five or more passes with the Er:YAG device exhibited similar results as those who received two to three passes with the CO",
"      <sub>",
"       2",
"      </sub>",
"      laser. Patients treated with the Er:YAG device showed faster resolution of post-treatment erythema and a lower incidence of laser-induced hypopigmentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Er:YAG laser has a lesser coagulative effect that the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser. In practice, bleeding can be a limiting factor for the performance of multiple passes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long pulse Er:YAG lasers have been used in an attempt to improve the efficacy of Er:YAG devices for deep rhytides through increasing the depth of thermal damage. However, CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers remain more effective for this indication. In a bilateral comparison study of 12 patients with perioral and periorbital rhytides, both a 10 ms pulsed Er:YAG laser and high energy pulsed CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resulted in good improvement, yet the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser was more efficacious for deep rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/35\">",
"     35",
"    </a>",
"    ]. A split-face randomized trial that compared the response of periorbital rhytides to two nonoverlapping passes with a pulsed CO",
"    <sub>",
"     2",
"    </sub>",
"    laser or six passes with a variable pulse Er:YAG laser (including one pass with a 10 ms pulse duration) found similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination therapy with CO",
"    <sub>",
"     2",
"    </sub>",
"    and Er:YAG lasers also has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In a randomized trial of 20 patients with facial rhytides, sequential treatment with a pulsed CO",
"    <sub>",
"     2",
"    </sub>",
"    laser and short pulse Er:YAG laser resulted in similar treatment efficacy as CO",
"    <sub>",
"     2",
"    </sub>",
"    laser treatment alone and a reduced incidence of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7559620\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of traditional ablative laser resurfacing include persistent erythema, dyspigmentation, infections, and scarring. Erythema usually resolves approximately one month after Er:YAG resurfacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and two months following CO",
"    <sub>",
"     2",
"    </sub>",
"    resurfacing, but can persist for up to one year in patients treated with CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2,29\">",
"     2,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient postinflammatory hyperpigmentation occurs in approximately 30 percent of patients and is more likely to occur in patients with skin phototypes III or higher (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/1,10,27\">",
"     1,10,27",
"    </a>",
"    ]. Hypopigmentation, which is more common in light skinned individuals, may not be evident until several months after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing is more likely to induce dyschromia than other forms of laser resurfacing. (See",
"    <a class=\"local\" href=\"#H903511\">",
"     'Dark skin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reactivation and local spread of herpes simplex virus (HSV) infection can occur after laser ablation. Because of the relatively high prevalence of HSV infection, all patients undergoing full face ablative resurfacing should be treated with prophylactic antivirals. Bacterial and candidal infections may also follow laser resurfacing. Clinical signs suggestive of infection include worsening pain, drainage, erosions, or crusting. (See",
"    <a class=\"local\" href=\"#H1449911\">",
"     'Prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Acneiform eruptions and milia can develop in the postoperative period and may be exacerbated by the occlusive ointments utilized for the maintenance of skin moisture during healing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2,3,29\">",
"     2,3,29",
"    </a>",
"    ]. In addition, compromise of the skin barrier in the treated area contributes to an increased susceptibility to contact dermatitis.",
"   </p>",
"   <p>",
"    The risk for scarring is greatest with traditional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing, but scarring can also occur after treatment with the traditional Er:YAG laser. Use of appropriate laser settings and careful preoperative screening may reduce the risk for this adverse event. (See",
"    <a class=\"local\" href=\"#H1449897\">",
"     'Patient selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449883\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of measures are necessary for the safe utilization of traditional ablative lasers. Safe practices begin with preoperative interventions and continue into the postoperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449890\">",
"    <span class=\"h3\">",
"     Preoperative",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449897\">",
"    <span class=\"h4\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the initiation of treatment, patients must be fully informed of treatment risks and expectations. Patients also should be assessed for contraindications to therapy. Laser resurfacing is contraindicated in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       History of keloidal scarring",
"      </strong>",
"      &ndash; The exclusion of patients with a history of keloids is based upon concern for an elevated risk for severe scarring after ablative laser treatment. However, this has not been specifically studied.",
"     </li>",
"     <li>",
"      <strong>",
"       Oral",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      <strong>",
"       therapy within one year &ndash;",
"      </strong>",
"      The recommendation to avoid laser resurfacing in patients recently treated with oral isotretinoin is generally accepted; however, data on the risk of scarring after laser resurfacing are lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2\">",
"       2",
"      </a>",
"      ]. Atypical scarring has been reported after dermabrasion in patients treated with isotretinoin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/41,42\">",
"       41,42",
"      </a>",
"      ], but the validity of this risk has been questioned [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Sites of morphea, scleroderma, or prior radiation therapy &ndash;",
"      </strong>",
"      Treatment should be avoided in these sites. In affected areas, a diminished supply of the adnexal stem cells necessary to repopulate the epidermis may contribute to impaired wound healing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2,23\">",
"       2,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Ectropion &ndash;",
"      </strong>",
"      Infraorbital resurfacing is contraindicated in patients with ectropion, and in patients with lax infraorbital skin, care must be taken to treat the infraorbital skin less aggressively than other facial areas [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"       3",
"      </a>",
"      ]. Skin tightening after laser resurfacing may exacerbate or induce ectropion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Underlying cutaneous diseases that can appear in sites of cutaneous injury, such as vitiligo, lichen planus, and psoriasis, are relative contraindications for laser resurfacing due to the potential for the appearance or worsening of lesions in treated areas (Koebner phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2\">",
"     2",
"    </a>",
"    ]. The risks and benefits of treatment should also be considered carefully in patients with a history of facial surgery (eg, face-lifts or blepharoplasty). Surgical procedures may result in an altered blood supply and a higher risk for necrosis and scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the patient&rsquo;s skin color influences the decision to proceed with therapy. The risk of dyspigmentation rises with increasing skin pigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/10\">",
"     10",
"    </a>",
"    ], making patients with skin phototypes I to IV the preferred candidates for ablative laser resurfacing (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ). Because the risks for temporary and permanent dyspigmentation are greatest with the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser, we generally avoid CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing for skin rejuvenation in patients with skin phototypes IV or higher and prefer to use fractional ablative or traditional Er:YAG lasers in this subgroup of patients. (See",
"    <a class=\"local\" href=\"#H903511\">",
"     'Dark skin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449911\">",
"    <span class=\"h4\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antiviral prophylaxis is recommended to prevent reactivation of facial herpes simplex virus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. We typically administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    200 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    500 mg twice daily, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    500 mg twice daily, one day before treatment and continue until reepithelialization is complete (usually two weeks for patients receiving CO",
"    <sub>",
"     2",
"    </sub>",
"    laser ablation).",
"   </p>",
"   <p>",
"    Opinions vary on the use of prophylactic therapy for bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The routine administration of antibiotics with gram positive coverage has been recommended by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/47\">",
"     47",
"    </a>",
"    ], while others have suggested that prophylactic antibiotics may not be necessary in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. We typically do not use antibiotic prophylaxis, and limit its use for patients who we perceive to be at high risk for infection, such as immunosuppressed individuals.",
"   </p>",
"   <p>",
"    Pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    is often recommended as a measure to improve healing time; however, there are insufficient data on the efficacy of this practice [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. One randomized trial in which topical tretinoin 0.05% or a placebo cream was applied to the forearm for three weeks prior to CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing found no evidence that topical tretinoin enhanced collagen formation, accelerated reepithelialization, or stimulated more rapid resolution of postoperative erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/51\">",
"     51",
"    </a>",
"    ]. Additional studies are necessary to determine whether these findings are applicable to the treatment of facial skin.",
"   </p>",
"   <p>",
"    The efficacy of another common practice, the use of preoperative topical skin-lightening agents, was brought into question by a randomized trial of 100 patients. No significant difference in the incidence of post-laser hyperpigmentation was detected among patients given no pretreatment, pretreatment with 10% glycolic acid cream, or pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    4% cream plus tretinoin 0.025% cream [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/57\">",
"     57",
"    </a>",
"    ]. However, patients in the trial were limited to skin phototypes I to III, and it is unclear whether these results apply to patients with darker skin tones, in whom the risk of hyperpigmentation is much higher (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ). We typically do not use skin lightening products before treatment, but utilize these agents in the post-treatment setting. (See",
"    <a class=\"local\" href=\"#H1449925\">",
"     'Postoperative'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Oral glucocorticoids are used by some clinicians to reduce post-treatment edema. The value and safety of oral glucocorticoids in this setting has not been formally studied, and we generally do not use oral glucocorticoids in the management of our patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449918\">",
"    <span class=\"h3\">",
"     Intraoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablative laser therapy is painful. Topical anesthetics often are sufficient for focal procedures utilizing the Er:YAG laser. Local infiltrative anesthesia or nerve blocks can be used when additional anesthesia is required. Local anesthesia plus systemic anxiolytics, oral narcotics, or intramuscular sedation are usually needed for full face procedures or localized CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"     23",
"    </a>",
"    ]. Intravenous anesthesia is often utilized during full face CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing.",
"   </p>",
"   <p>",
"    More than one laser pass (retreatment of a site during the same treatment session) is often performed in ablative laser resurfacing. The effacement of wrinkles indicates the treatment endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2\">",
"     2",
"    </a>",
"    ]. A yellow or brown color noted after wiping away desiccated tissue after a pass with a CO",
"    <sub>",
"     2",
"    </sub>",
"    laser suggests tissue necrosis; additional laser passes should not be performed if this is detected. &nbsp;Two passes are often performed during treatment of rhytides with the CO",
"    <sub>",
"     2",
"    </sub>",
"    laser, and between four and ten passes typically are required to achieve desired results with Er:YAG devices. The direction of treatment should be altered with subsequent passes to prevent the development of a striped pattern after healing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of focal areas can result in an unfavorable color contrast between treated and untreated skin. If the entire face is not treated, the treatment should at least incorporate an entire cosmetic unit to minimize this effect (",
"    <a class=\"graphic graphic_figure graphicRef69743 \" href=\"UTD.htm?22/5/22611\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449925\">",
"    <span class=\"h3\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema and exudate are expected within the first few days after ablative resurfacing. The initial appearance after treatment may be disturbing for some patients, which underlies the importance of careful preoperative counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/58\">",
"     58",
"    </a>",
"    ]. Postoperative management includes the use of cool compresses, head elevation, and saline or water soaks applied as often as is necessary to keep the skin moist. Moisture promotes wound healing, and both open and closed wound care techniques have been advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"     3",
"    </a>",
"    ]. We favor the open technique and instruct patients to apply petrolatum ointment to the treatment area after each soak until reepithelialization is complete. Advocates of the closed technique tend to utilize wound dressings for the first 24 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/2,3,59\">",
"     2,3,59",
"    </a>",
"    ]. Pain can be managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or stronger oral analgesic agents when necessary.",
"   </p>",
"   <p>",
"    Erythema may persist for months, particularly after CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing. Makeup with a green tint is useful for masking erythema. Throughout this period, patients should engage in daily sun protective practices and daily sunscreen use to reduce to development of postinflammatory hyperpigmentation. When it occurs, postinflammatory hyperpigmentation improves slowly over time; daily application of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    cream, retinoids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peeling agents such as glycolic acid can be prescribed to accelerate resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. We typically use topical hydroquinone and low potency glycolic acids. Topical retinoids are added if tolerated.",
"   </p>",
"   <p>",
"    If scarring occurs, treatments such as topical or intralesional steroids, silicone gel, pulsed dye laser therapy, or nonablative fractional laser resurfacing can be utilized to minimize the cosmetic impact.",
"   </p>",
"   <p>",
"    Most patients can return to work two to three weeks after full face CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing. After Er:YAG laser resurfacing, the recovery period is between three and eight days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7559191\">",
"    <span class=\"h1\">",
"     ABLATIVE FRACTIONAL LASERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively long recovery period required for CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing and its associated adverse effects stimulated the search for alternative methods for laser skin rejuvenation. Ablative fractional photothermolysis is a newer form of laser therapy that has some advantages over traditional ablative laser resurfacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H214335\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to traditional ablative lasers, the target chromophore for fractional lasers is water. The ablative fractional lasers include the 2940 nm fractional erbium:yttrium aluminum garnet (Er:YAG) laser, the 2790 nm fractional yttrium scandium gallium garnet (YSGG) laser, and the 10,600 nm fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser. Nonablative fractional lasers emit wavelengths of light that are less strongly absorbed by water molecules in the skin. Nonablative fractional lasers have also been used for skin rejuvenation, but are less effective for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fractional lasers deliver a multitude of narrow columns of laser light to the skin, resulting in the creation of numerous microscopic vertical zones of thermal damage called microscopic thermal zones (MTZs) (",
"    <a class=\"graphic graphic_figure graphicRef53757 \" href=\"UTD.htm?38/15/39153\">",
"     figure 1",
"    </a>",
"    ). MTZs are usually less than 400 &micro;m in diameter and up to 1300 &micro;m deep; the type of fractional laser and specific laser settings determine the size of the MTZ [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The undamaged surrounding skin immediately adjacent to an MTZ serves as a reservoir of viable tissue, permitting the rapid repopulation of the epidermis observed after fractional laser therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/61\">",
"     61",
"    </a>",
"    ]. Reepithelialization typically occurs within a few days. In contrast, reepithelialization after traditional laser ablation is dependent on migration of epidermal cells from adnexal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/7\">",
"     7",
"    </a>",
"    ]. A skin tightening effect also occurs after treatment with ablative fractional lasers; both immediate and delayed collagen contraction and collagen remodeling may contribute improvements in skin laxity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/7,62\">",
"     7,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7559526\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence in support of the efficacy of ablative fractional lasers for the treatment of photoaged skin is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/9\">",
"     9",
"    </a>",
"    ]. However, published studies of this form of therapy for photodamaged skin are primarily limited to uncontrolled studies. Examples of studies investigating the use of ablative fractional lasers include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study of 30 adults with cutaneous photodamage (skin phototype I to IV), facial and neck skin were treated with a fractional CO",
"      <sub>",
"       2",
"      </sub>",
"      laser for one or two treatment sessions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/15\">",
"       15",
"      </a>",
"      ]. Based upon the investigators&rsquo; assessment of clinical photographs, 23 out of 30 patients (83 percent) exhibited at least 50 percent improvement in the overall appearance of photodamaged skin three months after the completion of therapy.",
"     </li>",
"     <li>",
"      Another uncontrolled study (n = 55) evaluated the efficacy of a fractional CO",
"      <sub>",
"       2",
"      </sub>",
"      laser device in patients with severe photodamage (skin phototype II or III) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/63\">",
"       63",
"      </a>",
"      ]. Patients were given one treatment session. Statistically significant improvement in fine lines, mottled pigmentation, sallow complexion, and skin texture were evident one month after treatment. Scores for coarse wrinkles and telangiectasias exhibited a nonsignificant trend towards improvement. Additional statistically significant improvement was noted for fine lines, sallowness, and skin texture three months after the completion of therapy.",
"     </li>",
"     <li>",
"      The efficacy of a fractional Er:YAG laser was investigated in an uncontrolled study of 28 patients with mild to moderate photodamage (skin phototype II to IV) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/64\">",
"       64",
"      </a>",
"      ]. Patients were treated for one to four treatment sessions with a treatment interval of four weeks. Two months after the completion of therapy, clinical outcomes for photodamage and wrinkling were rated by the investigators as excellent in 75 percent of patients and good in 25 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other studies have also documented improvement in signs of photoaging following treatment with fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    , Er:YAG, or YSGG lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparative trials of fractional lasers are limited. In a randomized split-face trial of 28 patients with facial rhytides that compared a single treatment with a fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser to one treatment with a fractional Er:YAG laser, no significant difference in clinical effect was detected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/68\">",
"     68",
"    </a>",
"    ]. The investigators found that 64 percent and 57 percent of sites treated with the fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser or fractional Er:YAG laser, respectively, showed clinical signs of improvement. Wrinkle depth was modestly, but significantly improved in sites treated with both lasers. Wrinkle depth decreased from 1.97&plusmn;2.05 mm to 1.64&plusmn;2.04 mm and from 1.97&plusmn;1.29 to 1.63&plusmn;1.20 mm, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1449770\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with traditional ablative laser resurfacing, complications of ablative fractional laser resurfacing appear to be less severe and less frequent. Treatment-induced erythema is expected and usually resolves within a few days. Prolonged erythema (lasting more than one month) occurs in approximately 12 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ] and usually resolves within three months. In one small randomized split-face trial, use of a 590 nm light-emitting diode array reduced the severity and duration of post-treatment erythema by one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral, bacterial, or fungal infections can follow treatment. The risk for herpes simplex virus (HSV) infection after fractional laser resurfacing is lower than for traditional laser resurfacing (0.3 to 2 percent versus 2 to 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ]. However, all patients undergoing fractional resurfacing of the entire face or who have a history of facial HSV infection should be treated with antiviral prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ]. We typically administer either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    200 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    500 mg twice daily, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    500 mg twice daily. Treatment should begin one day prior to treatment and should be continued for five to seven days after treatment. Patients with HSV infection may present only with nonspecific superficial erosions in the treated area.",
"   </p>",
"   <p>",
"    Bacterial infection is uncommon, and as with traditional ablative laser resurfacing, the routine use of antibiotic prophylaxis is controversial. We generally reserve antibiotic prophylaxis for people who we perceive to be at high risk for infection, such as immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ]. Signs of infection include worsening pain, drainage, erosions, or crusting within the first few days after treatment. In our experience, patients who develop candidal infections frequently complain of intense pruritus.",
"   </p>",
"   <p>",
"    When infection is suspected, the involved sites should be cultured and broad-spectrum antibiotic therapy should be administered while awaiting culture results. Candidal infections are managed with oral antifungal agents.",
"   </p>",
"   <p>",
"    Similar to traditional ablative laser resurfacing, the risk of postinflammatory hyperpigmentation rises with increasing baseline skin pigmentation. However, the duration and severity of hyperpigmentation tends to be less in patients treated with fractional lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ]. We instruct patients to avoid sun exposure for two weeks prior to treatment and for two weeks after therapy to reduce this risk. Longer treatment intervals and adjustments to the energy and density settings may be beneficial for reducing the incidence of hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/11,46\">",
"     11,46",
"    </a>",
"    ]. Hypopigmentation is rare after fractional laser resurfacing.",
"   </p>",
"   <p>",
"    Scarring also is uncommon, but can be devastating when it occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Initial signs of scarring include a focal, persistent area of erythema or induration that appears a few weeks after therapy. Most cases scarring after fractional laser resurfacing have involved treatment of the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications of fractional ablative laser resurfacing include transient acneiform eruptions, milia, and ectropion. Ectropion may be most likely to occur in patients with a history of eyelid surgery or reduced skin elasticity in this area at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1450050\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693277\">",
"    <span class=\"h3\">",
"     Preoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative measures are similar to those for traditional ablative laser resurfacing. (See",
"    <a class=\"local\" href=\"#H1449890\">",
"     'Preoperative'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693270\">",
"    <span class=\"h3\">",
"     Intraoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preparation for treatment, the skin should be cleansed thoroughly with a gentle cleanser. A topical anesthetic is applied one hour prior to treatment and cold air is used to further improve patient comfort during the treatment session. The use of cold air is supported by a nonrandomized prospective split-face study that found that treatment with a fractional C0",
"    <sub>",
"     2",
"    </sub>",
"    laser was less painful when given with both cold air anesthesia and topical anesthesia than when given with topical anesthesia alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/72\">",
"     72",
"    </a>",
"    ]. For more aggressive procedures, local nerve blocks, oral sedatives, or intravenous anesthesia may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser settings are not transferable between different ablative fractional laser devices, and clinician familiarity with the device utilized is essential. In general, the use of higher energies with small spot sizes increases the depth of laser injury. Increasing the pulse duration widens the diameter of the MTZ and may increase the depth of ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/73\">",
"     73",
"    </a>",
"    ]. The density setting, which determines the amount of space between the MTZs, can also be altered. It is advisable to reduce density settings in areas at greater risk for complications such as the neck and periocular skin; higher densities may be appropriate for deep rhytides, such as those in the perioral area [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early fractional lasers required the application of a blue dye to the skin to optimize functioning, but this is no longer necessary with most devices. A thick layer of gel is applied before the start of treatment, and the number of laser passes needed is determined by the specific laser system and laser settings. Similar to nonfractional ablative lasers, treatment of an entire cosmetic unit is preferred if full-face treatment is not being performed (",
"    <a class=\"graphic graphic_figure graphicRef69743 \" href=\"UTD.htm?22/5/22611\">",
"     figure 4",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H1449918\">",
"     'Intraoperative'",
"    </a>",
"    above). Immediate edema and bleeding, and crusting can occur during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693263\">",
"    <span class=\"h3\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after treatment, we apply ice-cold wet compresses followed by a bland occlusive ointment (usually Aquaphor healing ointment). Home care after less intense treatments involves gentle skin cleansing and repeated application of the ointment to maintain constant skin moisture until crusting ceases (usually by day three) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"     23",
"    </a>",
"    ]. In more aggressively treated individuals (bleeding associated with treatment), we apply a biologic dressing which is removed 24 hours later and is followed by soaking and gentle cleansing of the skin every three to four hours for five to seven days. After each soak the ointment should be reapplied to maintain skin moisture. Subsequently, a nongreasy moisturizing cream can be utilized.",
"   </p>",
"   <p>",
"    For patients who develop pruritus during the healing period, we prescribe a mid-potency topical corticosteroid for application twice daily for a few days. Itching most commonly begins on the third postoperative day.",
"   </p>",
"   <p>",
"    Desquamation for several days after treatment is normal. Scratching or rubbing of the skin should be avoided. As with ablative laser resurfacing, photoprotection is important to reduce risk for hyperpigmentation. Hyperpigmentation is managed similarly to hyperpigmentation associated with traditional ablative lasers.",
"   </p>",
"   <p>",
"    Most patients can return to work 4 to 10 days after fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser resurfacing depending on the extent and intensity of treatment. After fractional Er:YAG laser resurfacing, the recovery period is between one and three days. We find that most patients require one to three treatments to achieve desired results (",
"    <a class=\"graphic graphic_picture graphicRef81643 \" href=\"UTD.htm?20/42/21152\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18975821\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ablative laser resurfacing procedures can lead to improvement in the clinical signs of photoaging. The ablative lasers used for skin resurfacing include pulsed and rapidly scanning carbon dioxide (CO",
"      <sub>",
"       2",
"      </sub>",
"      ) lasers, pulsed Er:YAG lasers, and fractional ablative lasers. (See",
"      <a class=\"local\" href=\"#H15356078\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8009623\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be thoroughly informed of the expected treatment outcome, anticipated recovery period, and treatment risks prior to proceeding with ablative laser resurfacing. A variety of factors influence the selection of the appropriate laser resurfacing technique, including the severity and location of photodamage, the patient&rsquo;s skin color, and patient preference regarding the length of time required for healing. (See",
"      <a class=\"local\" href=\"#H18975495\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both traditional CO",
"      <sub>",
"       2",
"      </sub>",
"      lasers and traditional Er:YAG lasers are effective for the treatment of photoaging. CO",
"      <sub>",
"       2",
"      </sub>",
"      lasers appear to have a greater effect on skin tightening, which may be related to greater transfer of heat to underlying dermal collagen after during irradiation with the CO",
"      <sub>",
"       2",
"      </sub>",
"      laser. However, CO",
"      <sub>",
"       2",
"      </sub>",
"      laser resurfacing is associated with a relatively longer recovery period, higher risk for scarring and dyspigmentation, and a longer period of persistent erythema after treatment. Due to an elevated risk for dyspigmentation in patients with dark skin, we typically limit CO",
"      <sub>",
"       2",
"      </sub>",
"      laser resurfacing to patients with skin phototypes I to III. (See",
"      <a class=\"local\" href=\"#H18975495\">",
"       'Approach to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H832338\">",
"       'Traditional ablative lasers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional ablative laser resurfacing is contraindicated in patients with a history of keloidal scarring, recent history oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      therapy, and sclerotic disorders involving the site to be treated. Infraorbital resurfacing should not be performed in patients with ectropion. Relative contraindications include cutaneous disorders that may Koebnerize and a history of facial surgery. (See",
"      <a class=\"local\" href=\"#H1449897\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic antiviral therapy should be provided to all patients undergoing full facial traditional or fractional ablative laser resurfacing due to a risk for herpes simplex virus reactivation. The need for antibiotic prophylaxis is controversial. If bacterial infection is suspected, the affected area should be cultured and systemic antibiotic therapy should be initiated. (See",
"      <a class=\"local\" href=\"#H1449911\">",
"       'Prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1449770\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain management is often necessary during laser resurfacing. Depending on the type of procedure, patients may require only topical anesthetics or the addition of systemic agents. (See",
"      <a class=\"local\" href=\"#H1449918\">",
"       'Intraoperative'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1693270\">",
"       'Intraoperative'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fractional ablative lasers operate through the creation of numerous microscopic columns of thermal damage involving the epidermis and dermis (",
"      <a class=\"graphic graphic_figure graphicRef53757 \" href=\"UTD.htm?38/15/39153\">",
"       figure 1",
"      </a>",
"      ). Due to a relatively short recovery period, and a relatively low risk of adverse effects, fractional ablative lasers are increasingly becoming the preferred devices for ablative laser resurfacing. Additional studies are necessary to explore the efficacy and safety of fractional ablative lasers for rejuvenation. (See",
"      <a class=\"local\" href=\"#H7559191\">",
"       'Ablative fractional lasers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/1\">",
"      Ross EV, Grossman MC, Duke D, Grevelink JM. Long-term results after CO2 laser skin resurfacing: a comparison of scanned and pulsed systems. J Am Acad Dermatol 1997; 37:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/2\">",
"      Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol 2008; 58:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/3\">",
"      Alster TS, Lupton JR. Erbium:YAG cutaneous laser resurfacing. Dermatol Clin 2001; 19:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/4\">",
"      Perez MI, Bank DE, Silvers D. Skin resurfacing of the face with the Erbium:YAG laser. Dermatol Surg 1998; 24:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/5\">",
"      Teikemeier G, Goldberg DJ. Skin resurfacing with the erbium:YAG laser. Dermatol Surg 1997; 23:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/6\">",
"      Ross EV, McKinlay JR, Anderson RR. Why does carbon dioxide resurfacing work? A review. Arch Dermatol 1999; 135:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/7\">",
"      Tierney EP, Eisen RF, Hanke CW. Fractionated CO2 laser skin rejuvenation. Dermatol Ther 2011; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/8\">",
"      Riggs K, Keller M, Humphreys TR. Ablative laser resurfacing: high-energy pulsed carbon dioxide and erbium:yttrium-aluminum-garnet. Clin Dermatol 2007; 25:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/9\">",
"      Tierney EP, Kouba DJ, Hanke CW. Review of fractional photothermolysis: treatment indications and efficacy. Dermatol Surg 2009; 35:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/10\">",
"      Shah S, Alster TS. Laser treatment of dark skin: an updated review. Am J Clin Dermatol 2010; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/11\">",
"      Chan HH, Manstein D, Yu CS, et al. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med 2007; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/12\">",
"      Kim YJ, Lee HS, Son SW, et al. Analysis of hyperpigmentation and hypopigmentation after Er:YAG laser skin resurfacing. Lasers Surg Med 2005; 36:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/13\">",
"      Tan KL, Kurniawati C, Gold MH. Low risk of postinflammatory hyperpigmentation in skin types 4 and 5 after treatment with fractional CO2 laser device. J Drugs Dermatol 2008; 7:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/14\">",
"      Avram MM, Tope WD, Yu T, et al. Hypertrophic scarring of the neck following ablative fractional carbon dioxide laser resurfacing. Lasers Surg Med 2009; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/15\">",
"      Rahman Z, MacFalls H, Jiang K, et al. Fractional deep dermal ablation induces tissue tightening. Lasers Surg Med 2009; 41:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/16\">",
"      Stebbins WG, Hanke CW. Ablative fractional CO2 resurfacing for photoaging of the hands: pilot study of 10 patients. Dermatol Ther 2011; 24:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/17\">",
"      Tierney EP, Hanke CW. Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol 2009; 8:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/18\">",
"      Tierney EP, Hanke CW. Treatment of Poikiloderma of Civatte with ablative fractional laser resurfacing: prospective study and review of the literature. J Drugs Dermatol 2009; 8:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/19\">",
"      Jimenez G, Spencer JM. Erbium:YAG laser resurfacing of the hands, arms, and neck. Dermatol Surg 1999; 25:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/20\">",
"      Goldberg DJ, Meine JG. Treatment of photoaged neck skin with the pulsed Erbium:YAG laser. Dermatol Surg 1998; 24:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/21\">",
"      Goldman MP, Fitzpatrick RE, Manuskiatti W. Laser resurfacing of the neck with the Erbium: YAG laser. Dermatol Surg 1999; 25:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/22\">",
"      Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/23\">",
"      Brightman LA, Brauer JA, Anolik R, et al. Ablative and fractional ablative lasers. Dermatol Clin 2009; 27:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/24\">",
"      Fulton JE Jr, Barnes T. Collagen shrinkage (selective dermaplasty) with the high-energy pulsed carbon dioxide laser. Dermatol Surg 1998; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/25\">",
"      Ross EV, Yashar SS, Naseef GS, et al. A pilot study of in vivo immediate tissue contraction with CO2 skin laser resurfacing in a live farm pig. Dermatol Surg 1999; 25:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/26\">",
"      Walia S, Alster TS. Prolonged clinical and histologic effects from CO2 laser resurfacing of atrophic acne scars. Dermatol Surg 1999; 25:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/27\">",
"      Alster TS, Garg S. Treatment of facial rhytides with a high-energy pulsed carbon dioxide laser. Plast Reconstr Surg 1996; 98:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/28\">",
"      Fitzpatrick RE, Goldman MP, Satur NM, Tope WD. Pulsed carbon dioxide laser resurfacing of photo-aged facial skin. Arch Dermatol 1996; 132:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/29\">",
"      Waldorf HA, Kauvar AN, Geronemus RG. Skin resurfacing of fine to deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg 1995; 21:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/30\">",
"      Somoano B, Hantash BM, Fincher EF, et al. The erbium micropeel: a prospective, randomized trial of the effects of two fluence settings on facial photoaging. J Drugs Dermatol 2011; 10:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/31\">",
"      Orringer JS, Ritti&eacute; L, Hamilton T, et al. Intraepidermal erbium:YAG laser resurfacing: impact on the dermal matrix. J Am Acad Dermatol 2011; 64:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/32\">",
"      Khatri KA, Ross V, Grevelink JM, et al. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol 1999; 135:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/33\">",
"      Ross EV, Miller C, Meehan K, et al. One-pass CO2 versus multiple-pass Er:YAG laser resurfacing in the treatment of rhytides: a comparison side-by-side study of pulsed CO2 and Er:YAG lasers. Dermatol Surg 2001; 27:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/34\">",
"      Papadavid E, Katsambas A. Lasers for facial rejuvenation: a review. Int J Dermatol 2003; 42:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/35\">",
"      Adrian RM. Pulsed carbon dioxide and long pulse 10-ms erbium-YAG laser resurfacing: a comparative clinical and histologic study. J Cutan Laser Ther 1999; 1:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/36\">",
"      Newman JB, Lord JL, Ash K, McDaniel DH. Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/37\">",
"      McDaniel DH, Lord J, Ash K, Newman J. Combined CO2/erbium:YAG laser resurfacing of peri-oral rhytides and side-by-side comparison with carbon dioxide laser alone. Dermatol Surg 1999; 25:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/38\">",
"      Collawn SS. Combination therapy: utilization of CO2 and Erbium:YAG lasers for skin resurfacing. Ann Plast Surg 1999; 42:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/39\">",
"      Dijkema SJ, van der Lei B. Long-term results of upper lips treated for rhytides with carbon dioxide laser. Plast Reconstr Surg 2005; 115:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/40\">",
"      Tierney EP, Hanke CW. Treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing: case report and review of the literature. J Drugs Dermatol 2010; 9:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/41\">",
"      Rubenstein R, Roenigk HH Jr, Stegman SJ, Hanke CW. Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol 1986; 15:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/42\">",
"      Zachariae H. Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. Br J Dermatol 1988; 118:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/43\">",
"      Bagatin E, dos Santos Guadanhim LR, Yarak S, et al. Dermabrasion for acne scars during treatment with oral isotretinoin. Dermatol Surg 2010; 36:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/44\">",
"      Hayes DK, Berkland ME, Stambaugh KI. Dermal healing after local skin flaps and chemical peel. Arch Otolaryngol Head Neck Surg 1990; 116:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/45\">",
"      Nestor MS. Prophylaxis for and treatment of uncomplicated skin and skin structure infections in laser and cosmetic surgery. J Drugs Dermatol 2005; 4:s20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/46\">",
"      Metelitsa AI, Alster TS. Fractionated laser skin resurfacing treatment complications: a review. Dermatol Surg 2010; 36:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/47\">",
"      Ross EV, Amesbury EC, Barile A, et al. Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. J Am Acad Dermatol 1998; 39:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/48\">",
"      Walia S, Alster TS. Cutaneous CO2 laser resurfacing infection rate with and without prophylactic antibiotics. Dermatol Surg 1999; 25:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/49\">",
"      Gaspar Z, Vinciullo C, Elliott T, Vincuillo C. Antibiotic prophylaxis for full-face laser resurfacing: is it necessary? Arch Dermatol 2001; 137:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/50\">",
"      Alt TH. Technical aids for dermabrasion. J Dermatol Surg Oncol 1987; 13:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/51\">",
"      Orringer JS, Kang S, Johnson TM, et al. Tretinoin treatment before carbon-dioxide laser resurfacing: a clinical and biochemical analysis. J Am Acad Dermatol 2004; 51:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/52\">",
"      Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates healing after trichloroacetic acid chemical peel. Arch Dermatol 1991; 127:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/53\">",
"      Mandy SH. Tretinoin in the preoperative and postoperative management of dermabrasion. J Am Acad Dermatol 1986; 15:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/54\">",
"      Vagotis FL, Brundage SR. Histologic study of dermabrasion and chemical peel in an animal model after pretreatment with Retin-A. Aesthetic Plast Surg 1995; 19:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/55\">",
"      Mandy SH. Dermabrasion. Semin Cutan Med Surg 1996; 15:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/56\">",
"      Drake LA, Dinehart SM, Goltz RW, et al. Guidelines of care for chemical peeling. Guidelines/Outcomes Committee: American Academy of Dermatology. J Am Acad Dermatol 1995; 33:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/57\">",
"      West TB, Alster TS. Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. Dermatol Surg 1999; 25:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/58\">",
"      Batra RS, Jacob CI, Hobbs L, et al. A prospective survey of patient experiences after laser skin resurfacing: results from 2 1/2 years of follow-up. Arch Dermatol 2003; 139:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/59\">",
"      Batra RS, Ort RJ, Jacob C, et al. Evaluation of a silicone occlusive dressing after laser skin resurfacing. Arch Dermatol 2001; 137:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/60\">",
"      Bogdan Allemann I, Kaufman J. Fractional photothermolysis--an update. Lasers Med Sci 2010; 25:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/61\">",
"      Hantash BM, Bedi VP, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg Med 2007; 39:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/62\">",
"      El-Domyati M, Abd-El-Raheem T, Abdel-Wahab H, et al. Fractional versus ablative erbium:yttrium-aluminum-garnet laser resurfacing for facial rejuvenation: an objective evaluation. J Am Acad Dermatol 2013; 68:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/63\">",
"      Clementoni MT, Gilardino P, Muti GF, et al. Non-sequential fractional ultrapulsed CO2 resurfacing of photoaged facial skin: preliminary clinical report. J Cosmet Laser Ther 2007; 9:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/64\">",
"      Lapidoth M, Yagima Odo ME, Odo LM. Novel use of erbium:YAG (2,940-nm) laser for fractional ablative photothermolysis in the treatment of photodamaged facial skin: a pilot study. Dermatol Surg 2008; 34:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/65\">",
"      Trelles MA, Mordon S, Velez M, et al. Results of fractional ablative facial skin resurfacing with the erbium:yttrium-aluminium-garnet laser 1 week and 2 months after one single treatment in 30 patients. Lasers Med Sci 2009; 24:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/66\">",
"      Dierickx CC, Khatri KA, Tannous ZS, et al. Micro-fractional ablative skin resurfacing with two novel erbium laser systems. Lasers Surg Med 2008; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/67\">",
"      Kotlus BS. Dual-depth fractional carbon dioxide laser resurfacing for periocular rhytidosis. Dermatol Surg 2010; 36:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/68\">",
"      Karsai S, Czarnecka A, J&uuml;nger M, Raulin C. Ablative fractional lasers (CO(2) and Er:YAG): a randomized controlled double-blind split-face trial of the treatment of peri-orbital rhytides. Lasers Surg Med 2010; 42:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/69\">",
"      Alster TS, Wanitphakdeedecha R. Improvement of postfractional laser erythema with light-emitting diode photomodulation. Dermatol Surg 2009; 35:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/70\">",
"      Fife DJ, Fitzpatrick RE, Zachary CB. Complications of fractional CO2 laser resurfacing: four cases. Lasers Surg Med 2009; 41:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/71\">",
"      Ross RB, Spencer J. Scarring and persistent erythema after fractionated ablative CO2 laser resurfacing. J Drugs Dermatol 2008; 7:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/72\">",
"      Tierney EP, Hanke CW. The effect of cold-air anesthesia during fractionated carbon-dioxide laser treatment: Prospective study and review of the literature. J Am Acad Dermatol 2012; 67:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/36/1610/abstract/73\">",
"      Tierney EP, Hanke CW, Petersen J. Ablative fractionated CO2 laser treatment of photoaging: a clinical and histologic study. Dermatol Surg 2012; 38:1777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13629 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-E85F879F22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1610=[""].join("\n");
var outline_f1_36_1610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18975821\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15356078\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8009623\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18975495\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92421460\">",
"      Patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92421453\">",
"      Choice of laser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H903511\">",
"      Dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693104\">",
"      Nonfacial sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H832338\">",
"      TRADITIONAL ABLATIVE LASERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H214349\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7559533\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1146740\">",
"      - CO2 lasers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92421580\">",
"      - Er:YAG lasers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7558968\">",
"      - Comparative studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7559620\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1449883\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1449890\">",
"      - Preoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1449897\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1449911\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1449918\">",
"      - Intraoperative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1449925\">",
"      - Postoperative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7559191\">",
"      ABLATIVE FRACTIONAL LASERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H214335\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7559526\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1449770\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1450050\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1693277\">",
"      - Preoperative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1693270\">",
"      - Intraoperative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1693263\">",
"      - Postoperative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18975821\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13629|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/15/39153\" title=\"figure 1\">",
"      Fractionated photothermolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/30/44516\" title=\"figure 2\">",
"      Laser penetration into skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/29/24017\" title=\"figure 3\">",
"      Thermal relaxation time in skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/5/22611\" title=\"figure 4\">",
"      Cosmetic units of the face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13629|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/42/21152\" title=\"picture 1\">",
"      Ablative fractional resurfacing - before and after",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13629|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=related_link\">",
"      Overview of botulinum toxin for cosmetic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=related_link\">",
"      Principles of laser and intense pulsed light for cutaneous lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_36_1611="Management organ donor";
var content_f1_36_1611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Goals of pediatric organ donor management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Correct electrolyte disturbances and maintain fluid and electrolyte balance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maintenance of normal cardiac output and tissue perfusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ensure adequate ventilation and pulmonary viability; minimize atelectasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prevent aspiration around endotracheal tube",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prevent and treat infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Control diabetes insipidus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maintain skin integrity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maintain normothermia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce inflammation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1611=[""].join("\n");
var outline_f1_36_1611=null;
var title_f1_36_1612="Changing practice behavior";
var content_f1_36_1612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Options for changing clinicians' practice behavior*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Passive: Providing information by CME, journals, books, electronic media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active: Provide answers to questions as they arise (\"just-in-time learning\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Change the work environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make it easier to do the right thing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Case managers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feedback on performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Practice pattern reports for physician's use only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Public report cards: HEDIS and others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical Practice Guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Authoritative, recommendations, tailored to local situation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should include an evidence-based rationale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Local opinion leaders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Informal, disease-specific network of respected colleagues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persuasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Academic detailing\" methods similar to advertisements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Economic incentives/disincentives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capitation, risk contracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tying compensation to performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Change patients' expectations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popular media, books, patient help hotlines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct-to-patient marketing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In descending order of strength.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1612=[""].join("\n");
var outline_f1_36_1612=null;
var title_f1_36_1613="Drug therapy for treatment of histoplasmosis infections in HIV";
var content_f1_36_1613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug therapy for treatment and chronic maintenance therapy of AIDS-associated histoplasma capsulatum infections in adults and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preferred therapy, duration of therapy, chronic maintenance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternative therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other options/issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred therapy for moderately severe to severe disseminated disease",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Induction therapy",
"         </em>",
"         (for 2 weeks or until clinically improved)",
"        </p>",
"        <ul>",
"         <li>",
"          Liposomal amphotericin B at 3 mg/kg IV daily",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance therapy",
"         </em>",
"        </p>",
"        <ul>",
"         <li>",
"          Itraconazole 200 mg PO tid for 3 days, then bid",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          Preferred therapy for less severe disseminated disease",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Induction and maintenance therapy",
"         </em>",
"        </p>",
"        <ul>",
"         <li>",
"          Itraconazole 200 mg PO tid for 3 days, then 200 mg PO bid",
"         </li>",
"        </ul>",
"        <p>",
"         Duration of therapy: at least 12 months",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          Preferred therapy for meningitis",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Induction therapy",
"         </em>",
"         (4-6 weeks)",
"        </p>",
"        <ul>",
"         <li>",
"          Liposomal amphotericin B 5 mg/kg/day",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance therapy",
"         </em>",
"        </p>",
"        <ul>",
"         <li>",
"          Itraconazole 200 mg PO bid-tid for &ge;1 year and until resolution of abnormal CSF findings",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          Preferred therapy for long term suppression therapy",
"         </strong>",
"        </p>",
"        <p>",
"         In patients with severe disseminated or CNS infection and in patients who relapse despite appropriate therapy (CIII)",
"        </p>",
"        <ul>",
"         <li>",
"          Itraconazole 200 mg PO daily",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Alternative therapy moderately severe to severe disseminated disease",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Induction therapy",
"         </em>",
"         (for 2 weeks or until clinically improved)",
"        </p>",
"        <ul>",
"         <li>",
"          Amphotericin B deoxycholate 0.7 mg/kg IV daily",
"         </li>",
"         <li>",
"          Amphotericin B lipid complex 5 mg/kg IV daily",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance therapy",
"         </em>",
"        </p>",
"        <p>",
"         Same as \"Preferred therapy\"",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Itraconazole levels should be obtained in all patients to ensure adequate absorption. Serum concentrations of itraconazole + hydroxyitraconazole should be &gt;1 mcg/mL.",
"        </p>",
"        <p>",
"         Itraconazole oral solution is preferred over capsule by certain specialists because of&nbsp;improved absorption",
"        </p>",
"        <p>",
"         Acute pulmonary histoplasmosis in HIV- infected patients with CD4+ count &gt;300 cells/microL should be managed as non-immunocompromised host",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2009; 58:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1613=[""].join("\n");
var outline_f1_36_1613=null;
var title_f1_36_1614="Thyroid hormone structure";
var content_f1_36_1614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structures of the thyroid hormones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 376px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1614=[""].join("\n");
var outline_f1_36_1614=null;
var title_f1_36_1615="IDUS pancreatic duct mucin";
var content_f1_36_1615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Guidewire placement for intraductal ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Placement of a guidewire, for intraductal ultrasound, into the pancreatic duct in a patient with a widely patent papilla that is extruding mucus as a result of an intraductal papillary mucinous neoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_36_1615=[""].join("\n");
var outline_f1_36_1615=null;
